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ABSTRACT 
 
Mechanisms Underlying Antimicrobial Efficacies of Non-Thermal Dielectric Barrier 
Discharge (DBD) Plasma-Treated N-Acetyl Cysteine (NAC) Solution 
 
Utku Kürşat Ercan 
Advisors: Suresh G. Joshi, MD, PhD and Kenneth A. Barbee, PhD 
 
 
Hospital-acquired infections are a major challenge for healthcare professionals and 
patients, and have gained an increasing importance for overall public health. According to 
the Center for Disease Control and Prevention, hospital-acquired infections affect about 1.7 
million people every year, and increase mortality, morbidity rates and healthcare costs. 
Commercially available biocides used in medical practice are not sufficient to completely 
decontaminate sources of nosocomial infections, including sessile biofilms with embedded 
pathogens, and are cytotoxic.  Furthermore, antibiotics remain ineffective against multidrug 
resistant virulent pathogens. Therefore, a new non-toxic, broad-spectrum antimicrobial agent 
is needed. 
Plasma medicine is rapidly growing interdisciplinary field that explores novel 
solutions and applications in biology and medicine. Plasma is the fourth state of matter, 
consists of charged particles, ions, radicals, UV photons and excited molecules and atoms. 
Antimicrobial effect of non-thermal plasma is characterized and the underlying mechanisms 
are investigated. Liquids, which are treated with non-thermal plasma acquire antimicrobial 
properties through the creation of plasma generated ROS and RNS and their interactions. N-
acetyl cysteine (NAC) is an amino acid derivative and acquires antimicrobial property upon 
plasma-mediated chemical modifications. 
In this thesis study, we introduce non-thermal, dielectric barrier discharge (DBD) 
plasma-treated NAC solution as a novel antimicrobial agent, which is non-toxic and has 
! xxii!
broad-spectrum activity against an array of multidrug resistant pathogens in their planktonic 
and biofilm forms. The present research also involves the detection of plasma-generated 
species and their products in NAC solution and their contribution in antimicrobial effect.  
Damaging effects of plasma-treated NAC solution in E. coli cells are studied such as 
DNA damage, cell membrane damage and intracellular oxidative and nitrosative stress. In 
addition, most commonly reported oxidative and nitrosative stress mediated gene 
activation/repression are studied in E. coli (a model organism). This study also investigates 
in vitro cytotoxicity and in vivo acute systemic toxicity in rats, and the stability of plasma-
treated NAC solution as a part of development of novel antimicrobial solution. 
 This study provides a better understanding of non-thermal plasma activated NAC 
solution and the associated chemical changes, which lead to antimicrobial effect. Non-
thermal plasma- treated NAC solution is thus being explored as a new antimicrobial 
compound for the control of the reservoirs of nosocomial pathogens. Thus this dissertation 
contributes new knowledge in the field of plasma medicine and infection control. 
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1    CHAPTER I: INTRODUCTION AND BACKGROUND 
 
 
1.1 Hospital-Acquired Infections: 
 Hospital-acquired infection (HAI), or healthcare-associated infection (HCAI) is 
nosocomial infection, which originates from any healthcare delivery setting such as; 
hospitals, retirement houses, ambulatory care setting, etc. An infection can be classified 
as hospital-acquired infection if it wasn’t present or in incubation period when the 
patient was admitted to a health care facility [1]. Most of the hospital-acquired infections 
are observed in patients before discharge from hospital. However depending on the 
duration of hospitalization it also can be observed after the discharge of the patient. 
Hence infections that occur 48-72 hours after the admission of patient to a healthcare 
facility, and within 10 days after discharge from the hospital are referred as hospital 
acquired infections. However it further can be altered depending on type of infection 
agent, their incubation periods, etc. [2]. Hospital acquired infection, can be spread after 
the admission of an already infected patient to a health care facility, contact in between 
healthcare professionals and patients, contact with contaminated surfaces or medical 
devices [3]. The prevalence of hospital-acquired infections has increased over the past 
few decades in spite of utilization of several new infection control methods. In spite of 
number of patients hospitalized has decreased from 38 million to 36 million and the 
duration of hospitalization has reduced from 7.9 days to 5.3 days, the rate of hospital-
acquired infections has increased from 0.72% to 0.98% in between 1970s and 2000s due 
to the higher average age of patients [4]. Also for pediatric patients numbers become 
more remarkable where the prevalence of hospital-acquired infections reaches up to 25% 
! 2!
in [5].  Hospital-acquired infection is a major challenge for clinicians and other health 
care providers and has assumed increasing importance for overall public health. It is one 
of the most common causes of health care complications and death in the United States. 
According to the Center for Disease Control and Prevention, about 1.7 million infections 
occur annually, of which about 100,000 deaths are associated with hospital-acquired 
infection, and are responsible for increased rates of mortality, morbidity and medical 
costs [6]. Also hospital acquired infections increase average hospital stay and cost per 
patient, to existing $28-$36 billion burden annually [7]. With the development and 
widespread use of antimicrobial agents, including antibiotics, resistant microorganisms 
have emerged. Observations about antibiotic usage over the time have shown that, 
whenever a broader spectrum of an existing antibiotic or a new generation of antibiotic 
is introduced to for clinical use, either existing resistance increases or a new clinically 
important resistance arises. Increase in existing resistance or occurrence of new 
resistance limits the usage of currently available antibiotics and antimicrobial agents and 
makes infections a great challenge for clinicians and a threat for patients. Due to 
extensive and constant use of antibiotics and large population of microorganisms, 
hospitals and other health care stings are adequate microenvironments for developing 
resistance [8-9]. Antibiotic resistances has important influence on patient morbidity and 
mortality and in the United States more than 50% of all hospital-acquired infections are 
caused by antibiotic resistant bacteria [10-11]. Because of their high prevalence in 
hospitals, Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, and 
Staphylococcus epidermidis have become important members of the group of organisms 
that lead to nosocomial infections, and form biofilms on animate and inanimate surfaces 
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in hospitals. Biofilm is colonies of microorganisms, in which cells adhere to each other 
on a surface. In the biofilm form, cells excrete extracellular polysaccharides, which help 
to trap nutrients and prevent the detachment of cells [12]. The pathogen biofilms often 
act as a reservoir of contamination and infection and are likely disseminated by health 
care providers [13-15]. In hospitals, resistant bacterial strains favorably cause infections 
in particular sites such as urinary tract, respiratory tract, blood, surgical sites due to 
insertion of catheters and invasive medical interventions, joints following implantation 
of implants, and prosthesis [16-18]. One of the most remarkable agents of hospital-
acquired infections is methicillin-resistant Staphylococcus aureus (MRSA). It is a 
common source of ventilator-associated pneumonia (VAP), catheter associated 
infections, joint infections and infective endocarditis. In addition to S. aureus, other 
Staphylococcus species, E. coli, Enterococcus species, Pseudomonas aeruginosa, 
Candida albicans, and Klebsiella pneumoniae are also resistant strains and important 
causative agents of hospital-acquired infections [16,19] 
1.1.1 Catheter Related Infections: Intravenous (IV) catheters are the supplementary 
part of the patient care since 1935, when Dr. Forsmann inserted the first catheter. IV 
catheters are used to administrate IV drugs, nutrients, blood, to collect blood sample and 
to observe blood hemodynamics. While most IV catheters are relatively short (< 5 cm) 
and inserted to smaller veins, central vein catheters (CVC) are longer (> 15 cm) and are 
inserted to larger veins. Catheters are mostly inserted to patients who currently have an 
underlying health problem, which makes them more susceptible to infections [1]. 
Therefore catheter related blood stream infections (CR-BSI) (or also called as catheter 
related bacteremia (CRB)) are one of the most common challenges of catheter usage and 
! 4!
important part of HAIs. The source of the CR-BSI might be intrinsic, such as the 
catheter and/or catheter insertion equipment are already contaminated before the 
insertion, or might be extrinsic such as the catheter gets contaminated during insertion or 
during time it is placed on patient. Extrinsic contamination can occur due to natural flora 
of the patient or the spread of other microorganism from the hospital environment [20]. 
Figure 1 shows potential routes of contamination on IV catheter. Klebsiella, 
Enterobacter and Pseudomonas species are most common sources of the intrinsic 
contamination and Staphylococcus species are the most common source of the extrinsic 
contamination. 
 
Figure 1: Potential routes of contamination in catheters. (From: 
http://www.arrowintl.com/products/PressureCVC/help_prevent_infection/) 
Not only IV catheters but also urinary catheters and gastrointestinal (GI) catheters may 
cause catheter related infections. However IV catheter-related infections are relatively 
more dangerous than GI and urinary catheter related infections because IV catheters are 
in direct contact with blood stream, and lead sepsis. It was shown that nutrition through 
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nasogastric tube is directly related with nosocomial infections especially in pediatric 
intensive care units [21]. Since the inserted catheter is a foreign material, the host reacts 
against the catheter by producing fibrinous film outer and inner surface of the catheter, 
which is an appropriate surface for microorganism to form biofilm and may lead to 
infection on the catheterization site. Sterile insertion technique, topical antimicrobial 
solutions and antimicrobial catheter lock solutions have shown efficiency against the 
catheter related infections. Citrate-based solutions are currently in use as catheter lock 
solution. A high concentration of citrate (~30%) is required for prevention of infection in 
catheters, and many times it leads to leakage in blood stream. Leakage of citrate solution 
in to bloodstream may cause calcium complexation and hypocalcaemia, which can be 
followed by ventricular arrhythmia and sudden death [22,23]. Another approach to 
prevent catheter related infections is to use antibiotic based lock solutions. However 
aminoglycoside lock solutions are not effective as desired levels against Staphylococcus 
species and may reach toxic serum levels in case of leakage to bloodstream. Also 
gentamicin heparin lock solutions are currently used but because of low solubility of 
gentamicin, it remains ineffective on biofilms and also leads the development of 
resistance. Minocycline can be considered as antimicrobial catheter lock solution but it is 
no longer available for IV use, and also leads bacterial resistance. Overall antibiotic-
based lock solutions are not capable to eradicate catheter-related infections as anticipated 
since microbial colonization in catheters is in biofilm form and it is difficult to inactivate 
embedded biofilms [24]. Antimicrobial impregnated catheters (chlorhexidine, antibiotic, 
silver) are effective on prevention of catheter associated infection to some extend, 
nevertheless still there is a high rate of catheter related infection on patients with 
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catheterization for more than 5 days [25]. As the rate of urinary catheterization is 
relatively high (10% of all hospitalized patients), catheter related urinary tract infections 
(UTI) are common type of hospital-acquired infections. The risk of catheter-related 
urinary tract infections increase proportional to duration of catheterization (daily 3-10% 
per day and 26% of patients catheterized for 2-10 days) and almost 100% of patients 
catheterized for 4 weeks end up with urinary tract infections (cystitis, pyelonephritis) 
and bacteriurira. 4% of such patients with catheter related UTI develop bacteremia and 
13-30% die due to the infection [1,26]. Enteric Gram-negative organisms along with 
natural perineal flora including Enterococcus and Candida species are most common 
sources of UTIs. Under normal conditions urethral flora is tend to migrate into bladder, 
however these organisms are washed out due to urination. When the catheter is placed in 
to urinary tract, this flushing mechanism is not effective and natural flora causes 
colonization, which results in UTI. Also reflux from drainage bag increases the risk of 
infection [26,27]. In the urinary tract, microorganisms can be present in planktonic 
and/or biofilm forms. Even though planktonic forms of bacteria usually are not capable 
of starting infection, biofilm growth on the surface of the catheter is considered main 
risk factor for UTIs. Many antimicrobial agents are incapable to penetrate through 
biofilm and eradicate colonization and prevent UTIs. Prophylactic antibiotic treatment 
prior to catheter insertion may cause toxicity and doesn’t protect patients against 
antibiotic resistant bacteria. Because of resistant bacteria, there is no agreement on the 
duration of prophylactic and post infection treatment time, which makes UTIs a major 
challenge for health care professionals and threat for patients (like other HAIs) [28-29].  
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1.1.2 Ventilator Associated Pneumonia: Nosocomial pneumonia is the infection of the 
parenchymal tissue of the lung and occurs within 48 hours of admission to hospital. 
Even though there is no consensus for definition of the ventilator-associated pneumonia 
(VAP), symptoms such as; progressive pulmonary infiltration with fever, leukocytosis 
and purulent tracheobronchial secretion within 48 hours following the endotracheal 
intubation is considered as VAP [30]. VAP comprises around 15% of HAIs, and it is the 
most common cause of deaths due to HAIs having > 75% of mortality rate [1]. Similar to 
catheters, since the endotracheal tube is a foreign material, patient’s body shows reaction 
that is followed with fibrinous development around the tube leading biofilm growth. 
Also presence of the endotracheal tubing causes chemical and mechanical injury on the 
ciliated epithelium, which is the first-line of defense mechanism of the body in upper 
respiratory tract. Patients receiving mechanical ventilator support are severely ill, 
debilitated, and are susceptible to infections [5]. Consequently loss of protective 
mechanism and the presence of favorable environment for biofilm formation following 
aspiration of contaminated secretions, infection in the respiratory tract becomes 
inevitable. S. aureus, K. pneumonia, E. coli, Enterobacter species, P. aeruginosa, 
Acinetobacter species and Candida species are common pathogens responsible for the 
VAP [31]. Selective decontamination therapy that utilizes the administration of non-
absorbable antibiotics through the oral cavity, with the short course of prophylactic IV 
antibiotic administration is capable to prevent VAP. But it is not preferentially in use 
except Netherlands due to potential risk of toxicity and development of resistance. 
Nebulization of gentamicin has shown eradication of biofilm in endotracheal tube, and 
presented better prevention compared to systemic administration of cephalosporin but 
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with a risk of resistance [32].  Also effect of chlorhexidine oral rinse is less understood, 
and may lead to the colonization of gram-negative bacteria [33]. 
1.1.3 Surgical Site Infections: Surgical site infections (SSI) are the type of hospital-
acquired infections that occur within 30 days of the surgery or within 1 year following 
implantation of a medical device, implant or prosthesis. Surgical site infections are 
identifiable 3 days following surgery, however identification of infections after 
implantation of a medical device takes longer time (weeks to months) [1,34]. It is 
determined that SSIs increase duration of hospital stay by 7-10 additional days, and 
increase mortality rate by 2-11 times and put additional average $3000 of cost per 
patient compared to other patients, who don’t have surgical site infections [35,36]. Skin 
incision eliminates the barrier function of the skin and makes the patients more 
susceptible to infections. Also presence of foreign materials such as suture, drainage 
tube on the surgery site, increases the risk of SSI. For instance, 105 CFU per gram of the 
tissue remarkably increase risk of SSI and the presence of silk suture on the surgery site 
makes 102 CFU per gram tissue capable to cause SSI [37]. Depending on the surgical 
procedure, SSIs can occur on skin, subcutaneous tissue, deep soft tissue (fascia and 
muscle) and organ. Also following joint replacement surgeries, prosthetic joint infection 
(PJI) is an important part of SSIs with 0.5%-2% incidence, high mortality and morbidity 
rates and with additional cost [41]. Figure 2 depicts the CDC classification of surgical 
site infections [38].  
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Figure 2: CDC classification of surgical site infections. [38] 
Depending on surgical procedure, usually isolates from surgical sites infections are 
polymicrobial and consist of both aerobic and anaerobic Gram-positive and Gram-
negative microorganisms. S. aureus, S. epidermidis, Enterococcus species, E. coli, C. 
albicans from patient’s natural flora, are reported as common sources of surgical site 
infections. Due to excessive antibiotic use, MRSA and Vancomycin resistant 
Enterococcus (VRE) are increasingly isolated from surgical site infections [39,40]. 
Prevention and control of surgical site infections can be classified as; preoperative 
patient care, intraoperative patient care and postoperative patient care. As apart of 
preoperative care, preoperative showers reduce bacterial load on patient’s skin however 
a definite correlation with reducing SSIs has not been established. Shaving surgery site 
is also common practice for SSI prevention [40,42]. Skin disinfection is the most 
common method of preoperative and intraoperative infection control. Chlorhexidine and 
povidone iodide solutions are used with or without alcohol for preoperative surgical site 
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preparation. Presence of alcohol has an ignition risk, where the electro surgery 
techniques are used and also chlorhexidine and povidone iodide are toxic to tissues. 
Wound drains placed at surgical sites are used to expel accumulated blood and exudate, 
which are adequate environments for bacterial colonization. Drains also provide access 
to pathogens to surgery site, and therefore closed system wound drainage should be 
preferred [1,42,43].  Since early 1980s antibacterial surgical sutures are in consideration. 
Triclosan coated surgical sutures are currently in use [44]. Triclosan [5-chloro-2 (2,4-
dichclorophenoxyphenol)] is a broad-spectrum antimicrobial agent and has widespread 
usage in soaps, hand sanitizers, toothpastes, etc. Also its antimicrobial efficiency 
increases when it is combined with antibiotics [45]. Several in vitro studies have shown 
that triclosan coated sutures are capable to reduce methicillin susceptible and 
methicillin-resistant S. aureus as well as S.epidermidis and E. coli. Edmiston et al. have 
reported that triclosan coated sutures decrease adherence of MRSA, S. epidermidis, VRE 
and E. coli on the suture surface.  However, excessive use of triclosan-coated suture 
caused emergence triclosan resistance pathogens such as P. aeruginosa. Animal studies 
revealed that antibacterial triclosan coated sutures can be effective against ~50% of 
pathogens responsible for SSIs [44,46,47].  Additionally triclosan has potential risk of 
toxicity. Fiss et al. has reported that triclosan sutures produce chloroform, which is a 
carcinogen, when it comes in contact with chlorine-treated tap water. Separate animal 
studies have shown that it has toxic effect on animals. For example triclosan exposure to 
tadpoles accelerated metamorphosis, and decreased sperm production in rats [48,49]. 
Even though in vitro studies showed efficient antimicrobial efficiency of triclosan coated 
sutures, several clinical studies reported that any of triclosan-coated sutures do not have 
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significant antimicrobial efficiency as compared to uncoated sutures and its 
antimicrobial efficiency remains unclear [50].    
1.2 Antisepsis, Disinfection and Sterilization:  
In the consideration of biocidal process, there is an important distinction between 
sterilization, disinfection and antisepsis. Therefore it is important to recall some 
fundamental definitions. The term decontamination is a general term that refers to either 
removal or inactivation of microorganisms that is combination of cleaning and 
disinfection or sterilization. Decontamination generally covers sterilization, disinfection 
and antisepsis. Antisepsis is defined as the inhibition of microorganisms in or on living 
tissues that is capable to reduce or prevent the risk of infection. Certain number of 
bacterial cells is required to cause infection. Disinfection is the process of reducing the 
number of viable pathogenic organisms, so they will not be able to cause infection. 
Disinfection and antisepsis are used interchangeably, however antisepsis usually refers 
to the chemical disinfection of living tissue while disinfection is mostly applicable 
inanimate surfaces. Sterilization is the term that refers to destruction or removal of all 
living microbial forms of life (vegetative cells and spores) [1,8,12,51-53]. D-value is the 
indicator of the efficiency of an antimicrobial agent or disinfection or sterilization 
method. D-value is defined as the time required to achieve 1 log reduction (90%) of a 
given microbial population and expressed as; 
! = ∆!!"#$/∆! 
!!!"#$% = −1/! 
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where as Δlog N is the log10 reduction of microbial population, ΔT is change in the time 
and m is the slope of the survival curve [8,12]. 
1.2.1 Antisepsis Methods: Living tissues are more delicate to be damaged compared to 
inanimate surfaces. Therefore antiseptics should fulfill the requirement of nontoxicity. In 
general antiseptics should have following features:  
• Broad spectrum biocidal effect against bacteria, fungi and viruses 
• Rapid inactivation effect 
• Less or no irritation, damage or toxicity to the living tissue 
• Persistency or residual biocidal effect [1,8,54]. 
Skin hygiene, pre-surgical disinfection of skin, treatment of wound infections and 
treatment of mucosal membranes are considered as the important applications for 
antisepsis. Pre-surgical disinfection of the skin is one of the most important steps in 
order to prevent surgical site infections [55,56]. Disinfection of skin prior to surgical 
procedure consists of cleaning of site of incision, followed by antiseptic application. 
Currently alcohols, iodine tinctures, iodophors and chlorhexidine are the most widely 
used biocides for the purpose of skin disinfection. Also plain soaps and antimicrobial 
soaps provide physical removal and some inactivation of microorganisms [57,58]. Table 
1 summarizes antimicrobial spectrum and toxicity of most widely used skin antiseptics.  
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Table 1: Examples of most widely used skin antiseptics. [8]  
Biocide Antimicrobial activity Persistence Toxicity 
Alcohols Bactericidal, fungicidal, 
virucidal 
None Skin drying and 
irritancy 
Chlorhexidine Bactericidal, fungistatic, some 
virucidal 
Yes Keratitis, irritancy, 
ototoxicity 
Iodine and iodophors Bactericidal, fungicidal, 
virucidal 
Some Irritation and toxicity 
Chloroxylenol Some bactericidal, fungistatic, 
some virucidal 
Yes Mild irritancy, 
allergic reactions 
Triclosan Some bactericidal, fungistatic Yes Irritancy, potential 
carcinogenesis 
 
1.2.2 Disinfection Methods: According to application of disinfection method, 
disinfection processes can be classified as physical and chemical disinfection [59].  
 Processes that utilize heat are the most widely used physical disinfection method. 
In the heat disinfection method, the rate and the efficiency of the disinfection are directly 
dependent on applied temperature and exposure time [60]. Uniform exposure of heat to 
the material that is being disinfected is crucial. Heating can damage liquids, especially 
organic material containing heat sensitive materials. Also heat disinfection can cause the 
release of endotoxins, which are pyrogenic and resistant to disinfection temperatures 
[61]. Nonionizing radiation (UV, IR radiation and microwaves) is another method of 
physical disinfection. UV lights are used for the disinfection of different materials 
including liquids and food. It is also cost effective method for area decontamination, 
such as biological safety cabinets, operating rooms, food processing areas and air 
conditioning systems [62]. Presence of organic and inorganic matter reduces the contact 
of UV radiation with surface and limits the efficiency of disinfection method. UV 
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irradiation doesn’t have any residual effect, which increases the risk of recontamination 
right after the application of UV irradiation. The adverse effects of UV involve burn and 
irreversible eye damage [63-64].  
 IR lamps are used as heat sources for the disinfection of heat sensitive materials. 
Penetration issue is a remarkable limitation of nonionizing radiation disinfection 
methods [65]. Filtration provides physical removal of microorganisms rather than 
inactivation; however biocide integrated filters are also for more efficient disinfection 
[66]. Filtration method can remove wide range of contaminants including 
microorganisms, biological molecules such as endotoxins and chemicals such as metals 
and salts, depending on the pore size of the filter. Filtration is considered as physical 
sterilization method as well [66].  
 Besides physical disinfection methods, a wide range of chemicals is currently in 
use for disinfection. Different acids are used as preservatives. Acetic acid, propionic 
acid, benzoic acid, citric acid and sorbic acid are acids used for antimicrobial purposes. 
Acids possess mostly bacteriostatic and fungistatic properties at the concentration that 
they are used. At higher concentrations, which are needed for microbial inactivation, 
acids cause irritation and can cause allergic reactions, and corrosion of surfaces 
including metals. Some microorganisms are capable to use acids as carbon sources and 
able to degrade them [8,59]. Alkalis are able to break down proteins into peptides, and 
this property is utilized for the cleaning and disinfection of blood fractionating columns. 
Strong alkalis are very harmful to skin and mucosal membranes, and corrosive to metal 
surface [8,59]. Reaction of alkalis with metal surfaces may lead to release of flammable 
gases. Glutaraldehyde, orthophthalaldehyde (OPA) and formaldehyde are the most 
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common aldehydes used as disinfectant, fixative and preservative [66]. Formaldehyde is 
used in fumigation process, and is sporicidal with extended contact time. Formaldehyde 
is environmental friendly; it breaks down to carbon dioxide and water through 
conversion to formic acid in few hours however it is highly toxic, irritant, mutagenic, 
carcinogenic, causes irreversible olfactory tissue damage, and even at very low 
concentrations (0.05 ppm) causes skin and eye irritation [52,67]. Glutaraldehyde is used 
for the disinfection of heat sensitive liquids and medical devices such as endoscopes. 
Glutaraldehyde is highly irritant to skin, eye mucosal membranes and respiratory tract. 
Even as low as 0.3 ppm concentration, glutaraldehyde causes respiratory tract irritation 
[68,69]. Isopropanol, ethanol and n-propanol are common alcohols used as disinfectants. 
Alcohols show the optimum antimicrobial effect in the presence of water, therefore 60-
70% alcohol solutions are in practice. Alcohols show rapid inactivation of bacteria (70% 
ethanol within 30 seconds) and relatively slower activity on fungus (70% ethanol >2 
minutes). Even though alcohols are not sporicidal they have sporstatic activity [59,70].  
Alcohols are flammable therefore precautions should be taken during handling and 
application, and cause drying and irritation on skin, and occasionally allergic reactions. 
Extended use of alcohols may result cracking of particular delicate inanimate surfaces 
[66]. Biguanides are the chemical compounds that contain C2H5N7 ligand, including 
chlorhexidine. Chlorhexidine is the most widely used biguanide not only in hospital 
environment, but also in antimicrobial wound dressings, antimicrobial soaps and mouth 
wash solutions. Biguanides are broad-spectrum bactericidal agents (except Pseudomonas 
species) but less virucidal [66]. Some bacteria have developed tolerance to biguanides 
through plasmid-mediated antibiotic resistance and it is speculated to trigger antibiotic 
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resistance. Even though not common, it is reported that chlorhexidine (also other 
biguanides) can cause anaphylactic shock and they are irritant to eyes and skin [71,72]. 
Halogens are group of elements that have high electronegativity and reactivity including, 
fluorine, chlorine, bromine and iodine. Iodine is the most widely used skin antiseptic, 
used as surgical scrubs, for the decontamination of skin prior to surgical interventions 
and for the treatment of wounded skin and burns. Chlorine is one of the most widely 
used chemical agent for water disinfection and responsible for the control and prevention 
of the transmission of earlier common diseases such as cholera and typhoid. Even 
though limitations, chlorine is used as wound and mucosal membrane antiseptics. One of 
the remarkable applications of chlorine is inanimate surface disinfection as in the form 
of hypochlorite, commonly known as bleach [74]. Chlorine is a reactive agent that has 
strong corrosion effect on metal surfaces. Repetitive application of chlorines cause skin 
irritation and hypersensitivity and high concentrations of chlorine is poisonous to 
humans. Reaction of chlorine with particular organic compounds leads to generation of 
carcinogenic by-products such as; chloroform [66]. Iodine solutions have toxic effect 
when their concentration exceeds 5% and they also cause irritation of skin and mucosal 
membranes. Iodine solutions have corrosive effect on metal and some plastic surfaces. 
Disadvantages of iodine solutions are notably reduced with the use of iodophors (such as 
povidone-iodide (PVPI)) but there are some speculative studies reporting complications 
of PVPI such as; impairment of thyroid function [75]. Variety of metals (including 
heavy metals; such as mercury, lead, arsenic, cadmium) has been traditionally used for 
disinfection purposes, however accumulation of metals in the tissues, and high toxicity 
limited their applications. Currently copper and silver are mostly utilized metals for 
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disinfection [12]. Copper is bactericidal even at low concentrations and mostly 
fungistatic and fungicidal in to some extent, but it is not sporicidal (but have sporstatic 
effect at higher concentrations). Copper is used for water disinfection as an alternative to 
chlorine application and for the control of Legionella spread in the hospital pipelines. 
Also copper is able to prevent biofilm formation, therefore it is used as preservative on 
various surfaces including some medical devices [76]. Silver nitrate (AgNO3) and silver 
sulfadiazine (AgSD) are mostly used silver containing disinfection agents, in which 
silver is in Ag+2 active form. Silver sulfadiazine containing preparations are used to 
prevent infection on skin burns, mucosal membranes and eyes. Silver is also used for the 
recreational water disinfection. Silver impregnated dressings are currently used 
especially around catheters for the control and the prevention of HAIs. Silver has 
bactericidal and fungicidal effect at even low concentrations, but have very limited 
virucidal effect [74]. Overuse of silver may cause burns on skin, delayed wound healing, 
and although rarely reported severe toxicity. Also silver resistance in E. coli and some 
Pseudomonas species has been reported [78]. Copper is toxic at higher concentrations 
and causes skin irritation. Some bacteria and fungus including E. coli and Candida 
species can generate resistance against copper [66]. Peroxygens are chemical compounds 
containing a single oxygen-oxygen bound or peroxide ion (O-O-2). Peroxides are 
important group of chemical disinfectants including hydrogen peroxide, chlorine dioxide 
and peracetic acid (PAA). Peroxygens are considered as environmental friendly since 
they decompose to water and oxygen. Hydrogen peroxide is used as antiseptic agent at 
3% concentrations. Benzoyl peroxide is one of the most widely used organic peroxide 
for disinfection purpose and used for the treatment of acne [8,66]. Due to its rapid 
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biocidal activity, hydrogen peroxide is used as surface disinfectant with in combination 
of PAA. PAA is highly unstable; therefore it is used synergistically with acetic acid 
and/or hydrogen peroxide. In medicine, PAA is considered as an alternative to 
glutaraldehyde for low temperature disinfection of reusable medical devices such as 
endoscopes [79]. Hydrogen peroxide demonstrates bactericidal, fungicidal, virucidal and 
sporicidal effect at relatively higher concentrations. Hydrogen peroxide gas is reported 
effective against parasite eggs, prions, and bacterial endotoxins. PAA is more potent 
oxidizer compared to hydrogen peroxide and shows broad spectrum antimicrobial 
activity at relatively low concentrations (0.35%), however it is more irritating to skin, 
mucosal membranes and respiratory tract [59]. When hydrogen peroxide comes in 
contact with particular surfaces such as; brass, copper, cellulose-containing materials, 
degrades rapidly and loses its activity. High concentrations of hydrogen peroxide cause 
instantaneous burn on skin and mucosal membranes. Some studies are available 
reporting allergic reactions of hydrogen peroxide [75]. Other chemical disinfection 
agents include antimicrobial dyes, anilides and diamidines [8, 52].  
1.2.3 Sterilization Methods: In contrast to disinfection, sterilization is the process that 
inactivates all living forms of microorganisms including bacterial spores. Theoretically, 
any disinfection method that is effective against broad range microorganisms and spores 
can be developed as sterilization method. But it is important to emphasize that 
sterilization is a validated process that provides totally alive microorganism-free product 
[1,8,12]. Requirements for sterilization validation are determined in ISO 14937 
standards, which are as follows: 
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• Characterization of the biocidal agents(s), including safety, 
antimicrobial efficacy and the effects of materials. 
• Characterization of the sterilization process and any delivery 
equipment. 
• Definition of the sterilization process for a given application 
• Definition of the product to be sterilized within the process 
• Validation of the sterilization process for its intended use [80]. 
 Physical sterilization methods utilize; steam sterilization, dry heat sterilization 
and ionizing radiation application and chemical sterilization methods utilize the 
application of epoxides, low temperature steam formaldehyde (LTSF), high temperature 
formaldehyde-alcohol, hydrogen peroxide, electrolyzed water and ozone.    
 Steam sterilization is one of the most widely used sterilization method that 
utilizes the gas form of water. In the stem sterilization process increased pressure in a 
fixed volume sterilization chamber, increases the boiling point of the water so higher 
sterilization temperatures can be achieved [8]. Steam sterilization process is made in 
controlled containers, which can resist high gas pressures required for sterilization, 
called autoclaves. In the steam sterilization process, steam is used as the source of heat, 
which causes rapid denaturation of proteins and nucleic acids. High pressure increases 
the penetration of steam through the protective layers of microorganisms, especially in 
bacterial spores. Steam sterilization is typically performed at 121OC and 15 psi for at 
least 15 minutes, but can also be performed at temperatures and pressures, where 
sterilization can be achieved faster. Steam sterilization method is mostly used for the 
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sterilization of reusable medical devices such as metal surgical equipment [66,81]. Dry 
heat sterilization methods include sterilization ovens and incineration. Incineration is 
performed by passing materials through a flame and used for the disposal of medical 
devices. Sterilization oven is basically a chamber where the heated air is fed during 
sterilization. Dry heat sterilization is an effective dehydrogenation method however it 
has limited application due to heat sensitivity of materials [81].  
 Radiation sterilization method utilizes ionizing radiation such as γ radiation 
which is capable to penetrate through all cellular protective layers.. 60Co and 137Cs are the 
most common sources of γ radiation for sterilization purposes. Ionizing radiation 
sterilization process can be applied to wide range of materials including, medical 
devices, prosthesis, pharmaceutical products, food and water. Nucleic acids, particularly 
DNA, are the main target of ionizing radiation, where it causes mutations, DNA breaks 
causing cell death. Also ionizing radiation exposure results with intracellular free radical 
formation that enhances sterilization effect. Use of radiation sterilization is limited due 
to safety requirements and risks on human health [66,81].     
 Despite of the availability of various chemical disinfectants, limited amount of 
them have been developed for sterilization applications. Chemical sterilization methods 
are alternatives to physical sterilization methods, for the sterilization of materials that are 
sensitive to physical methods such as thermal sensitivity [8,66,81]. Ethylene oxide  (EO 
or ETO) is a flammable gas that is used for the sterilization of heat sensitive medical 
equipment and pharmaceutical products. Because of its penetration ability, ethylene 
oxide is used for the sterilization of medical devices having long lumens such as 
endoscopes. Activity of EO is directly dependent on the presence of humidity and it 
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shows excellent sterilization features at 40-80% humidity. Its compatibility with wide 
range of materials makes ethylene oxide an appropriate solution for the sterilization of 
sensitive medical devices. Ethylene oxide shows its activity through alkylation process, 
where it is tend to replace any available hydrogen atom with hydroxylethyl radical that 
causes crosslinking of nucleic acids and proteins [66]. Ethylene oxide is reported as 
mutagenic, carcinogenic, teratogen and toxic at relatively low concentrations, and further 
exposure to ethylene oxide can cause skin, eye, mucosal membrane irritation, and 
sensitivity in the respiratory tract, which leads to allergic reactions and asthma [81]. 
Formaldehyde is used for sterilization in two different methods: low temperature steam 
formaldehyde (LTSF) and high temperature alcohol-formaldehyde sterilization. LTSF is 
used for the sterilization of reusable medical devices in health care facilities. High 
temperature alcohol-formaldehyde sterilization system combines the biocidal effect of 
steam penetration, formaldehyde and alcohols, and usually used for the sterilization of 
dental equipment [8,66,]. Sterilization of porous materials with formaldehyde requires 
further aeration due to formaldehyde absorbance, and formaldehyde can polymerize with 
the material. As previously described, formaldehyde is toxic, mutagenic and causes 
irritation in skin, mucosal membranes and eyes [67]. As previously mentioned, hydrogen 
peroxide is a potent oxidizing agent with a broad range of antimicrobial efficacy. Even 
though relatively low concentrations of hydrogen peroxide demonstrate bactericidal, 
fungicidal and virucidal effect, higher concentration (25-60%) is needed for sporicidal 
activity. In order to enhance sterilization effect, hydrogen peroxide can also be combined 
with different oxidizing agents such as PAA. In gaseous form lower concentration of 
hydrogen peroxide can provide sporicidal activity, therefore in heated or vacuum 
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chambers hydrogen peroxide is used as sterilization [81]. There is an increasing interest 
in hydrogen plasma gas sterilizers. In these systems, following the exposure of hydrogen 
peroxide in to the sterilization chamber, plasma discharge is generated which also 
generates ozone and reactive oxygen species contributing biocidal effects [83]. 
1.3 Plasma: Plasma is first described by Langmuir in 1930 as the fourth state of matter, 
which consists of ionized gas, charged particles, free electrons, electrically excited 
particles and other reactive species, and constitutes ~99% of the universe [84]. 
Depending on the gas temperature and electron temperature, plasmas can be classified as 
thermal and non-thermal or equilibrium or non-equilibrium plasma. In all plasmas that 
are generated in the presence of an electric field, electrons receive energy much faster 
than heavier particles. In non-thermal plasmas cooling of heavier particles, such as gas 
ions and uncharged atoms, is much faster than the energy transfer from heated electrons 
to their environment, which leads to the gas to remain at low temperature. As opposed to 
non-thermal plasmas, in thermal plasmas energy transfer from electrons to heavier 
particles is in equilibrium to energy transfer from heavier particles to the environment, 
where in heavier particle’s temperature is almost equal to electron temperature. In other 
words, in non-thermal plasmas electron temperature is much higher than ambient gas (Te 
>> Tg) and in thermal plasmas electron temperature is in equilibrium with ambient gas 
(Te=Tg) [85]. Plasma can exist in nature or can be generated artificially under an electric 
field. Sun and lightning are examples of natural thermal plasmas, DC corona discharge is 
an example of thermal plasma generated by electric field, aurora borealis (also know as 
northern lights) is an example of natural non-thermal plasma, and plasma jet and 
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dielectric barrier discharge (DBD) plasma are examples of non thermal plasmas 
generated by electrical field (Figure 3) [85-88].  
 
 
 
Figure 3: Examples of natural and man-made plasmas:(a) Lightning, (b) Aurora borealis 
(c) Dielectric Barrier Discharge (DBD) Plasma !
1.3.1 Non-Thermal Dielectric Barrier Discharge (DBD) Plasma: DBD is known for 
more than a century, and first introduced by Werner von Siemens for ozone production 
[89]. DBD plasma setup employs one high voltage electrode and one grounding 
electrode, where at least one of the electrodes is insulated with a dielectric material. 
Depending on the arrangement of electrodes, DBD plasma setup can be utilized as 
planar or cylindrical electrodes as shown in Figure 4 [94]. Most widely used dielectric 
materials in DBD plasma setup are glass, quartz and some ceramic materials. When AC 
is applied to DBD plasma setup, the dielectric material limits the current and prevents 
spark formation. When the generated electrical field is enough to break down gas, 
electron discharge starts between high voltage and grounding electrodes. The dielectric 
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constant, thickness of dielectric material and the derivative of applied voltage with 
respect to time determine gas breakdown point. Because of the low mean current in spite 
of high breakdown voltage in air at atmospheric pressure, DBD can be applied to living 
materials [90-91]. According to method of application, there are two types of plasma 
treatments: direct plasma treatment and indirect plasma treatment. In direct plasma 
treatment, material that is being treated acts as a grounding electrode, and electron 
discharge gets in direct contact with the material that is being treated. In indirect 
treatment a jet of plasma products (plasma after glow) get in contact with material that is 
being treated. For indirect treatment a metal mesh can be used in order to capture 
charged particles [92]. Besides direct and indirect plasma treatment, recently a new 
plasma treatment has been reported by our laboratory, which is called fluid-mediated 
plasma treatment. Fluid-mediated plasma treatment can be considered as a combination 
of direct and indirect plasma treatment, where the plasma treatment of liquid fits the 
definition of direct plasma treatment. In terms of transferring plasma generated product 
and species with fluid, it fits to the definition of indirect plasma treatment [93].  
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Figure 4: Upper row depicts the different planar arrangements and lower row depicts the 
different cylindrical arrangements of DBD setup according to the position of dielectric 
material   [94] 
 Floating electrode dielectric barrier discharge (FE-DBD) plasma is employed for 
the living tissue treatment, in which the living tissue serves as the counter, grounding 
electrode [95].  
 When an electrical field is applied between two electrodes, first an electron 
avalanche is initiated by a free electron, which produces a streamer. In few nanoseconds, 
the streamer forms a conducting channel of weakly ionized plasma. An intense electron 
current will flow through this channel till the local electric field is terminated due to the 
accumulation of charges on the dielectric surface. After the termination of electron 
current between the electrodes, high volume of vibrational and electronic excitation in 
the channel volume still exist along with charges deposited on the surface, which is 
called as microdischarge remnant Figure 5. The microdischarge remnant facilitates the 
formation of new microdischarge in the same location, when the polarity of the applied 
voltage changes. 
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Figure 5: Process of microdischarge formation [96]. 
 
This phenomenon allows us to see single filaments in DBD. When microdischarges form 
at different location on all over the electrode surface, the discharge becomes uniform. In 
case of a microdischarge remnant is not totally dissipated before the formation of the 
next microdischarge is called memory effect [96]. Typical microdischarge parameters in 
a 1 mm discharge gap in atmospheric pressure air are shown in the Table 2. 
Table 2: Typical microdischarge parameters in a 1 mm discharge gap in atmospheric 
pressure air. [97] 
Lifetime 1-20 (100) ns Filament Radius 50-100 μm 
Peak current 0.1 A Current Density 0.1-1kAcm-2 
Electron density 1014-1015 cm-3 Electron energy 1-10eV 
Total transported 
charge 
0.1-1 nC Reduced electric field E/n=(1-2)(E/n)paschen 
Total dissipated 
energy 
5 μJ Gas temperature ~300 K 
 
1.3.2 Plasma Chemistry: When an electrical field is applied to a gas, seed electrons are 
accelerated to obtain higher kinetic energy. Collision of these electrons with ambient gas 
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atoms and molecules leads to formation of positively charged atomic and molecular ions 
due to the electron loss from ambient gas. Electrons that unbound from ambient gas are 
rapidly accelerated by the applied electric field and take part in ionizing collisions with 
other atoms and molecules [88].  Chemical species generated by plasma treatment, play 
major role on the biological effects of non-thermal plasmas [85,98,99]. Plasma produces 
biologically active reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), 
hydroxyl radical (OH!), ozone (O3), superoxide (O2−), singlet oxygen (O2(1Δg)) and 
reactive nitrogen species (RNS) such as nitric oxide (NO), nitrite (NO2−), nitrate (NO3−), 
peroxynitrite (ONOO−) [93,100-102]. During the plasma generation, energy transfer 
from electron discharge region to ambient gas triggers various effects such as excitation 
and ionization. These processes cause O2, N2 molecules in the ambient air to raise their 
excited states and hemolytic braking of H-OH and O=O bonds resulting the formation of 
H!, OH! and O! radicals. Chemical reactions induced by electron discharge can be 
summarized as follows: 
 Dissociation of oxygen molecules by electron impact leads to ozone formation: 
e- + O2 " O! + O! + e-      (1) 
M + O + O2 " O3!                (2) 
O3! + M " O3 + M            (3) 
Reaction of free electrons in the plasma discharge is able to convert molecular oxygen to 
superoxide anion: 
    e- + O2 " O2-                (4) 
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Electron impact on nitrogen molecules leads to formation of nitrogen atoms: 
e- + N2 " N + N + e-      (5) 
Plasma discharge causes hydrolysis of water molecule and electron impact on excited 
water molecules leads to formation of hydroxyl radical: 
H2O " H+ + OH-       (6) 
e- + H2O " H! + OH!     (7) 
Fixation of H! radicals on O2 and reaction of hydroxyl radical with ozone and hydrogen 
peroxide generate peroxyl radical: 
H! + O2 + M " HO2! + M       (8) 
OH! + H2O2  " HO2! + H2O            (9)      
OH! + O3  " HO2! + O2                  (10) 
Reaction of two hydroxyl radicals and two peroxyl radicals separately yields to 
formation of hydrogen peroxide, also in thermal plasmas reaction of peroxyl radical with 
ozone yields to hydrogen peroxide and molecular oxygen:  
OH! + OH! " H2O2                      (11) 
HO2! + HO2!  " H2O2 + O2          (12) 
In the discharge zone reaction between N2 and O2 yields the formation of NO with a 
series of reactions according to Zeldovich model:  
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N2 + O2 " 2 NO!         (13) 
N2 + O! " NO! + N!                     (14) 
N! + O2 " NO! + O!                     (15)  
N! + O! " NO!                             (16) 
In the gas phase dissociation of nitrogen and oxygen (reactions 1 and 5) yields to 
formation of nitric oxides, nitric acid nitrous acid:  
  3 NO2 + H2O " 2 H+ + 2 NO3- + NO           (17) 
                         2 NO " N2O4 + H2O " HNO3 + HNO2     (18) 
Reaction between nitric oxide and peroxyl radical and/or the reaction nitrogen dioxide 
and hydroxyl radical give rise to the formation of peroxynitrous acid: 
NO! + HO2 " ONOOH                 (19) 
NO2 + OH! " ONOOH                (20) 
In aqueous media, dissociation of peroxynitrous acid and reaction between nitric oxide 
and superoxide form peroxynitrite:  
ONOOH " ONOO- + H+             (21) 
NO + O2- " ONOO-                     (22)  
Above mentioned reactions occur in gaseous media, however products of given reactions 
are capable to diffuse into liquid media [103-108]. After plasma treatment of a given 
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liquid in air, pH reduction is well known and documented consequence of plasma 
treatment. Lowering pH of liquid is attributed to H+ cation via dissociation of plasma 
generated acids in the liquid medium [86,93,109-111]. Table 3 shows the primary acid 
base dissociation reactions in atmospheric air plasma treated liquid systems.   
Table 3: Primary acid-base dissociation reactions in atmospheric pressure plasma-
treated liquid system[103] 
Reaction pKa 
HNO3 " NO3- + H+ <0 
HNO2 " NO2- + H+ 3.3 
HOONO " ONOO- + H+ 6.8 
HO2 " O2- + H+ 4.7 
H2O2 " HO2- + H+ 11.75 
OH " O- + H+ 11.9 
H3O+ "  H2O + H+ <0 
H2O "  OH- + H+  
(Dissociation and electrolysis) 
15.74 
 
1.3.3 Plasma Medicine: Thermal plasmas are already in use in medicine for 
cauterization, tissue removal (ablation), cutting tissues, sterilization of thermally stable 
medical instruments [112-114]. Argon plasma coagulation (APC) technique is used to 
control bleeding during surgery and for the treatment of vascular abnormalities, such as 
hemangioma [115]. The Helium Thermal Ablation System (Helica) is used to ablate 
endometrial tissue in endometriosis. Another system called Coblation allows tissue 
ablation at lower temperatures with lesser damage on surrounding tissue [116-117]. Also 
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thermal plasma employing Argon gas is used as plasma scalpel that helps cutting tissue 
in a similar a way to cutting diathermy [118]. Thermal pulsing nitrogen plasma 
developed by Rhytec Inc. is used for cosmetic applications such as rejuvenation of skin, 
treatment of scars and wrinkles [119]. Besides thermal plasmas, there is an increasing 
interest on applications of non-thermal plasmas in medical field due to their possibility 
to use on living tissues. Following pages explain different applications of non-thermal 
plasma in medical field. 
1.3.3.1 Plasma Assisted Blood Coagulation: Blood coagulation is a natural response of 
the body in order to establish homeostasis following blood vessel injury. Non-thermal 
FE-DBD plasma treatment accelerates blood coagulation in vitro (Figure 5) [120]. It was 
reported that non-thermal FE-DBD plasma treatment enhances blood coagulation by 
activating some of coagulation proteins that leads rapid fibrinogen aggregation and by 
increasing Ca2+ ion concentration via a redox mechanism caused by hydrogen ions 
generated in plasma [120,121].  
 
Figure 6: Plasma assisted blood coagulation: (a) Untreated blood, (b) Blood droplet 
after 5 seconds of DBD plasma treatment. 
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In another study Kuo et al. reported enhanced blood coagulation following treatment 
with a portable non-thermal air plasma torch and the accelerated blood coagulation is 
attributed to stimulation of red blood cells (RBC) and platelets by plasma generated 
reactive atomic oxygen and NO. However, further studies are needed to confirm the 
contribution of NO to enhanced blood coagulation [122].  
1.3.3.2 Plasma Applications for Cancer Therapy: Recent studies show that non-
thermal plasma treatment can have a place in cancer therapy. Fridman et al. have 
reported that melanoma cells undergo necrosis at high doses (15 s at 1.4 W/cm2) of 
plasma treatment and apoptosis at lower plasma doses (5 s at 0.8 W/cm2) [123]. Also in a 
similar study Huang et al. reported deactivation of A549 human lung cancer cell line 
following 120 seconds of treatment with DBD plasma needle. Deactivation of A549 
cancer cells is attributed to generation of ROS and RNS during plasma treatment [124]. 
Vandamme et al. have tested antitumor activity of non-thermal DBD plasma on U87MG 
malignant glioma and HCT-116 colorectal carcinoma. They have reported, accumulation 
of cancer cells in S phase, which is an indicator of decreased cancer cell proliferation 
and formation of DNA damage leading to apoptosis and multiphase cell cycle arrest due 
to plasma generated ROS. They have also reported reduction of tumor volume after in 
vivo plasma treatment of U87 human glioma xenograft on mouse [125,126]. Kim et al. 
have suggested a new cancer treatment method with non-thermal plasma, where they 
have shown that cultured TC-1 lung carcinoma cells are more sensitive to non-thermal 
He (helium) microplasma jet treatment than cultured fibroblasts and undergo apoptosis 
[127]. Furthermore in addition to deactivation of cancer cells due to apoptosis, it was 
shown that non-thermal helium plasma torch inhibits the migration and inhibition of 
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SW480 colorectal cancer cells. Addition of O2 gas to He in the plasma jet improved the 
inhibition efficiency of migration and invasion of SW480, where these effects can be 
attributed to ROS generation during plasma treatment [128]. In brief, above-mentioned 
studies indicate that non-thermal plasma could be a promising method for cancer therapy 
in future.   
1.3.3.3 Applications of Plasma in Dentistry: Conventional oral cavity and dental 
treatment methods have pitfalls such as pain, and long-term treatment duration [129]. 
Park et al. have demonstrated the use of non-thermal plasma helium jet combined with 
30% H2O2 significantly increases tooth whitening compared to 30% H2O2 application by 
itself, which is conventional method for tooth whitening, without any thermal damage 
(Figure 6) [130,131]. ! 
 
Figure 7: Plasma assisted tooth whitening: Upper row; conventional method with 30% 
hydrogen peroxide, (a) before, and (b) after hydrogen peroxide treatment. Lower row; 
non-thermal plasma and 30% hydrogen peroxide combination, (c) before, and (d) after 
plasma assited hydrogen peroxide treatment. [131] 
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 Microleakage of dental fillings reduces the stability of dental restorative 
treatments and invites repetitive filling procedures. Treatment of dental surface has 
demonstrated significant surface modification on dentin, which leads the deeper 
penetration and better mechanical stability via increased bonding strength of filling 
materials [132]. Treatment of powder injection molded zirconia (PIM) implants with 
non-thermal helium plasma jet has increased the hydrophilicity of implant surface 
without altering microtopoghraphy, which leads to the enhanced bone integration on 
implant surface, bone implant contact ratio, bone volume on implants and implant 
removal torque [133]. 
1.3.3.4 Plasma Applications in Dermatology and Wound Healing: In vitro studies 
have revealed that non-thermal plasma treatment has a potential to induce wound 
healing, by reducing the microbial colonization and direct effects on skin cells. The first 
clinical trial on wound healing by using non-thermal, indirect Argon plasma jet 
(MicroPlaSter®), has shown that plasma treatment is capable to accelerate wound 
healing, by reduction of bacteria such as Klebsiella oxytoca and Enterobacter cloacae 
[134,135]. Figure 7 shows the progress of venous ulcer wound with the treatment with 
MicroPlaSter®  
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Figure 8: Treatment of venous ulcer: with 2-minute daily treatment with 
MicroPlaSter®. (a) Before treatment, (b) 7th and (c) 11th treatment [134]   
FDA has approved the plasma skin regeneration (PSR) technology, which is a thermal 
nitrogen plasma jet, for the treatment of wrinkles, superficial skin lesions, actinic 
keratosis, seborrheic keratosis and viral papilloma. Effects of PSR are attributed to 
controlled thermal damage due to rapid cooling of plasma that stimulates collagen, 
reduced elasticity production and the regeneration of photo-damaged skin [136,137].  
Emmert et al. has reported that the DBD plasma treatment for 30 days, 1 min/day has 
significantly improved the healing of atopic eczema, where they have observed the 
reduction of S. aureus colonization on the skin with reduced itching [138].  
1.3.3.5 Plasma Assisted Cell Transfection: The basis of the gene therapy is the 
introduction of the genetic material to the target cell via viral vectors, which may cause 
the virus-mediated adverse host response. Leduc et al. reported the transfection of  
hrGFP-II-1 plasmid in HeLa cells with the atmospheric pressure glow discharge torch by 
forming pores ranging between 4.8 to 6.5 nm without any DNA damage [139]. In a 
similar study Sakai et al. have transfected HeLa-S3, HT-1080 and MCF-7 cell lines with 
pEGFP-C1 plasmid using electric pulse-activated gas plasma generator, which increases 
membrane permeability by forming momentarily pores on the cell membrane [140]. 
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1.3.3.6 Plasma-Eukaryotic Cell Interactions: Non-thermal DBD plasma treatment 
promotes cell proliferation at sub-lethal doses through the FGF-2 release from 
endothelial cells by creating sub-lethal membrane damage in a plasma dose dependent 
manner. Arjunan et al. have reported that plasma generated ROS and RNS contributes 
the sub-lethal membrane damage that leads to FGF-2 release, causing endothelial cell 
proliferation leading to angiogenesis [101,141].  Haertel et al. has demonstrated 
interaction of non-thermal plasma with immune cells. In this, study rat spleen 
mononuclear cells (MNC) were treated with surface DBD non-thermal plasma at 
atmospheric pressure in air and argon. They have shown that the treatment of MNC 
increases the ratio of B cells over the T cells and can alter surface characteristics and 
migration and proliferation of immune cells, which may trigger the sensitization of 
immune cells against tumors [142].   Furthermore oxygen DBD plasma treatment of 
poly(ε-caprolactone) (PCL) scaffold causes the surface modification. Plasma treatment 
of PCL scaffold increases the hydrophilicity of the scaffold, which improves the mouse 
osteoblast cell proliferation on the scaffold [143].   
1.3.3.7 Plasma Disinfection: Plasma disinfection has become one of the most widely 
studied biological applications of non-thermal plasma since last decade. Recent studies 
have shown that different non-thermal plasma treatment arrangements including DBD, 
surface DBD, plasma jet, corona discharge, gliding arc discharges can inactivate wide 
range of microorganisms both in planktonic and biofilm forms in treatment time 
dependent manner [85,92,98,102,144-148]. Biofilm forms of microorganism are more 
resistant to disinfectants than their planktonic forms. However non-thermal plasma 
treatment shows excellent antimicrobial activity on biofilms as well. Alkawareek et al. 
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have shown total eradication of biofilms of Gram-positive bacteria (B. cereus and S. 
aureus) in 4 minutes and Gram-negative bacteria (E. coli and P. aeruginosa) in 10 
minutes with non-thermal plasma jet containing 99.5% helium and 0.5% oxygen gas 
flow. [149] In another study, Joaquin et al. have reported eradication of C. violaceum 
biofilms in plasma treatment time dependent manner, where the total inactivation of 
biofilm was achieved after 60 minutes treatment with helium-nitrogen plasma jet [150]. 
Not only bacterial biofilms, but also fungal biofilms can be inactivated with plasma 
treatment. Direct treatment of C. albicans biofilms with surface microdischarge plasma 
for 10 minutes resulted with 6 log reduction of biofilm forming fungal cells [147].  In 
addition to bactericidal and fungicidal effects, also virucidal and prion inhibition effects 
of non-thermal plasma are demonstrated. Treatment of recombinant adenovirus 
(AdeGFPLuc) with surface microdischarge plasma resulted 240 seconds resulted with 
the 6 log reduction of adenovirus. It was shown that plasma is able to both inhibit the 
replication of adenovirus after infecting HEK293 cells and inactivate adenovirus. The 
virucidal effect of plasma treatement is attributed to diffusion of plasma generated ROS 
and RNS to the medium, and not to the acidic pH or localized heating [151]. Elmoualij 
et al. have reported prion inactivation by treating stainless steel inserts contaminated 
with infectious 139A prion and non-infectious prion containing brain homogenate. 
Following the 40 minutes treatment of steel inserts with N2-O2 cold plasma afterglow, 
treated and untreated steel inserts were implanted on mice brains and mice were 
observed over the time. After 555 days 4 out of 5 mice that were received plasma 
treated, infectious 139A prion containing inserts, survived. On the other hand, all mice 
that were received untreated, infectious 139A prion containing insert, died by the end of 
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the observation period [152]. In addition to plasma disinfection effect where the plasma 
or plasma after glow comes in direct contact with microorganisms, also antimicrobial 
effects through plasma treated materials is reported. Yorsaeng et al. have shown that 
DBD plasma treatment of chitosan coated, natural rubber latex is able to inactivate S. 
aureus and E. coli. Their results have revealed that antimicrobial activity was obtained 
after 20 seconds DBD plasma treatment of 2% chitosan coated latex, followed by 3 
hours exposure to bacteria [153]. Poor et al. have demonstrated that 3 minute of DBD 
plasma treated calcium alginate gels can efficiently inactivate wide range of 
microorganisms, including bacterial and fungal strains, in both planktonic and biofilm 
forms without any significant cytotoxicity on eukaryotic cells [154].  Plasma treatment 
of water and water-based solutions, including PBS and saline solution, demonstrated that 
liquid acquires antimicrobial properties. This method comprises treatment of the liquid 
with a plasma source, then exposure of the microorganism to treated liquid for particular 
time [93,102,110,155-157].  
 In general, we have revealed a method wherein liquid is first treated, then 
exposed to bacteria for antimicrobial efficacy as fluid mediated plasma treatment [93]. 
Details of antimicrobial effects of fluid-mediated plasma treatment and its mechanism of 
action will be discussed in following chapters of this thesis. 
 
1.4 Thesis Organization:  It is hypothesized that DBD plasma generates reactive 
oxygen and reactive nitrogen species in N-acetyl cysteine (NAC) solution, and also leads 
to chemical modification of N-acetyl cysteine molecule, which makes NAC solution a 
strong antimicrobial agent.  
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The specific aims of this study are as follows:  
•  Determine antimicrobial efficacy and antimicrobial kinetics of DBD 
plasma-treated N-acetyl cysteine (NAC) solution on representative 
pathogens. 
•  Determine chemical species and products generated by non-thermal 
DBD plasma in NAC solution, and their contributions on microbial 
inactivation. 
• Determine antimicrobial the stability and toxicity of non-thermal DBD 
plasma-treated NAC solution. 
• Understand the cellular mechanisms of microbial inactivation in E. coli 
upon exposure to non-thermal DBD plasma treated NAC solution. 
This thesis divided into 6 chapters as follows:  
Chapter 2 describes the optimization of plasma system for treatment of NAC solution, its 
antimicrobial effect on most common sources of hospital acquired infections, including 
Gram-positive organisms, Gram-negative organisms, multidrug resistant bacterial 
isolates and fungal pathogens in their planktonic and biofilm forms. The parameters such 
as holding time, and inactivation kinetics of plasma-treated NAC solution are also 
presented. Chapter 3 describes chemical analysis and the quantification of plasma-
generated species in plasma treated NAC solution. In this chapter contribution of 
detected species toward antimicrobial effect is tested. The efforts are directed understand 
chemical mechanisms underlying antimicrobial properties of plasma-treated NAC 
solution. In Chapter 4 we have investigated the stability and retention of antimicrobial 
properties of plasma treated NAC solution over time. We have also presented both the 
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systemic toxicity (in vivo) and cytotoxicity (in vitro) of plasma-treated NAC solution to 
explore the possibility of clinical application as a an antimicrobial solution. Chapter 5 
aims to describe effects of oxidative and nitrosative stress on E. coli cells caused by 
plasma treated NAC solution to understand their cellular responses. We investigated the 
status of protein oxidation and nitrosylation, lipid peroxidation on cell membrane and 
DNA damage upon exposure to plasma-treated NAC solution. This chapter also presents 
the expression of some of the genes mediating oxidative and nitrosative stress 
management, which defend E. coli cells from inactivation. Chapter 6 concludes this 
thesis by giving a brief summary of results, which explain the both chemical and 
biological mechanisms of antimicrobial properties of plasma-treated NAC solution, 
provides original scientific contributions of, and the future directions to continue this 
research project. 
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2    CHAPTER II: ANTIMICROBIAL PROPERTIES AND INACTIVATION 
KINETICS OF NON-THERMAL DBD PLASMA-TREATED N-ACETYL 
CYSTEINE (NAC) SOLUTION 
 
 
 
2.1 Introduction: 
 Hospital-acquired infection (HAI) is a major challenge for clinicians and other health 
care providers and has assumed increasing importance for overall public health. HAI is 
one of the most common causes of health care complications and death in the United 
States. According to the Center for Disease Control and Prevention, about 1.7 million 
infections occur annually, of which about 100000 deaths are associated with hospital-
acquired infection, which increases rates of mortality and morbidity and medical costs 
[6] and adds an estimated about $28–$336 billion in excess annual health care costs [7]. 
Because of their high prevalence in hospitals, Escherichia coli, Staphylococcus aureus, 
Acinetobacter baumannii, and S. epidermidis have become important members of the 
group of agents leading to nosocomial infections, partly because they are able to form 
biofilms on animate and inanimate surfaces in hospitals. Biofilm is colonies of 
microorganisms, in which cells adhere to each other on a surface. In the biofilm form, 
cells excrete extracellular polysaccharides, which help to trap nutrients and prevents the 
detachment of cells [12]. Biofilm growth has a significant impact on human health. 
Diseases such as cystic fibrosis, dental plaques, tuberculosis, etc. are directly related to 
biofilm formation. Medical devices, catheters, and implants have perfect surfaces for 
biofilm formation, which contribute to biofilms’ threat to human health [1,12]. As the 
pathogen biofilms often act as a reservoir of contamination and infection and are likely 
disseminated by health care providers. Soft tissue infections, catheter-related bacteremia, 
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urinary tract infections, hospital-acquired pneumoniaes, and open wound infections are 
often the result of the transmission of such nosocomial pathogens [13-15]. Although 
medically approved, commercially available surface disinfectants and hand washes are 
routinely used, many of them are not sufficient to disinfect surfaces, and they fail to 
inactivate a substantial percent of the pathogens found in biofilms [13,14,98]. Also 
contamination of surfaces with multidrug-resistant pathogens is one of the major risk 
factors in hospitals, and an effective disinfection agent is required to prevent the 
transmission of these pathogens [98,158,159]. It has been reported that recent biocides 
containing benzalkonium chloride, chlorhexidine gluconate, and triclosan used 
commercially in medicine, and powerful agents such as Acticide Bac-50 (Thor Group 
Ltd, Canterbury, Kent, UK) and MediHex-4 (Medichem International, Sevenoaks, Kent, 
UK), are not sufficient to completely decontaminate sources and reservoirs of 
nosocomial infections, including sessile biofilm with embedded pathogens [158, 159]. 
Therefore, a new compound or formulation is needed to prevent hospital-acquired 
infections that are more effective, rapid, less deleterious to surfaces being treated, and 
able to prevent transmission [98,158-162]. Recently, direct or indirect application of 
non-thermal, dielectric-barrier discharge (DBD) plasma is under investigation for its 
ability to disinfect and sterilize biomaterial or the surfaces likely to be damaged by 
thermal plasma [135]. Cold plasmas are mediated by an electric field; electrons receive 
energy faster than heavier ions, and reach thousands of degrees before the surrounding 
ions heat up. Consequently, ionized gas remains at a lower temperature (room 
temperature) instead of receiving energy from excited ions, and the heated ions can be 
efficiently cooled down [86]. It is also reported that plasma creates charged and 
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uncharged species, which in part are responsible for the disinfection and sterilization 
effects. The most notable species created by treatment with plasma that play a major role 
in the inactivation of bacteria are superoxide, hydrogen peroxide, singlet oxygen, OH-
radicals, ozone, nitric oxide, peroxynitrite, ultraviolet light, and electrons [86,98].   
 N-acetyl cysteine (NAC) is an N-acetyl derivative of the amino acid L-cysteine 
and the precursor of the antioxidant glutathione. In NAC, the acetyl group is bound to 
nitrogen atom of the cysteine group. Its chemical formula is C5H9NO3S and its molecular 
weight is 163.2 g/mol (Figure 9) [167]. NAC plays important roles in the biochemical 
pathways in cells such as reducing disulfide bonds in proteins, binding metals to form 
complexes and scavenging reactive species. From a chemical point of view, NAC is 
similar to cysteine, however the existence of the acetyl group reduces the reactivity of 
the thiol group. In contrast to cysteine, NAC is less toxic, more resistant to oxidation, 
and is more water-soluble [168]. It is used as a nutritional supplement and 
pharmacological drug. It is widely used as a mucolytic agent and as an antidote for 
paracetamol (acetaminophen) toxicity. Also NAC has preventive properties, and positive 
effect on the prognosis of interstitial lung disease (ILD), and radiocontrast induced 
nephropathy, and it is beneficial for reducing symptoms of schizophrenia and bipolar 
disorder [169-171].  
 
Figure 9: Chemical structure of the N-acetylcysteine molecule 
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  In a previous study that was carried out in our laboratories the scavenging effect 
of different antioxidants including NAC along with Vitamin E, Histidine, Mannitol, 
Pyruvate and Ascorbic Acid were tested on direct plasma treatment. All antioxidants 
have shown protection of bacteria except NAC. Bacteria that were treated in NAC 
solution showed higher inactivation rates than in negative control groups. These results 
directed our attention to the NAC solution since it has turned into a strong antimicrobial 
solution as a result of plasma treatment. 
   There are two types of plasma treatments: direct plasma treatment and indirect 
plasma treatment. In direct plasma treatment, the material that is being treated serves as 
a counter electrode and directly comes in contact with the electron discharge. In indirect 
plasma treatment, the plasma is generated remotely from the material that will be treated 
and the plasma-generated species are carried via flow of gas through a plasma discharge 
region [163-166]. In the present work, the treatment of NAC solution with non-thermal 
DBD plasma is defined as “fluid mediated plasma treatment” that can be considered as a 
combination of direct and indirect plasma treatment. The fluid mediated plasma 
treatment can be considered as direct plasma treatment in terms of the treatment of NAC 
solution, where it comes to direct contact with electron discharge. At the same time, it 
can also be considered as indirect plasma treatment in terms of treatment of bacteria, 
where NAC solution acts as a vehicle that carries plasma-generated species to bacteria 
for disinfection purpose. Although, the physical and chemical compositions are different, 
and the exact differences are not yet known, both direct and indirect plasma treatment 
techniques are being investigated in infection control and surface sterilization. Joshi et 
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al. have previously demonstrated the unique technique of applying plasma to biological 
material, or to the surface to be sterilized, known as the dielectric barrier discharge 
(DBD) plasma technique, wherein the temperature at the site of the plasma application is 
maintained close to room temperature and thus does not harm heat-sensitive or heat-
labile surfaces, yet completely inactivates bacterial pathogens in both planktonic and 
embedded biofilm forms [98,144]. It was also demonstrated that the DBD plasma 
generates high amounts of reactive oxygen species (ROS), which rapidly inactivate 
pathogens in planktonic and embedded biofilm forms [144]. With the direct application 
of the DBD plasma treatment, the plasma effect is composed of physical and chemical 
species created in normal atmospheric air (no other gas or air under pressure) between 
the high voltage electrode and the surface contaminated with the biological material 
(secondary electrode).  
  In the present study, we introduced the application fluid mediated plasma 
treatment and demonstrate how effectively the DBD plasma-treated NAC solution 
carries antimicrobial properties and inactivates bacterial and fungal pathogens. We 
evaluated the ability of the fluid-mediated, non-thermal plasma treatment to inactivate 
the most common nosocomial pathogens in their planktonic and biofilm (sessile) forms 
and its inactivation kinetics in terms of holding time, inactivation capacity, and 
temperature pH changes. 
2.2 Materials and methods:  
 
 
2.2.1 Preparation of N-Acetyl Cysteine (NAC) Solution: A 100 mM stock solution of 
N-Acetyl cysteine (NAC) solution was prepared by dissolving NAC powder (Sigma, St 
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Louise, MO) in 1X sterile phosphate buffered solution (PBS) and filter sterilized through 
a 0.2 μm filter; aliquots were stored at -20O C until they are used. A 5 mM working 
solution of NAC was freshly prepared by diluting 100 mM stock solution appropriately 
in 1X sterile PBS prior to subsequent experiments.  
2.2.2 Isolates and Cultivation of Microroganisms: Escherichia coli (ATCC 25922), 
Staphylococcus aureus (ATCC 25923), Acinetobacter baumannii (ATCC 19606), 
Staphylococcus epidermidis (ATCC 12228), Enterococcus faecalis (ATCC 29212), 
Pseudomonas aeruginosa (ATCC 484054), MRSA USA300 (BAA-1680) (Methicillin-
Resistant S. aureus), MRSA USA400 (BAA-1683) K. pneumoniae NDM-1 (New Delhi 
Metallo-β-lactamase-1), and E. coli O157:H7 strains were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). Clinical isolate of A. baumannii was 
isolated from patients with cardiac device-related infections at Hahnemann University 
Hospital. Reference strains of Candida albicans and Candida glabrata were kindly 
provided by Dr. Thomas Edlind of, Drexel University College of Medicine.  All 
bacterial strains were grown overnight in trypticase soy broth (TSB) (Fischer Scientific 
Inc., Pittsburgh, PA) medium at 37O C and stock culture plates were prepared on 
trypticase soy agar (TSA) (BD, Franklin Lakes, NJ) plates and stored at 4O C. Reference 
strains of Candida albicans and Candida glabrata were grown overnight in yeast 
extract-peptone-dextrose (YPD) medium (Fischer Scientific Inc., Pittsburgh, PA) at 37O 
C, and stock culture plates were prepared on YPD agar plates and stored at 4O C. 
2.2.3 Plasma Treatment of NAC Solution: To generate non-thermal plasma DBD 
plasma discharge, a custom made copper electrode (38 mm x 64 mm) was used. The 
surface of the copper electrode was covered with a 1- mm thick glass slide (50 mm x 75 
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mm) as dielectric barrier  (Fischer Scientific Inc., Pittsburgh, PA). For the electrical 
insulation, the electrode was covered with waterproof bath silicone.  Also a custom-
made quartz fluid holder (fluid contact area sizes: 32 mm x 57 mm) that is capable to 
hold up to 1.8 mL of fluid with maximum 1 mm of fluid column was designed (Figure 
10 and 11).  
 
Figure 10: Technical drawing of custom-made fluid holder. Sizes are given in inches. 
 
However in the present study, the fluid treatment volume was fixed to 1 mL where the 
average liquid column was 0.6 mm. The discharge gap between the high voltage 
electrode and the fluid holder was fixed at 2 mm.  5mM NAC solution was treated with 
non-thermal plasma for 1, 2, and 3 minutes for the assessment of antimicrobial effect.  
! 48!
    
Figure 11: Experimental set up and the schematic of quartz fluid holder 
Non-thermal DBD plasma discharge was generated by applying alternating 
polarity pulsed voltage between an insulated high voltage electrode and quartz fluid 
holder filled with 1 ml NAC solution. The voltage and current were measured using a 
voltage probe (North Star PVM-4, 100 MHz bandwidth) and a current probe (Pearsons 
Model 2878) respectively. The signals were recorded with an oscilloscope (TDS 5052B, 
Tektronix Inc). The pulse waveform had a 5 μs pulse duration at 31.4 kV and 1.5 kHz 
where 0.29 W/cm2 power density was generated. 
2.2.4 Temperature and pH Measurements of Plasma-Treated NAC Solution: In 
order to determine plasma treatment dependent temperature changes in NAC solution, 
temperature was measured before and after plasma treatment by using an ultrasensitive 
K-type thermocouple (Thermo Works, Lindon, UT, USA).  Similarly, to measure pH 
change in plasma treated NAC solution after plasma treatment, an ultrasensitive pH 
meter (Thermo Fisher Scientific, Waltham, MA) was used. 
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2.2.5 Treatment Time Dependent Antimicrobial Effect of Plasma-Treated NAC 
Solution: In order to determine the required plasma treatment time of NAC solution for 
the desired inactivation rate, 1 ml of NAC solution was treated with non-thermal DBD 
plasma at 31.4 kV and 1.5 kHz for 0.5, 1, 2, 3 and 5 minutes. E. coli (ATCC 25922) was 
used as the model organism and zone of inhibition (ZOI) assay was used to qualitatively 
evaluate bacterial inactivation. In the zone of inhibition assay, 1 ml of overnight grown 
culture was plated and spread on TSA plates and held under the biological safety hood 
until excess liquid evaporated. Once the plates are dried, 50 μl droplets of NAC 
solutions, treated for various time points, were dripped on plates. Plates were incubated 
at 37O C for 24 hours. Following incubation of plates we have compared the plasma 
treatment time dependent inhibition zones with the inhibition zones (Figure 11) that 
were obtained by the treatment of 100 μl NAC solution, with a smaller electrode in a 
smaller treatment chamber, that we previously utilized in our laboratory [144]. 
Comparison of inactivation zones was taken in consideration in order to determine 
required plasma treatment time points (1, 2 and 3 minutes) that were used for the 
quantification of inactivation rates with colony counting assay by exposing E. coli  
 
Figure 12: Zone of inhibition on bacterial lawn following the exposure of 1 minute (a), 
2 minute (b) and 3 minute (c) plasma-treated NAC solution with previously used smaller 
treatment chamber and newly designed scaled up treatment chamber. Arrows indicate 
inhibition zone caused by NAC solution, which is treated with scaled up treatment 
chamber. 
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2.2.6 Holding (Contact) Time Kinetics: Holding time is defined as the time that 
microorganisms come in contact with plasma treated fluid. E. coli  was used as model 
organism for optimization of holding time. To evaluate the effect of holding time on 
inactivation rate, 3-minute plasma-treated fluid was exposed to bacteria for 0, 1, 2, 3, 5, 
10 and 15 minutes. Following given holding time periods bacteria were diluted in 1X 
sterile PBS solution and colony counting assay was performed as previously described.  
2.2.7 Effect of Initial Bacterial Load on Antimicrobial Efficiency of Non-Thermal 
Plasma-Treated NAC Solution: As opposed to previous experiments where 107 
CFU/ml bacteria exposed to plasma treated NAC solution, 5x107, 108, 5x108 and 109 
CFU/ml of initial concentrations of bacteria were exposed to plasma treated NAC 
solution. E. coli was used as model organism to determine initial concentration 
dependent inactivation rates. In order to obtain 5x107, 108, 5x108 and 109 CFU/ml 
concentrations of bacteria, overnight grown culture’s optical density was adjusted to 0.2 
at 600 nm to have 107 CFU/ml bacterial concentration. Then bacterial suspension with 
107 CFU/ml concentration was spun down at 8000 rpm for 10 minutes, supernatant was 
removed and concentrated appropriately by suspending bacteria pellet less the volume of 
the TSB medium to increase bacterial concentration. Bacteria suspension with different 
initial concentrations were mixed with the same volume of plasma treated NAC solution 
(50μl: 50μl) and held for 15 minutes. Following holding time bacteria were diluted 
appropriately in 1X sterile PBS solution and plated on TSA plates and incubated at 37O 
C for 24 hours in order to evaluate inactivation rates. 
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2.2.8 Antimicrobial Effect of Plasma-Treated NAC Solution on Planktonic Forms 
of Different Pathogens: In order to determine antimicrobial efficacy of non-thermal 
DBD plasma treated NAC solution on planktonic forms of various pathogens, colony 
counting assay was used. Bacteria colonies were collected with 10 μl inoculation loop 
from stock plates and inoculated into 10 ml of TSB medium, vortexed gently and 
incubated overnight at 37O C. Following incubation, the optical density of bacteria 
culture was adjusted to 0.2 at 600 nm, where the culture’s concentration becomes 107 
CFU/ml, with appropriate dilution in TSB. Cultures with 107 CFU/ml concentration were 
exposed to equal volume of NAC solutions treated for 1,2, and 3 minutes (50 μl:50 μl) 
and held together for up to 15 minutes. MRSA USA300, MRSA USA400, K. 
pneumoniae NDM-1 and clinical isolate of A. baumannii were exposed to equal volume 
of NAC solution treated only for 3 minutes. 3% H2O2 (Sigma Aldrich, St. Louise, MO) 
and 1X sterile PBS solution were used as positive and negative controls respectively. 
Following 15 minutes of holding time, cultures were appropriately diluted in 1X sterile 
PBS, plated on TSA plates and incubated at 37O C for 24 hours. After incubation 
surviving colonies on TSA plates were counted manually. All plates were incubated for 
48 more hours in order to assure bacteria hadn’t developed dormancy. Similarly fungus 
colonies were collected with 10 μl inoculation loop from stock plates and inoculated into 
10 ml of YPD medium, vortexed gently and incubated overnight at 37O C. Following 
incubation, the optical density of fungus culture was adjusted to 0.38 at 520 nm where, 
culture’s concentration becomes 107 CFU/ml, with appropriate dilution in YPD medium. 
Fungus cultures with 107 CFU/ml concentration were exposed to equal volume plasma 
treated NAC solutions (50 μl:50 μl) and held together for 15 minutes. 3% H2O2 (Sigma 
! 52!
Aldrich, St. Louise, MO) and 1X sterile PBS solution were used as positive and negative 
controls respectively. Following 15 minutes of holding time, cultures were appropriately 
diluted in 1X sterile PBS, plated on YPD agar plates and incubated at 37O C for 24 
hours. After incubation surviving colonies on YPD agar plates were counted manually. 
All plates were incubated 48 hours more in order to assure bacteria hadn’t developed 
dormancy. Colony numbers acquired form colony counting assay were multiplied by 
dilution factor, which is the measure of dilution amount made from initial concentration 
to the plated concentration. Obtained results were converted to logarithmic scale on base 
10.  
2.2.9 Antimicrobial Effect of Plasma-Treated NAC Solution on Biofilm Forms of 
Different Pathogens: The antimicrobial efficiency of plasma treated NAC solution 
biofilm forms of organisms were tested by using three different approaches. In the first 
approach biofilms of different strains, including fungal and bacterial strains, were grown 
on polyurethane catheter slices and exposed to plasma treated NAC solution. In the 
second approach biofilms of E. coli were grown on the bottom of the 12 well plate and 
treated with nebulized plasma treated NAC solution. In the third approach biofilms of P. 
aeruginosa PA01 were grown on air-liquid interface by using drip flow reactor system in 
order to mimic natural biofilm formation such as found in the respiratory tract and inside 
of catheters; and grown biofilms were treated by circulating plasma treated NAC 
solution through biofilm grown surface. In order to determine antimicrobial efficacy of 
non-thermal DBD plasma treated NAC solution in the first approach, XTT assay 
(Molecular Probes Inc., Grand Island, NY) was used. Biofilms were grown on 1 mm 
thick polyurethane catheter slices. Catheters were cut to 1 mm thick slices and held in 10 
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ml of 70% ethanol for 30 minutes then washed in sterile dH2O and kept under UV light 
for 30 minutes for sterilization purposes.  Overnight cultures of bacteria were prepared 
as previously explained. 100 μl of bacterial overnight culture was added into 10 ml of 
TSB medium with 100 μl of 50% of glucose solution to yield 0.5% (w/v) final 
concentration in order to enhance biofilm formation. Sterilized catheter slices were 
transferred in 24 well plates. 700 μl of biofilm culture suspension was added on catheter 
slices and incubated at 37O C for 24 hours (Figure 13). Following incubation medium 
containing floating bacteria was removed and each well was washed with 1X sterile PBS 
solution in order to remove non-biofilm forming bacteria. Then 700 μl of plasma treated 
NAC solution was added on biofilms that are grown on catheter slices and held for 15 
minutes. Following holding time plasma treated NAC solution was removed, biofilms 
were washed with 1X sterile PBS solution and 700 μl of XTT reagent was added and 
incubated at 37O C for 2 hours. After incubation 100 μl of reacted XTT was transferred 
into 96 well plates and samples were read at 492 nm with a spectrophotometer (Thermo 
Scientific, Waltham, MA).  
   
Figure 13: Biofilm growth on polyurethane catheter slices. (24 h. maturation) 
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For fungal biofilm experiments, overnight cultures of fungus strains were prepared as 
previously explained. 100 μl of fungal overnight culture was added into 10 ml of YPD 
medium with 100 μl of 50% of glucose solution to yield 0.5% (w/v) final concentration 
in order to enhance biofilm formation. Sterilized catheter slices were transferred in 24 
well plates. 700 μl of biofilm culture suspension was added on catheter slices and 
incubated at 37O C for 72 hours by replacing medium at every 24 hours. Following 
incubation medium containing floating fungus was removed and each well was washed 
with 1X sterile PBS solution in order to remove non-biofilm forming fungus. Then 700 
μl of plasma treated NAC solution was added to biofilms grown on catheter slices and 
held for 15 minutes. Following holding time plasma treated NAC solution was removed, 
biofilms were washed with 1X sterile PBS solution and 700 μl of XTT reagent was 
added and incubated at 37O C for 2 hours. After incubation 100 μl of reacted XTT was 
transferred in to 96 well plates and samples were read at 492 nm with a 
spectrophotometer (Thermo Scientific, Waltham, MA).  3% H2O2 (Sigma Aldrich, St. 
Louise, MO) and 1X sterile PBS solution were used as positive and negative controls 
respectively for both bacterial and fungal biofilm experiments. Negative control survival 
rates were fixed as 100% survival rate and survival of treated samples were normalized 
according to negative control groups.  
XTT (2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay 
is a quantification method based on the respiratory metabolic activity of viable cells. 
XTT is a tetrazolium salt, which is based on the modification of the yellow tetrazolium 
salt XTT to form an orange formazan dye by metabolic active cells (Figure14) [167]. 
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Figure 14: Reduction of XTT due to cellular respiration to form the orange formazan 
dye. 
The stock solution of 10 mg/mL XTT was prepared in 10 mL 1X sterile PBS solution. 
Aliquots of 100μl XTT were stored at -20°C. The working solution was prepared by 
adding 50 μl stock solution in 1 ml dH2O to yield a final concentration of 0.5 mg/mL, 
and 1μl of 50 mM menadione to yield a final concentration of 50 μM. 
 In the second approach biofilms of E. coli were grown in a similar manner as 
previously described, but 2 ml of biofilm culture suspension was added into 12 well 
plate instead of 700 μl. The grown biofilms were washed with 1X PBS as previously 
described. 2 ml of 3 minutes plasma treated NAC solution was nebulized on biofilms by 
using Invacare Reusable Jet Nebulizer (Elyria, OH) that was connected to sterile 
compressed air under 30 psi (Figure 15b). The nebulizer can generate 5 μm particles and 
nebulize 3 ml of liquid in 7 minutes. Bacterial viability following treatment was 
quantified by using XTT assay.   
 In the third approach P. aeruginosa PA01 biofilm culture suspension was 
prepared in TSB, as previously described, in the presence of 0.5% serum to enhance 
biofilm formation.   In the batch phase of the experiment, 15 ml of medium was added 
Cellular!Respiration!
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on to glass slides in reactor channels, and the reactor cover was tightened and incubated 
at 37O C for 6 hours. In the continuous phase, the reactor was beveled to achieve 10O 
downward slope. Nutrient inlet and outlet tubing lines were connected to reactor and 
fresh nutrient was circulated over the biofilm at 37O C for 24, 48 and 72 hours. In this 
system fresh nutrient drips on biofilm through a needle connected to nutrient inlet line 
and then flows through biofilm due to the slope and accumulates in a reservoir (Figure 
15a) [172]. After desired time of incubation grown biofilms were treated by circulating 5 
ml, 3 minutes plasma treated NAC solution over biofilm for 30 minutes. Following the 
treatment, glass slides with biofilms were placed into 50 ml conical tubes containing 10 
ml PBS. Tubes were vortexed for 30 seconds, sonicated for 2 minutes, and vortexed for 
and additional 30 seconds and colony-counting assay was performed.  
Figure 15: Experimental design for different biofilm treatment approaches: (a) Drip 
flow biofilm reactor (DFR) set up, (b): Set up for biofilm treatment with plasma-treated, 
nebulized NAC solution  
2.3 Results:  
2.3.1 Temperature and pH Measurements of Plasma Treated NAC Solution: The 
temperature measurement of untreated and plasma treated NAC samples were performed 
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to demonstrate whether non-thermal plasma treatment causes increase in temperature.  
Results revealed that after 1,2, and even 3 minutes of plasma treatment, temperature of 
NAC solutions remain around the room temperature, reaching to 25.33O C, 25.17O C and 
26.13O C respectively. No linear relation was seen between temperature and different 
treatment times (Figure 16a). We also noted that the pH of the liquid decreased with 
plasma treatment time, moving toward acidity, when tested with pH strips. Therefore, we 
measured the pH using an ultrasensitive pH meter with a digital display system. Figure 
16b shows that the pH of plasma treated NAC solution drastically drops after 1minute of 
treatment to pH 2.82 and, after this point, acidity keeps increasing slightly to pH 2.39 
and 2.35 after 2 and 3 minutes of plasma treatment respectively.  
 
Figure 16: Temperature (a) and pH (b) change of non-thermal DBD plasma treated 
NAC solution depending on plasma treatment duration. 
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2.3.2 Antimicrobial Effect of Plasma Treated NAC Solution: To determine treatment 
time dependent antimicrobial effect of plasma-treated NAC solution, preliminary 
experiments were done using 107 CFU/ml initial bacteria concentration, which is 
clinically significant bacterial load [12]. As it is shown on Figure 17, 1 and 2-minute 
plasma treated NAC solution can inactivate 1.3 and 1.9-log bacteria respectively; while 
3-minute plasma treated NAC solution is capable 7-log complete inactivation of 
bacteria.  
 
Figure 17: Plasma treatment time dependent antimicrobial 
efficiency of non-thermal plasma-treated NAC solution on E. coli 
 
2.3.3 Effect of Holding Time on Inactivation: It is important to know the required 
contact time of plasma treated NAC solution with bacteria (previously described as 
holding time) in order to understand inactivation properties of plasma treated NAC 
solution such as; inactivation kinetics and inactivation mechanism. For this reason 3-
minute plasma treated NAC solution was held with bacteria for different time points. 
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achieved with increasing holding time. We have observed a slightly increasing 
inactivation rate from 1 to 5 minutes of holding time and complete inactivation was 
observed when 3-minute plasma treated NAC solution comes in contact with 107 
CFU/ml E. coli for 15 minutes (Figure 18). Unless otherwise stated 15 minutes of 
holding time has been kept constant for all experiments. 
 
Figure 18: Effect of holding (contact) time on antimicrobial efficacy of 3-minute DBD 
plasma-treated NAC solution 
 
2.3.4 Cell Density Dependent Inactivation by Plasma-Treated NAC Solution: In 
previously explained experiments 107 CFU/ ml initial bacterial load was exposed to 
plasma treated NAC solution. In order to better understand how much bacteria can be 
inactivated by 3 minutes non-thermal plasma treated NAC solution under given 
conditions such as 15 minutes of holding time and exposure to equal volumes of bacteria 
and plasma treated NAC solution, higher initial bacterial loads were exposed to 3-minute 
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solution is capable of inactivating up to 108 CFU/ ml E. coli when exposed at equal 
volume after 15 minutes of holding time. 3-minute plasma treated NAC solution was 
ineffective when it was exposed to 5x108 CFU/ ml and, 109 CFU/ ml of initial bacterial 
load. Presented results shows that 3-minute plasma treated NAC can achieve up to 8-log 
reduction. However 107 CFU/ ml initial bacterial load was kept constant for other 
experiments in this thesis unless otherwise stated.    
 
Figure 19: Initial bacterial load dependent antimicrobial efficiency of 3-minute non-
thermal plasma-treated NAC solution 
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Solution: In the following experiments, plasma treatment time dependent antimicrobial 
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treated one. While all strains showed less than 1 log reduction after 1 and 2-minute 
treatment of NAC solution, 7 log of complete inactivation of P. aeruginosa was 
achieved even after 2-minute treatment of NAC solution. In fungal strains 7 log 
inactivation was observed only for C. albicans while 5.1 log reduction was achieved for 
C. glabrata.  
Figure 20: Plasma treatment time dependent antimicrobial efficiency of non-thermal 
plasma-treated NAC solution on planktonic forms of different bacteria and fungus 
strains 
 
 The bactericidal effect of plasma treated NAC was also tested on MRSA 
USA300, MRSA USA400, K. pneumoniae NDM-1 and clinical isolate of A. baumannii 
that are highly antibiotic resistant bacterial strains. As shown in Figure 21, 3-minute 
plasma treated NAC solution achieves 7 log reduction of highly antibiotic resistant 
bacteria.  
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Figure 21: Bactericidal effect of 3-minute plasma-treated NAC on antibiotic resistant 
bacteria strains 
 
 In biofilm experiments 3-minute plasma treated NAC solution was capable of 
inactivating 100% of bacterial biofilms of various strains similar to planktonic form 
experiments. S. epidermidis showed the most biofilm activation after 2-minutes 
treatment of NAC solution with 98% reduction rate. However, the maximum reduction 
rate on fungus biofilms was around 85% for both two fungal strains even after 3 minutes 
plasma treatment of NAC solution (Figure 22). 
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Figure 22: Plasma treatment time dependent antimicrobial efficiency of non-thermal 
plasma-treated NAC solution on biofilm forms of different bacteria and fungus strains 
  
 Also nebulization of 3 minutes, non-thermal plasma treatment of NAC solution 
has shown a significant effect on E. coli biofilms. We have shown that up to 85% of E. 
coli biofilms can be eradicated by nebulization of 3-minute plasma treated NAC solution 
(Figure 23).  
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Figure 23: Antimicrobial efficiency of nebulized, 3-minute non-thermal plasma-treated 
NAC solution on E. coli biofilm  
 Furthermore, 3-minute non-thermal plasma treated NAC solution has shown 
antimicrobial activity on stronger biofilms of P. aeruginosa mPA01 strain, which are 
potent biofilms, grown under shear stress on a liquid-air interface by a drip flow reactor 
(DFR) system for an extended period of time. Around to 3.5-log inactivation was 
observed for even 3-day-old biofilms grown with DFR system as depicted in Figure 24.  
 
Figure 24: Biofilm maturation duration dependent antimicrobial efficiency of 3-minute 
non-thermal plasma-treated NAC solution on P. aeruginosa mPA01 biofilms grown on a 
drip flow reactor  
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2.4 Discussion:  
 It is widely reported that direct application of non-thermal plasmas such as 
plasma jets mediated by argon gas or gliding arc plasmas decontaminate bacteria 
[150,157,173]. The gas and the type of application technique used largely determine 
plasma-generated reactive species; thus, the antimicrobial efficacy is also likely differ 
[105,157,174,175]. Treatment of water with the gliding arc plasma and its bactericidal 
effect has been reported [157,175]. Direct current (DC) electrical discharges in 
atmospheric air has also been tried by exposing either static or flowing water to 
decontaminate bacteria in water, wherein three different types of discharges were tested 
such as streamer corona, transient spark, and glow discharge [145].  
 Our approach and, plasma device design is different than the previously reported 
corona, spark, or glow plasma discharge. We use alternate current (AC) dielectric barrier 
discharge (micro pulsed plasma), and treat NAC solution first, and then expose treated it 
to microorganisms as previously reported from our laboratories [144,171]. Our goal is to 
understand the uniquely different DBD plasma technique and evaluate the antimicrobial 
efficacies of the NAC solution treated by this technique against planktonic and biofilm 
forms of microorganisms. 
 Joshi et al. have previously reported how direct plasma treatment inactivates 
contaminating pathogens when the non-thermal DBD plasma treatment is used. That 
study suggests that the NAC solution, which turns into a powerful antimicrobial solution 
is highly biocidal against a range of pathogens, including pathogenic fungi, and is as 
effective as the direct plasma treatment previously reported [144].  In the present study, 
non-thermal DBD plasma electrode was larger than reported earlier, to cover a larger 
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treatment area. The fluid holder was also large enough to hold 1 ml of liquid but the 
discharge gap between the electrode and the surface of the fluid remained same as 2 mm.  
 There are two reasons to adopt fluid-mediated plasma application. Briefly, it is 
known that non-thermal (cold) plasma generates electric field, magnetic field, and 
certain physical species, such as charged particles, ultraviolet photons and electrons in 
addition to chemical species, such as reactive oxygen species (ROS) or reactive nitrogen 
species (RNS). Physical species are more detrimental and damaging to surfaces, so it is a 
challenge to apply them to delicate, contaminated surfaces and to biological materials 
[176]. The antimicrobial effect of plasma treated fluids that permits one to sterilize or 
disinfect such surfaces without damage is an advantage. These fluids can be used to 
improve hospital hygiene, to treat bacterial skin diseases, and cosmetically, to control 
acne-causing organisms. The skin is not needed as a counter electrode, which 
significantly simplifies their practical use on patients. Furthermore, the risks of electric 
current, thermal damage of tissue, and UV irradiation can be avoided by using fluid-
mediated plasma treatment. Also, the purpose of investigations of plasma-activated 
liquids is to search for a better option as an antimicrobial agent over existing chemical 
preparations (such as chlorhexidine and silver containing compounds), which have 
toxicity.  
 The concentration of NAC (5 mM) selected for this study is considerably lower 
than the clinically permitted amount of NAC for therapeutic purposes. Also, the bacterial 
load (107 CFU/ml  and more) used for inactivation experiments is high and therefore 
covers the clinically significant number of bacterial cells. Most other studies have used 
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<6-log, which is clinically less relevant to represent severe sepsis. 
 Therefore, we performed a cell density-dependent experiment with treated NAC. 
A large quantity of CFUs (108 CFU/ml) was completely inactivated by the treated NAC 
solution, again indicating its strong antimicrobial effect. 
 The type and concentration of pathogen are important in deciding the outcome of 
the processes of disinfection, decontamination, or sterilization. Multidrug resistance is an 
additional hurdle in these processes and helps disseminate hospital-acquired infections, 
either by direct transmission or through biofilm-loaded surfaces [162,177]. Therefore, to 
investigate the antimicrobial efficacy of plasma-treated fluids, we chose multidrug-
resistant nosocomial pathogens in moderately high concentration (7-log CFU) known to 
form biofilms [144,158]. Because these pathogens also contaminate the surfaces of 
stethoscopes, catheters, and the hands of health care providers they are ideal candidates 
with which to test the decontamination regime [158]. Our results clearly demonstrate the 
strong antimicrobial effect of the plasma-treated fluid. The effect was comparable to that 
of 3% hydrogen peroxide solution. The holding time of these fluids with given bacteria 
is also crucial for decontamination of surfaces. Different biocidal solutions that are 
generated by plasma treatment have variable holding times [178]. Plasma treated NAC 
solution presented in this study was as effective as the existing commercial disinfectants 
and required only 15 minutes of holding time to completely inactivate reference and 
antibiotic resistant strains of all of the pathogens in vitro (A. baumannii, C. albicans, C. 
glabrata, E. coli, E. faecalis, P. aeruginosa, S. epidermidis, and S. aureus, MRSA 
strains, E. coli O157:H7, K. pneumoniae NDM-1). Holding time dependent inactivation 
results are comparable to bacterial responses found in earlier reports, wherein fungus 
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was not inactivated even after 30 minutes of exposure [157,179]. In the present study, 
both species of fungus (C. albicans and C. glabrata) were inactivated in 15 minutes 
when exposed to 3-minute plasma-treated NAC solution, both in their planktonic form, 
and in biofilm forms suggesting that the plasma-treated NAC solution is a potent 
biocidal agent. Furthermore, clinical isolate of A. baumannii, MRSA strains, E. coli 
O157:H7 and K. pneumoniae used in this study are multidrug resistant and strong 
producers of biofilms. Inactivation of K. pneumoniae NDM-1 by plasma treated NAC 
solution deserves a special interest. K. pneumoniae NDM-1 is a strain that carries 
transmissible genetic element encoding multiple resistance genes called NDM-1 (New 
Delhi Metallo-β-lactamase). It was first isolated from a patient in India and has been 
spread around the world. NDM-1 carrying microorganisms are called “superbugs” due to 
their resistance ability against carbapenems [180]. Our results with K. pneumoniae 
NDM-1, along with other multidrug resistant bacteria, MRSA300 and MRSA400, 
showed that plasma treated NAC solution can inactivate broad range of even multidrug 
resistant microorganisms. Therefore, their rapid inactivation by the non-thermal plasma-
treated NAC solution supports its powerful biocidal effect.  
 Ventilator associated infection is major threat to patients that are hospitalized in 
intensive care units and assisted with mechanical ventilator with an increasing cost [30]. 
Treatment of E. coli biofilms with nebulized NAC solution suggest that, plasma treated 
NAC solution has a potential to prevent or cure ventilator associated infections. Also 
biofilm formation in respiratory tract is a major problem and source of infection for 
cystic fibrosis patients. Nebulized, plasma-treated NAC solution can provide a new 
solution for the treatment of severe respiratory tract infections. 
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 Drip flow bioreactor (DFR) system provides an environment for the growth of 
biofilm on air-liquid interface under low shear stress. DFR system provides continuous 
more potent biofilm growth.  It is an ideal system for modeling the hospital biofilm 
growth in lungs affected by cystic fibrosis, catheters and body cavities [172]. In the 
present study we showed that, plasma treated NAC solution is capable of inactivating 
significant amount of biofilms grown with DFR system. Our results suggest that plasma 
treated NAC solution can be considered as a potential antimicrobial agent for patients 
with severe biofilm infections.  
 During plasma treatment of NAC solution, pH decreased from neutral to acidic. 
Several authors have reported such a reduction in pH, and the acidification of solutions, 
but the exact mechanism is still not fully understood [105,110,156]. It is anticipated that 
a drop in pH could be due in part to generation of nitric acid via interaction of RNS, 
ROS, and hydrolysis of water that gives rise to proton and hydroxyl radical. The extent 
of acidification of solution being treated by plasma depends, upon the amount of plasma 
dose (depending on voltage and frequency) being deposited, duration of the treatment, 
amount of liquid being treated, height (column) of liquid, immediate environment 
around the high voltage electrode and the discharge gap. A relatively smaller amount of 
solution if treated with plasma for a relatively longer duration of time, with a narrow gap 
for plasma discharge, can make solution highly acidic, and saturated with acidifying 
species. The previous literatures that have reported a moderate reduction in pH of PBS 
or water solution always had a plasma discharge gap of more than 2 mm through 45 mm, 
and the amount of liquid more than 1.5 ml through 10 ml [105,110,156]. This drastically 
changes the chemical properties and pH equation of these solutions. We did not find any 
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significant temperature changes in these treated fluids; in fact, the temperature was close 
to room temperature even after 3 minutes of treatment and was not related to the change 
in pH. Acidification of treated fluid could be the result of factors other than H2O2, nitric 
acid and nitrous acid, such as hydroperoxyl (HO2) and peroxynitrous acid (HOONO), or 
a combination of all of these and other unknown species. Similar changes are reported in 
the gliding arc plasma treatment, which is different than the technique we used [178]. In 
brief, plasma treated NAC solution inactivates a wide range of multidrug-resistant 
bacteria and fungal pathogens, independently their gram staining classification in both 
their planktonic and biofilm forms faster than previously reported plasma treatment 
methods (within15 minutes of holding time). 
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3   CHAPTER III: CHEMICAL SPECIES IN PLASMA-TREATED N-ACETYL 
CYSTEINE (NAC) SOLUTION AND THEIR CONTRIBUTION TO 
MICROBIAL INACTIVATION 
 
3.1 Introduction: 
 The antimicrobial effect of direct application of non-thermal plasmas is a widely 
investigated and well-known phenomenon [98,176,148,152]. Different factors are 
effective on the antimicrobial effect on non-thermal plasmas. In brief, the most common 
mechanisms that are responsible for microbial inactivation are reported as: UVC photons 
generated during plasma discharge, plasma generated ROS and RNS in the gas phase 
and diffusion of these species through the bacterial cell wall and membrane, physical 
effect of electron discharge and electrical field that causes damage to the cell surface, 
and localized heating effect to cell surface. Given mechanisms are capable of 
inactivating microorganisms synergistically [106,148,181]. Furthermore, plasma treated 
liquids have an increasing interest due to their antimicrobial activity. Different groups 
have reported antimicrobial effect of liquids including water 0.9% saline solution and 
PBS that are treated with different non-thermal plasma sources (fluid mediated plasma 
treatment). Acidic pH following plasma treatment of liquids is the most commonly 
reported chemical modification [93,105,108-111,155-157,182-184]. In fluid mediated 
plasma treatment bacteria don’t come in contact with UV and electron discharge. 
Therefore diffusion of plasma generated ROS and RNS into treated liquid are thought to 
be the main cause for microbiocidal effect [93].  The decreased pH of plasma treated 
liquid is attributed to generation of HNO2, HNO3 and, H3O+ [93,109,156]. The 
acidification of plasma treated liquid is critical for microbiocidal effect; however, it was 
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reported that acidic pH is not the main source of antimicrobial effect [105,184,187]. 
Ikawa et al. have reported that acidic pH is essential for antimicrobial effect through 
plasma treated liquids. They have demonstrated that below pH 4.7 the antimicrobial 
effect is significantly higher compared to pH of greater than 4.7. They claimed that pH 
4.7 is the critical value for microbial inactivation and it is almost universal for different 
type of bacteria including Gram positive, Gram negative and anaerobic bacteria [111]. In 
addition to decreased pH also nitrate (NO3-), nitrite (NO2-) and hydrogen peroxide (H2O2) 
have been detected in plasma treated liquids [156,185,186]. Plasma also generates other 
ROS and RNS such as OH radical superoxide nitric oxide etc. Direct contact of liquid 
with electron discharge, reactions of plasma generated ROS and RNS, and their 
diffusion into liquid are responsible for the presence of NO3-, NO2- and H2O2 in plasma 
treated liquids. Reactions of ROS and RNS lead to the formation of other species that 
might contribute to antimicrobial effect. It is well known that plasma generates NO and 
superoxide (O2-), and their reaction yields to peroxynitrite (ONOO-) formation. Another 
possible route for peroxynitrite formation in the plasma treated liquid is the formation of 
nitrosooxidanium (H2NO2+) via the reaction of H+ cation with NO2- anion in highly acidic 
environment. Nitrosooxidanium (H2NO2+) is broken down into nitrosonium (NO+) cation 
that is highly reactive and can attack biomolecules in the cell, and form peroxynitrous 
acid (ONOOH) in the presence of hydrogen peroxide. Finally peroxynitrous acid is 
dissociated to peroxynitrite in aqueous medium [194,195]. Peroxynitrite is highly 
reactive and can easily diffuse to cell membrane due to its high permeability. It attacks 
various biomolecules in the cell and causes protein and lipid nitrosylation and also 
intracellular oxidation. Intracellular damage induced by peroxynitrite can’t be repaired 
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by cellular repair mechanisms and cells die [196-198].  Acidified nitrite and nitrate have 
been known for decades for their antimicrobial effect both in vitro and as a part of 
natural protection mechanism of the body [188-190]. Salivary nitrite comes in contact 
with acid in the stomach when swallowed and acts as a natural host defense mechanism 
through the formation of biocidal species [192]. Antimicrobial effect of acidified nitrite 
is closely related with RNS involving mechanisms. For example, NO release from skin 
has been reported. Also natural flora of the skin reduces nitrate to nitrite. In the acidic 
nature of the skin RNS, including nitrous acid (HNO2), dinitrogen trioxide (N2O3) and 
peroxynitrite (ONOO-) are produced, via NO and nitrite and nitrate that act as non-
specific protection against pathogens on the skin [191]. Various groups have 
demonstrated that acidified nitrite has antimicrobial effect on various skin and oral 
pathogens [191-193]. The composition of the liquid that is being treated should be 
considered in order to clarify the mechanism of antimicrobial effect. As opposed to 
water and PBS, Oehmigen et al. have reported the antimicrobial effect of 0.85% saline 
solution (NaCl).  However they concluded that effect of chlorine species that arises from 
Cl- ion could be neglected [155].  
 In brief, during plasma treatment of the liquid, ROS and RNS are generated both 
in gas phase and liquid-gas interface. Acidic pH is common consequence of liquid 
mediated plasma treatment. Even though acidic pH doesn’t contribute to antimicrobial 
effect, it is essential for microbial inactivation. Antimicrobial effects of plasma treated 
liquids originate from diffused ROS and RNS in to liquid as opposed to direct plasma 
treatment, where physical impacts such as UV, electrical field, and electron 
bombardment are contributors to the biocidal effect.  
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3.2 Materials and Methods:  
3.2.1 Hydrogen Peroxide Detection: Hydrogen Peroxide Assay Kit (National 
Diagnostics, Atlanta, GA, USA) was used for the detection of hydrogen peroxide in 
plasma treated NAC solution. The assay is based on the formation of a complex between 
Xylenol Orange and ferric iron, which is produced by the peroxide dependent oxidation 
of ferrous iron. This reaction is quantified colorimetrically, and the kit can detect as little 
as 15ng/ml of peroxide. The kit consists of Reagent A, which is an aqueous solution of 
2% sorbitol and Xylenol orange, and Reagent B, which is 14% solution of sulfuric acid 
with 1% ammonium ferrous sulfate. 19.8 ml of Reagent A and 0.2 ml of Reagent B were 
mixed, and 180 µl of assay mixture was mixed with 20 µl of plasma treated NAC sample 
and was incubated at room temperature for 30 minutes to allow for complete color 
development; dilutions were made where they were necessary. Different dilutions of 
30% hydrogen peroxide were used to generate a standard curve. After incubation for 
color development, absorbance of samples and standards were detected with a UV-
visible spectrophotometer (Thermo Scientific, Hudson NH, USA) at 560 nm. 
Concentration of hydrogen peroxide in plasma treated NAC solution was determined 
according to the standard curve.  
3.2.2 Nitrite and Nitrate Detection: Nitrite-Nitrate Test Kit from HACH (Loveland, 
CO, USA) was used for the detection of Nitrite and Nitrate in plasma treated NAC 
solution. Kit consists of two powder components; one is NitraVer 5 for Nitrate detection 
that contains Cadmium and Sulfanic Acid and NitriVer 3 for Nitrite detection that 
contains Potassium Pyrosulfate. Kit is able to detect 2 mg/l Nitrate and 0.01 mg/l Nitrite. 
For Nitrate detection 5 ml of plasma treated NAC solution was mixed with NitraVer 5 
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reagent and shaken vigorously for 1 minute; we then waited for 1 more minute to 
observe complete color development and color change was observed by using color 
comparator. Similarly, for Nitrite detection plasma treated NAC solution was mixed with 
NitriVer 3 reagent and was shaken vigorously for 1 minute; we then waited for 10 more 
minute for complete color development and color change was observed by using color 
comparator. Samples were diluted with deionized water, when the dilution is needed. 
Detection results were validated by using standard solutions of nitrite that was prepared 
by dissolving NaNO2 (Sigma, St. Louise MO, USA) in deionized water and nitrate that 
was prepared by dissolving HNO3 (Fischer Scientific, Pittsburgh, PA, USA) in deionized 
water.  
3.2.3 UV-Visible Spectrum Analysis: UV-visible spectra was collected for NAC 
solution that was treated for different time points, peroxynitrite standard solution, 
bacterial cell suspension after treatment with plasma treated NAC solution, peroxynitrite 
solution and ATL buffer. UV-visible spectra were generated with a UV-visible 
spectrophotometer (Thermo Scientific, Hudson, NH, USA) between 190 nm and 1100 
nm wavelengths with 1 nm interval. Untreated NAC solution, deionized water and 
bacterial suspension and substance of interest were used as blank for the UV-visible 
spectra of plasma treated NAC solution, peroxynitrite and bacterial suspension that was 
treated with the substance of interest as respectively. Also UV-visible spectrum of dried 
and rehydrated plasma treated NAC solution was generated in the same manner, where 
the dried and rehydrated, untreated NAC solution was used as blank. Findings regarding 
to dried and rehydrated plasma treated NAC solution will be given and discussed at 
Chapter 4. 
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3.2.4 Fourier Transform Infrared Spectroscopy (FT-IR) Analysis of Plasma-
Treated NAC Solution:!Untreated and plasma treated NAC solutions were evaporated 
with a rotary evaporator. Infrared spectra of remaining powder from the evaporation of 
untreated and 3-minute plasma treated NAC solution were obtained with an Olympus 
BX51 microscopy system (Olympus, Japan) and modified with a Fourier-Transform 
infrared spectrometer IlluminatIR that is equipped with an ATR lens (Smith Detection, 
USA).  
3.2.5 Nuclear Magnetic Resonance (NMR) of Plasma-Treated NAC Solution: NAC 
stock solution for NMR analysis was prepared in heavy water (D2O) (Sigma Aldrich, St. 
Louise, MO, USA) in order to avoid signal that rises from hydrogen in water. 1 X PBS 
solution was prepared by dissolving PBS tablets (Sigma Aldrich, St. Louise, MO, USA) 
in D2O and then NAC powder was dissolved in PBS solution that was prepared in D2O 
to have 100 mM of final concentration. NAC stock solution was stored at -20O C, and 5 
mM of working solution was prepared by appropriately diluting stock solution in D2O. 
NAC solution that was prepared in D2O was treated in the same manner as described in 
Chapter 2. Proton nuclear magnetic resonance spectra were collected using a Varian 
INOVA 500 MHz FT-NMR device (Palo Alto, CA, USA). Antimicrobial effect of 
plasma treated NAC solution, which was prepared in D2O was tested in order to assure 
that its antimicrobial property is same as NAC solution that was prepared in H2O. 
3.2.6 Antimicrobial Effect of acidic pH and Plasma-Generated Species: In order to 
determine if low pH after plasma treatment is responsible for plasma disinfection effect, 
acetic acid (CH3COOH), nitric acid (HNO3) (Fischer Scientific, Pittsburgh, PA, USA), 
! 77!
sulfuric acid (H2SO4), hydrochloric acid (HCl) and phosphoric acid (H3PO4) (Sigma 
Aldrich, St. Louise, MO, USA) solutions were prepared at pH ~2.3 by titration. Prepared 
acid solutions were exposed to the same volume of 107 CFU/ml E. coli and held for 15 
minutes. Then colony-counting assay was performed for the quantification of surviving 
bacteria as described in Chapter 2. Antimicrobial effects of plasma-generated species 
were tested by preparing detected concentrations of each species in deionized water. For 
the combination experiments final concentrations of each species were adjusted 
accordingly. 30% hydrogen peroxide solution, 1 N nitric acid, glacial acetic acid (Fisher 
Scientific, Pittsburgh, PA, USA), sodium nitrite and cysteic acid (Sigma Aldrich, St. 
Louise, MO, USA) was used to prepare desired concentrations of tested substances. 
 Superoxide thermal source (SOTS-1) (Cayman, Ann Arbor, MI, USA) was used 
to prepare superoxide solution. SOTS-1 is provided as crystalline powder and its stock 
solution was prepared by dissolving in dimethyl sulfoxide (DMSO) and stored at -80O C. 
Working solution was prepared by dissolving it in PBS.  SOTS-1 is an azo compound 
that can be thermally decomposed in aqueous solution to generate superoxide radical 
anion at a constant controlled rate. SOTS-1 thermally decomposes to form an 
intermediate that reacts with oxygen at the diffusion-controlled limit to generate 
superoxide. The decay of SOTS-1 into the intermediate follows first order kinetics and 
exhibits a half-life of 4900 seconds at physiological pH and temperature. Since the stock 
solution of SOTS-1 was prepared in DMSO, antimicrobial effect of corresponding 
concentration of DMSO in working solution was also tested in order to assure that 
DMSO doesn’t interfere with antimicrobial effect.  
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 Peroxynitrite (ONOO-) (Cayman, Ann Arbor, MI, USA) solution was diluted in 
deionized water just before exposure to bacteria to obtain, plasma generated 
concentration of it. Peroxynitrite solution was provided in 0.3 M sodium hydroxide 
(NaOH). Therefore antimicrobial effects of corresponding concentrations of NaOH were 
tested in order to make sure that it doesn’t interfere with antimicrobial effect. All species 
and all combinations of them were exposed to same equal volume of 107 CFU/ml E. coli 
and held for 15 minutes. Then colony-counting assay was performed for the 
quantification of surviving bacteria as described in Chapter 2.      
 
3.3 Results: 
3.3.1 Hydrogen Peroxide Detection: Standard curve was plotted in between 0.2 and 4.1 
μM concentrations of hydrogen peroxide (Figure 25a). Appropriate dilutions of NAC 
solution were done after plasma treatment to fit hydrogen peroxide concentrations in 
plasma treated NAC solution to the standard curve. Calculated concentrations were 
multiplied by dilution factor to obtain real concentration of hydrogen peroxide in plasma 
treated NAC solution. We detected 0.42 mM, 1.67 mM and 0.93 mM of hydrogen 
peroxide after 1-minute, 2-minute and 3-minute treatment of NAC solution respectively. 
It is interesting that, hydrogen peroxide concentration reaches to saturation after 2 
minutes of plasma treatment and then drops after 3 minutes of plasma treatment (Figure 
25b). 
 
! 79!
 
 
Figure 25:  (a) Standard curve for hydrogen peroxide detection in plasma treated NAC 
solution and (b) Treatment time dependent hydrogen peroxide concentration in plasma-
treated NAC solution. 
 
 3.3.2 Nitrite and Nitrate Detection: Both nitrite and nitrate concentrations in plasma 
treated NAC solution increase with plasma treatment time. Nitrite concentrations in 
plasma treated NAC solution were determined as 0.03 mM, 0.16 mM and 0.33 mM after 
1-minute, 2-minute and 3-minute of plasma treatment respectively (Figure 26a). Nitrate 
concentrations in plasma treated NAC solution were measured as 1 order magnitude 
more than nitrite, where 2.07 mM, 5.46 mM, and 9.35 mM nitrate was generated after 1, 
2 and 3 minutes of plasma treatment respectively (Figure 26b).  
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Figure 26: Treatment time dependent concentrations of (a) NO2- (Nitrite), and (b) NO3- 
(Nitrate) in plasma-treated NAC Solution. Both concentrations increase with plasma 
treatment time. 
 
3.3.3 UV-Visible Spectrum Analysis of Plasma Treated NAC Solution:  UV-visible 
spectra of plasma treated NAC solutions were obtained after 1, 2 and 3-minute plasma 
treatement. In the spectrum of 1-minute plasma treated NAC solution, we have seen a 
specific peak at 332 nm, which belongs to S-nitroso-N-acetyl cysteine (SNAC) a type of 
S-nitrosothiol. This peak disappears in the spectra of 2 and 3-minute plasma treated 
NAC solution. In the spectrum of 2-minute plasma treated NAC solution a new peak 
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starts to appear at 302 nm and the absorbance value of this peak increases after 3 
minutes of plasma treatment (Figure 27a). In order to better understand chemical 
modifications in the NAC solution during plasma treatment, we have also obtained UV-
visible spectra after of NAC solution 30, 45, 75 and 90 seconds of plasma treatment. 
Figure 27b shows that the peak at 332 nm that is specific for S-nitrosothiols and in our 
case specifically belongs to S-nitroso-N-acetyl cysteine (SNAC) first appears after 30 
seconds of plasma treatment and increases with the plasma treatment duration until 75 
seconds of plasma treatment. After 90 seconds of plasma treatment the peak at 332 nm 
disappears and the peak at 302 nm appears. The peak at 302 nm increases with plasma 
treatment time until the end of plasma treatment (3 minutes). Concentration of 
peroxynitrite in plasma treated NAC solution is calculated by using the Beer-Lambert 
Law. The Beer-Lambert Law defines the correlation between concentration of a 
substance and its absorbance at particular concentration. It is expressed with following 
equation:  ! = ! ∙ ! ∙ !  
Where; A is absorbance, ε is extinction coefficient (M-1.cm-1), l is the path length that 
light passes through and c is the concentration of the substance.  εONOO- is given as 1670 
M-1.cm-1. From the given equation, concentration of peroxynitrite in 3-minute plasma 
treated NAC solution was calculated as 0.28 mM. 
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Figure 27: (a): UV-visible spectra of NAC solution treated for 1,2 and 3 minutes. (b): 
UV-visible spectra of NAC solution, showing the peaks depending on plasma treatment. 
The green dashed line shows the peak at 302 nm and the red dashed line shows the peak 
at 332 nm. 
 
3.3.4 FT-IR Analysis of Plasma Treated NAC Solution: As it is shown in Figure 28 
IR peaks of untreated NAC molecule at 3375 cm-1, 2547 cm-1, 1718 cm-1, and 1535 cm-1 
correspond to the stretching motion of N–H in CONH group, S-H, C=O and CONH 
group, respectively. The absorptions at these peaks disappear after plasma treatment of 
NAC solution. New peaks after plasma treatment appear at 3600-3000 cm-1 (broad), and 
1344 cm-1 (narrow), which corresponds to the stretching motion of -NH2 and -SO3H, 
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respectively. FT-IR spectra of untreated and 3 minutes of plasma treated NAC solution 
suggest that the SH group was converted to -SO3H. Moreover the cleavage of!N-acetyl 
group leads to formation of acetic acid (CH3COOH) and –NH2 formation due to the 
hydrogenation of NH group. These results suggest that NAC molecule was converted to 
acetic acid (CH3COOH) and cysteic acid (C3H7NO5S) due to oxidation of thiol group as 
a result of plasma treatment. Peaks corresponding acetic acid can’t be seen on the 
spectrum because of the evaporation of acetic acid during the evaporation of water 
before FT-IR analysis.  
 
 
Figure 28: (a): FT-IR spectra of NAC solution before and after 3 minutes of plasma 
treatment. (b): Chemical bonds and groups on untreated NAC molecule that are  
indicated on FT-IR spectrum. (c): Chemical bonds and groups on cysteic acid that are 
indicated on FT-IR spectrum.  
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3.3.5 Nuclear Magnetic Resonance (NMR) Analysis of Plasma Treated NAC 
Solution: As depicted in the Figure 29, NMR data corresponds with spin coupling 
patterns of N-acetyl cysteine, which is being chemically converted to cysteic acid by 
cleavage of the N-acetyl group from the NAC molecule and oxidation of the thiol to 
cysteic acid. Increasing duration of plasma treatment of N-acetylcysteine resulted in 
increase in intensity of multiplets found in 3.54-3.61 and 3.24-3.42 ppm, as well as 
decrease in intensity of the multiplet located at 2.95-3.01 ppm.  Proton shifts suggest that 
~90% of N-acetyl cysteine is converted to cysteic acid via cleavage of the thiol group.  
 
 
Figure 29: NMR Spectra of (a) untreated and  (b) 3-minute plasma treated NAC 
solution. (a): Peaks and corresponding H atoms in untreated NAC solution. Peak 1 
corresponds to signal form D2O. (b): Arrows indicate increased multiplets correspond to 
cysteic acid. 
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3.3.6: Antimicrobial Effect of Acidic pH and Plasma-Generated Species: As 
demonstrated in Figure 30, different acids at pH ~2.3, except acetic acid, don’t show 
significant antimicrobial effect on 107 CFU/ ml E. coli. Acetic acid caused 3.5-log 
reduction. Acetic acid is a weaker acid compared to other acids that were used in this 
experiment. Therefore higher amount of acetic acid is needed to obtain pH ~2.3 solution 
of it that leads higher concentration of acetate ion (CH3CO2-). When tested acids were 
combined with 0.93 mM H2O2, which is the detected concentration of H2O2 in NAC 
solution after 3-minute of plasma treatment no significant improvement of antimicrobial 
effect was not observed except in the HCl. The increased antimicrobial effect of HCl 
when it is combined with H2O2 is attributed to the formation of hypochlorous acid that is 
known as halogenating agent [8]. In addition, acetic acid loses its antimicrobial activity 
when it is combined with H2O2. 
 
Figure 30: Antimicrobial effect of different acids at pH ~2.3 alone and combined with 
0.93 mM H2O2 
Antimicrobial effects of detected concentrations of nitrite (0.33 mM), nitrate (9.35 mM), 
hydrogen peroxide (0.93 mM), acetic acid (~5 mM), and cysteic acid (~ 5 mM) in 3-
7.16"
0.00"
3.63"
7.20" 7.15" 7.08" 7.17"7.03" 7.09" 6.99" 7.07"
2.67"
7.03"
0.00"
1.00"
2.00"
3.00"
4.00"
5.00"
6.00"
7.00"
8.00"
log
10
N 
Su
rv
ivi
ng
 B
ac
ter
ia!
Acids tested!
"w. 0.93 mM H2O2""
! 86!
minute plasma treated NAC solution were tested on 107 CFU/ ml E. coli by itself and in 
combination with each other. The pH of all tested mixtures were set to ~2.3-2.5. H2SO4 
was used to set the pH in order to avoid possible interaction of HCl and HNO3 with 
tested species. Table 4 shows all tested species and their combinations.  
Table 4: Combinations of detected concentrations of plasma-generated species that are 
tested on 107 CFU/ml E. coli  
 Combination of 2 Combination of 3 Combination of 4 
H2O2 H2O2  + 
NO2- 
NO2- + 
A.A 
H2O2  + NO2- + NO3- NO2- + A.A. + 
C.A. 
H2O2  + NO2- + NO3- + 
A.A. 
NO2- H2O2  + 
NO3- 
NO3- + 
A.A 
H2O2  + NO2- + A.A. NO3- + A.A. + 
C.A. 
H2O2  + NO2- + NO3- + 
C.A. 
NO3- H2O2  + 
A.A 
NO2- + 
C.A 
H2O2  + NO2- + C.A. H2O2 + A.A. + 
C.A. 
NO2- + NO3- + A.A. + 
C.A. 
A.A. H2O2  + 
C.A 
NO3- + 
C.A 
NO2- + NO3- + A.A. H2O2  + NO3- + 
A.A. 
A.A. + C.A. + H2O2  + 
NO2- 
C.A. NO2-  + 
NO3- 
A.A. + 
C.A. 
NO2- + NO3- + C.A. H2O2  + NO3- + 
C.A. 
A.A. + C.A. + H2O2  + 
NO3- 
Combination of 5 
H2O2  + NO2- + NO3- + A.A. + C.A. 
*Note that all of tested mixtures achieved < 1log reduction.  
(A.A. = Acetic acid, C.A. = Cysteic acid) 
 
 Any of tested species and combinations were not able to present significant 
antimicrobial effect (< 1 log). In a further experiment, detected concentrations of H2O2, 
NO3-, and NO2- were combined with arbitrarily selected concentrations (0.1, 0.5 and 1 
mM) of superoxide that was generated by SOTS-1 (superoxide thermal source) 
compound. Since the SOTS-1 is dissolved in DMSO, antimicrobial effects of 
corresponding concentrations of DMSO were tested in order to make sure that DMSO 
doesn’t interfere with results. Superoxide in given concentrations and in combination 
with detected concentration of H2O2 didn’t present any significant antimicrobial effect (< 
1 log). Similarly 0.1 and 0.5 mM of superoxide and nitrate (9.35 mM) combinations 
have shown less than 1-log reduction. Combination of 1 mM superoxide with 9.35 mM 
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nitrate inactivated close to 1 log bacteria. Finally given concentrations of superoxide 
were combined with 0.33 mM nitrite. Results revealed that only combination of 1 mM 
superoxide with 0.33 mM nitrite was able to achieve more than 6.5-log reduction. This 
effect was disappeared when hydrogen peroxide and nitrate added to superoxide-nitrite 
mixture (Figure 31). These results led us to think that RNS might be primary reason for 
the antimicrobial effect of plasma treated NAC solution.  
 
Figure 31: Combination of nitrite and superoxide completely kills more than 6.5 log E. 
coli. Antimicrobial effect disappears when nitrate and hydrogen peroxide are added to 
nitrite-superoxide mixture. 
 
Therefore we have tested antimicrobial effect of detected concentration of peroxynitrite 
(ONOO-) on 107 CFU/ ml of E. coli. Since the peroxynitrite solution is provided in 
NaOH solution, antimicrobial effect of corresponding concentrations of NaOH were also 
tested in order to ensure that NaOH doesn’t interfere with antimicrobial effect. As it is 
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demonstrated in Figure 32 0.36 mM and 0.18 mM of peroxynitrite has shown more than 
5.5 and 3.5-log reduction respectively. 
 
 
Figure 32: Antimicrobial effect of different concentrations of peroxynitrite and 
corresponding concentrations of sodium hydroxide. 
 
3.4 Discussion: According to our findings, antimicrobial effect of plasma treated NAC 
solution seems to be from chemical modifications in NAC solution during plasma 
treatment. The previous literatures, which have reported a moderate reduction in pH of 
PBS or water always had a plasma discharge gap of more than 2 mm through 45 mm, 
and the amount of liquid more than 1.5 ml through 10 ml [105,156.157.184]. This 
drastically changes the chemical properties and pH equation of these solutions. Our 
findings show that acidic pH has no direct contribution on bacterial inactivation as has 
also been commonly reported by other groups [105,184,187]. However low pH seems to 
be a crucial for antimicrobial effect referring to antimicrobial effect of acidified nitrites 
[188-190].  
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We have attempted to provide a recipe of plasma treated liquids that is able to inactivate 
the same amount of bacteria as plasma treated liquids do under same conditions. In our 
experiments detected concentrations of plasma-generated species haven’t shown any 
significant antimicrobial activity. That might be due to lack of other plasma-generated 
species. Plasma treated liquids are complex mixtures of ROS and RNS and carry various 
charged and uncharged molecules. Further detailed chemical analyses and chemical 
kinetic experiments are required to better understand exact roles of plasma-generated 
species on microbial inactivation. Oehmigen et al. have reported that the mixture of 
0.074 mM H2O2 and 0.032 mM NO2- at pH 3 is able to inactivate 3.5-log E. coli [155]. 
However this effect is mostly related to exposure conditions of bacteria to hydrogen 
peroxide-nitrite mixture. In the mentioned study, bacteria was exposed 50 times more 
volume of mixture (50 μl bacteria: 2.45 ml mixture) as opposed to our 1:1 (50 μl 
bacteria: 50 μl mixture or plasma treated NAC) ratio and held for 60 minutes as opposed 
to our 15 minutes of holding time. Therefore our findings on nitrite-superoxide mixture, 
which demonstrates 7-log reduction under the same exposure conditions with plasma 
treated NAC, seems to be more reliable and relevant to our plasma treatment method. In 
addition, the inactivation rate of peroxynitrite in the detected range supports our 
approach on the more dominant contribution of RNS to microbial inactivation. However 
precise detection and quantification of superoxide is required for better understanding of 
interactions between oxygen and nitrogen species. 
  An interesting chemical modification was observed after 1-minute plasma treated 
NAC solution. In the UV-visible spectrum of 1-minute plasma treated NAC solution we 
have seen a peak at 332 nm, which is specific for S-nitrosothiols (in our case S-nitroso-
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N-acetyl cysteine).  Also S-nitrosothiols have another specific peak at 545 nm with 16 
M-1 cm-1 molar extinction coefficient, which is more suitable to for concentration 
calculation due to lack of possible interference of other nitrogen species [199]. 
According to absorbance of the peak at 545 nm and the molar extinction coefficient 
concentration of S-nitroso-N-acetyl cysteine is calculated as 0.75 mM by using Beer-
Lambert equation (Figure 33a).  S-nitrosothiols, with the general structure, RSNO (R is 
and organic group) are the S-nitrosylated products of thiols and are known as NO (nitric 
oxide) donors and carriers with characteristic pink color [199-201]. Our findings and 
observations on 1 minute plasma treated NAC solution regarding the formation of S-
nitroso-N-acetyl cysteine is consistent and supported by previous literature; we have 
observed a pinkish color development in 1 minute plasma treated NAC solution as 
demonstrated in Figure 33b. 
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Figure 33: (a) Specific absorbance peak of S-nitroso-N-acetyl cysteine at 545 nm.          
(b) Structure of S-nitroso-N-acetyl cysteine. (c) Color change in 1 minute plasma treated 
NAC solution. Pinkish color formation is indicator of S-nitroso-N-acetyl cysteine 
(SNAC) in NAC solution after 1-minute non-thermal plasma treatment. 
 
 
Formation of S-nitrosothiols (RSNO) involves the reaction of a thiol (RSH) with NO and 
NO derivatives such as NO2, NO2-, N2O3. By itself NO reaction with a thiol yield to 
disulfide formation rather than RSNO. However in the presence of oxygen or other 
oxygen species such as hydrogen peroxide, NO oxidation yields to formation of S-
nitrosothiols [202]. Oxidation of thiols with plasma generated ROS involves the 
production of sulfanyl radical that will later react with NO to form S-nitrosothiol as 
shown in the equations below [206]. 
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RSH + O2- ! RS" + HOO-                  (23) 
RSH + HOO- ! RS" + OH- + HO"     (24) 
RSH + HO" ! RS" + H2O                  (25) 
 
 Hence plasma generated ROS and RNS cause the modification of NAC to S-NAC by 
the end of 1-minute plasma treatment. It is well known that reaction of O2- and NO 
yields to peroxynitrite (ONOO-). S-nitroso-N-acetyl cysteine acts as NO donor via 
decomposition for peroxynitrite formation in plasma treated NAC solution. Not only 
plasma generated ROS and RNS but also UV light that is generated during plasma 
treatement and acidic pH as a result of plasma treatment of liquids have influence of the 
production and the decomposition of SNAC. UV light and the presence of thiols 
(unreacted NAC) in acidic environment induce decomposition of S-nitrosothiols (in our 
case S-NAC) [201]. Nitric oxide (NO) is released via the decomposition of S-NAC and 
reacts with plasma-generated superoxide (O2-) for peroxynitrite formation. Another 
mechanism for the S-nitrosothiol mediated peroxynitrite formation, which is relevant to 
plasma treated liquids, involves the reaction of hydrogen peroxide with S-NAC. The 
mentioned mechanism involves the dissociation of hydrogen peroxide and the reaction 
of hydroperoxyl (HO2-) with S-NAC as given in the following equations [204]. 
                 H2O2 ! H+ + HOO-                       (26) 
RSNO + HOO- ! RS- + ONOO- + H+           (27) 
In addition to plasma-generated superoxide, by itself S-nitrosothiol formation 
mechanism can lead superoxide production via reduction of O2 by RSNO-H, a radical 
intermediate, as given in following equations [205].  
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RSH + NO ! RSN"-O-H                                       (28) 
RSH + NO ! RSN"-O-H + O2 ! RSNO + O2-     (29) 
 
Our FT-IR and NMR data suggests that about ~90% NAC is converted to cysteic acid. 
This mechanism involves the oxidation of NAC as given in equations 23-25. Oxidation 
of thiols is resulted with formation of disulfides that later can be oxidized to sulfonic 
acid (in our case cysteic acid) [206,207]. In the reaction, where NAC is converted to 
cysteic acid, also acetic acid is formed due to cleavage of acetyl group. The overall 
reaction is shown in the equation below:  
 
C5H9NO3S + HOO-  !   C3H7NO5S   +  C2H4O2    (30) 
         (NAC)                       (Cysteic acid) (Acetic acid) 
 
It can be easily seen from equation 30 that, in order to fulfill the atomic balance in the 
reaction, NAC should react with HOO-, which might be presenting in the plasma treated 
NAC solution due to the dissociation of H2O2 as shown in equation 26, or protonation of 
superoxide This possible reaction mechanism explains the decreased hydrogen peroxide 
concentration in 3 minute plasma treated of NAC solution compared to 2-minute treated 
one. Also formation of cysteic acid and acetic acid contributes to the rapid and drastic 
pH drop in NAC solution following plasma treatment.   
 In conclusion, our findings suggest that plasma treatment turns NAC solution 
into an acidic mixture of ROS and RNS that both contribute to bacterial inactivation. 
NAC seems to be in the center of all reactions and interactions between ROS and RNS. 
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NAC by itself serves as a source of RNS by releasing NO and also source of ROS 
through intermediates on its reactions with other ROS. Even though antimicrobial effect 
can be attributed to both ROS and RNS, based on our results we speculate that 
dominantly ROS play a role in the modification of NAC molecule and RNS seems 
contribute to antimicrobial effect more dominantly. The action of mechanism of ROS 
and RNS on microbial inactivation will be discussed in detail in Chapter 5. 
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4    CHAPTER IV: ANTIMICROBIAL STABILITY AND TOXICITY OF 
PLASMA-TREATED N-ACETYL CYSTEINE (NAC) SOLUTION 
 
 
4.1 Introduction: 
 Effects of non-thermal plasmas on eukaryotic cells and living tissues have been 
studied by various groups, and also discussed in the Chapter 1. Direct applications of 
non-thermal plasmas have various effects on eukaryotic cells such as; blood coagulation, 
living tissue sterilization, tooth whitening, wound healing, etc. [95,99,120,146,173]. 
Next to exciting applications and biological effects of non-thermal plasmas on tissues, its 
toxicity is correlated with the plasma dose that is applied [85,95,141,209]. In particular 
cytotoxic effects of non-thermal plasma applications were attributed to DNA and cell 
membrane damage that rise from plasma-generated species and UV generation during 
plasma treatment [134,135]. However, reports regarding toxicity of plasma treated 
liquids on eukaryotic cells and tissues are limited. Since effects of electron discharge, 
UV generation and localized heating are excluded by fluid-mediated plasma treatment, 
toxicity of plasma treated liquids can be attributed plasma-generated species and 
chemical modifications in the plasma treated liquid. Kim et al. have investigated toxicity 
and antimicrobial effect of liquid phase discharge plasma. In their study, PBS was placed 
on human skin, which was harvested by biopsy and treated with the liquid plasma 
electrode where it is in direct contact with the PBS. In other words they have performed 
direct treatment of skin with plasma in the liquid interface and they have reported that 
their treatment method doesn’t cause any significant toxicity on the skin [210]. Even 
though this study doesn’t represent the fluid-mediated plasma treatment, it is a close 
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model that can be taken into consideration. We recently reported that non-thermal DBD 
plasma-treated calcium alginate gel isn’t cytotoxic to endothelial cells and induces cell 
proliferation after and transient slowed growth [154]. Plasma-generated species have 
effect on cell death in a concentration dependent manner. For instance, hydrogen 
peroxide either can stimulate or reduces cell proliferation or cell apoptosis depending on 
its concentration. Similarly nitric oxide can enrich or reduce hydrogen dependent cell 
apoptosis in concentration dependent manner [211-213].  
 Studies about antimicrobial effects of plasma treated liquids for extended period 
of time are limited in the literature. Traylor et al. have reported that indirect DBD 
plasma treated water can retain its antimicrobial activity for up to 7 days when exposed 
to bacteria for 3 hours. They have observed ~5 log and ~2.4 log reduction 2 and 7 days 
after plasma treatment respectively. However in case of 15-minute exposure of indirect 
DBD plasma treated water to bacteria, the antimicrobial effect diminishes in 30 minutes 
and completely disappears in seven days after plasma treatment [110]. In a similar study 
Julak et al. have reported that 1 ml water and PBS samples that are treated for 1 hour 
with positive corona discharge can preserve its antimicrobial activity for up to 1 month 
[182].   
 
4.2 Materials and Methods: 
4.2.1 Delayed Exposure and Aging of Non-Thermal DBD Plasma-Treated NAC 
Solution: The duration between the termination of plasma treatment and the exposure of 
plasma treated liquid to bacteria is defined as delay time. In order to see how long 3-
minute plasma treated NAC solution can retain its antimicrobial activity, plasma treated 
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NAC solution was kept at +4o C and room temperature from 0 to 28 days in 
microcentrifuge tubes with their caps sealed with parafilm. For each delay time point 
one microcentrifuge tube was opened, and 3-minute plasma treated NAC solution was 
exposed to 107 CFU/ml E. coli, held for 15 minutes and colony counting assay was 
performed as previously described. For 0 day delay time, plasma-treated liquid was 
exposed to bacteria immediately after plasma treatment. For aging experiments, protocol 
of the U.S. Food and Drug Administration for aging pharmaceutical compounds [208] 
was used. 1 ml of NAC solution was treated for 3 minutes and immediately transferred 
to glass vials, screw caps placed, and vials sealed with parafilm and kept in 
thermostatically controlled incubator at 37oC and 50oC for over the time. The protocol 
for accelerated aging (also known as 10 degree rule) was developed around the collision 
theory-based Arrhenius model. The equivalent aging time to actual incubation time is 
calculated from the following equation:  
 
Where as; TimeA is the actual incubation time, TimeRT is the equivalent time at room 
temperature to aging time at storage temperature, Q10 is reaction-rate coefficient, T1 is 
aging temperature and TRT is room temperature (ambient temperature, in which the 
compound is stored for practical application).  
Following steps should be considered in order to apply the given equation for the 
accelerated aging test: 
• The reaction rate coefficient should be selected Q10 =2 unless a specific 
rate coefficient is determined for the compound experimentally. 
€ 
TimeA =
TimeRT
Q10T1 −TRT( ) 10[ ]
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• The ambient temperature should be selected between 20 and 25oC 
• The aging temperature shouldn’t be selected more than 60oC 
Aging time points and corresponding equivalent time points for both 37 and 50OC aging 
temperatures are depicted in Figure 34.  
 
Figure 34: Relationship between aging time and corresponding equivalent time for 
accelerated aging experiment for 37 and 50OC aging temperature. 
 
 
In order to evaluate the antimicrobial effect of aged NAC solution at the indicated time 
point, one vial was removed, and the solution was exposed to equal volume of 
(50μl:50μl) 107 CFU/ml E. coli, held for 15 minutes and colony counting assay was 
performed as descried previously.  
 
4.2.2 Antimicrobial Effect of Components of Plasma-Treated NAC Solution: In 
brief, NAC solution is prepared by dissolving NAC powder (solute) in PBS (solution). 
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As discussed in Chapter 3, plasma treatment induces chemical modifications both in 
whole solution and NAC molecule. In order to evaluate the contribution of solute (NAC 
molecule) and solution (PBS) parts of plasma treated NAC solution, a separation 
experiment was carried out as demonstrated in Figure 35. After 3-minute plasma 
treatment, NAC solution was immediately transferred to a glass beaker, the glass beaker 
was closed with a glass petri dish and heated on a hot plate by not exceeding 50OC until 
the whole liquid part was evaporated. The evaporated liquid part condensed and 
collected separately in a microfuge tube. Dried, plasma-treated NAC powder (solute) 
was reconstituted in three different ways: 
 1st with PBS, same volume evaporated liquid that yields to 5 mM final 
concentration,  
2nd with PBS, the half of the evaporated liquid volume that yields to 10 mM final 
concentration and  
3rd in the same volume of evaporated liquid. (for a final concentration of 5 mM). 
Also the condensed liquid part of plasma treated NAC solution was exposed to bacteria 
in 1:1 (50μl bacteria: 50μl solution) and 1:2 (50μl bacteria: 100μl solution) ratios. 
The separation process was repeated for pH measurement, antimicrobial tests and UV-
vis spectra analyses separately. For antimicrobial tests, each liquid was exposed to equal 
volume of (50μl:50μl) 107 CFU/ml E. coli, held for 15 minutes and colony counting 
assay was performed as previously described.  
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Figure 35: Experimental method for separation experiment. Liquid part of plasma-
treated NAC solution is evaporated and then condensed. Dried powder was reconstituted 
with the same and half of the evaporated volume of PBS and same volume of condensed 
liquid part. Antimicrobial effects of all reconstituted liquids were tested and their UV-vis 
spectra were collected. 
 
Also NAC powder was treated with DBD plasma for 3 minutes and than NAC solution 
was prepared by dissolving the treated NAC powder in PBS to have 5 and 10 mM of 
final concentration. These solutions were exposed to equal volume of 107 CFU/ ml E. 
coli and colony counting assay and pH measurements were performed.  
 
4.2.3 Effect of Vitamin E on Antimicrobial Properties of Plasma-Treated NAC 
Solution: As previously described, plasma generated ROS and RNS are diffused into 
NAC solution during plasma treatment. Plasma treated NAC solution (1,2, and 3 
minutes) was exposed to equal volume of 107 CFU/ml E. coli suspension, which was 
prepared in varying concentrations of Vitamin E (alpha tocopherol) solution (10, 25, 50 
and 100 mM) in order to evaluate oxidative and nitrosative capacity of plasma treated 
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NAC solution. Following exposure of plasma treated NAC solution, bacteria were held 
for 15 minutes and colony-counting assay was performed as previously described. 
4.2.4 Repeated Exposures of Plasma-Treated NAC Solution: In order to assess how 
plasma treated NAC solution shows its antimicrobial activity on bacteria, we have 
repeatedly exposed plasma treated NAC solution on bacteria pellet. In other words we 
have tried to demonstrate if all plasma-generated species are consumed immediately 
following exposure to bacteria, or required amount of them are consumed and rest of the 
plasma treated NAC solution remained in plasma treated NAC solution. In repeated 
exposure experiments 100 μl of 107 CFU/ml bacteria suspension was spun down at 8000 
rpm for 10 minutes and supernatant was removed. Then 100 μl of 3-minute plasma 
treated NAC solution was exposed on bacteria pellet, homogenized by vortexing and 
held for 5 minutes and spun down for 10 minutes at 8000 rpm. So total holding time was 
kept 15 minutes (5 minutes exposure to bacteria and 10 more minutes during 
centrifugation) similar to previous experiments. After centrifugation supernatant, which 
is plasma treated NAC exposed to bacteria was collected and exposed to another bacteria 
pellet (Figure 36). Same procedure was repeated for 4 times.  
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Figure 36: Flow chart of the experimental procedure for repeted exposures of plasma-
treated NAC solution. 
 
 
After each exposure of plasma treated NAC to bacteria, reacted NAC was separated by 
centrifugation and treated bacterial pellet was resuspended in sterile PBS and colony 
counting assay was performed as previously described. 
 
4.2.5 Cytotoxicity of Plasma-Treated NAC Solution: Cytotoxicity of plasma treated 
NAC solution was tested on the EA.hy926 human somatic umbilical vein endothelial 
cell line. EA.hy926 cell line was kindly provided by Dr. Peter Lelkes’ laboratory, at 
Drexel University, School of Biomedical Engineering, Science & Health Systems. 
Frozen stocks of cell line were thawed in water bath at 37OC for 3 minutes. 1 ml of 
thawed cells was transferred to 15 ml centrifuge tube and diluted with 1% FBS (Fetal 
Bovine Serum) containing 9 ml of DMEM (Dulbecco’s Modified Eagle Medium) 
(Invitrogen, Grand Island, NY, USA). Afterwards cells were spun down at 1500 rpm for 
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5 minutes and supernatant was removed. 10% FBS and 1% penicillin-streptomycin 
containing 10 ml of fresh DMEM was added to the cell pellet and cells were gently 
homogenized by pipetting and transferred in to T25 cell culture flask (Corning, Corning, 
NY, USA) then incubated in CO2 incubator at 37OC for 24 hours. Grown cells were 
trypsinized and transferred to T75 cell culture flasks and incubated in CO2 incubator at 
37OC until cells become 90% confluent. Confluent cells were trypsinized and counted 
with hemocytometer in order to fix cell number to ~20000 to seed in 96 well plate. 10% 
FBS and 1% penicillin-streptomycin containing 200 μl of fresh DMEM was added to 
cells in each well and cells were incubated in CO2 incubator at 37OC until they get 90% 
confluent (~ 30000 cells/well). Confluent cells were washed with 1X sterile PBS for 
twice and 100 μl of serum free DMEM added on cells. Next, 100 μl of untreated and 
plasma treated NAC solutions (for 1, 2, and 3 minutes) were added on cells and held for 
5, 10, 15, and 30 minutes. Following holding time, media and plasma treated NAC 
solution was removed; cells were washed with 1X sterile PBS for twice and 10% FBS 
and 1% penicillin-streptomycin containing 200 μl of fresh DMEM was added. Cells 
were incubated in CO2 incubator at 37OC for 24 and 48 hours for recovery. Serum free 
DMEM and 4% chlorhexidine solution were used as negative and positive controls 
respectively. Following recovery period cell viability was determined by XTT assay as 
previously described.  
4.2.6 Systemic Toxicity of Plasma-Treated NAC Solution in Rats: One of the 
possible practical applications of plasma treated NAC solution is to use it as a catheter 
lock solution for the eradication of biofilms, grown in IV catheters that are one of the 
main causes of sepsis. In this application, there is always potential risk of leakage of 
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plasma treated NAC solution into the bloodstream. In order to evaluate the possible toxic 
effects of plasma treated NAC solution in the event of leakage, we have administrated 
different doses of 3-minute plasma treated NAC solution to 3-month old female rats 
(Sprague-Dawley strain). Rat infusion experiments were carried out in accordance with 
the Guide for the Human Care and Use of Laboratory Animals. The experimental 
procedure (Protocol# 19512) was approved by the Institutional Animal Care and Use 
Committee, Drexel University (IACUC). Sprague-Dawley rats were purchased from 
Harlan Laboratories (Indianapolis IN, USA). Upon arrival, rats were acclimatized for 5 
days. Rats were divided in to five groups; no injection was performed in the first group 
of rats, 1ml/day untreated NAC solution was administrated to the second group of rats 
for 3 days, 1ml/day plasma treated NAC solution was administrated to the third group of 
rats for 3 days, 3 ml of plasma treated NAC solution was administrated to the fourth 
group of rats for one time and 3 ml/day plasma treated NAC solution was administrated 
to the fifth group of rats for three days. Administration of plasma treated NAC solutions 
were performed using 20 gauge IV catheter via tail vain. Prior to catheter placement rats 
were anesthetized with 3% isoflurane inhalation. NAC solutions that are used in infusion 
experiments were prepared in 0.9% saline solution. Therefore antimicrobial effect of 
NAC solution prepared in 0.9% saline solution was tested as previously described in 
Chapter 2. Following the final injections, rats were closely observed for 1 week. After 1 
week of observation rats were euthanized with overdose sodium pentobarbital and 
phenytoin solution injection via portal vein. Liver, kidney, tail vein, heart and lung tissue 
samples were collected from euthanized rats and sent to ANTECH Diagnostics (Lake 
Succes, NY, USA) for histopathology evaluation. Also blood samples were collected 
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before scarification of rats and sent to ANTECH Diagnostics for analysis in order to 
evaluate alterations in blood chemistry.    
 Antimicrobial activity of plasma treated NAC solution can be considered as its 
oxidative and nitrosative capacity, which also cause toxicity in eukaryotic cells. In order 
to simulate the scavenging capacity of blood during infusion experiments, antimicrobial 
effect of plasma treated NAC solution (prepared in 0.9% saline solution for injection 
purpose) was tested in the presence of blood. For this aim 107 CFU/ml E. coli culture 
suspension was prepared in PBS containing 1%, 25% and 50% blood, equal volume of 
plasma treated NAC solution was added on bacteria suspension, held for 15 minutes and 
colony-counting assay was performed as previously described in Chapter 2.   
 
4.3 Results: 
4.3.1 Antimicrobial Effect of Plasma-Treated NAC Solution Over Time: As 
demonstrated in Figure 37, 3-minute plasma treated NAC solution can retain its 
antimicrobial activity for up to 28 days when it is stored at room temperature and +4OC 
separately. For clarity negative control results are represented for Day 0. However for 
each delay time point initial bacterial load was 107 CFU/ml (7-log surviving bacteria). 
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Figure 37: Plasma-treated NAC solution can retain its antimicrobial activity when 
stored at both room temperature and +4OC.  
 
Similarly, as demonstrated in Table 5, accelerated aging experiments showed the same 
occurrence, where all aged samples retained their antimicrobial activity for 255 and 103 
days, which are equivalent to 2 years (720 days) at room temperature when stored at 
37OC and 50OC respectively. pH measurement results suggest that pH of plasma treated 
NAC solution remains stable independent of storage duration or temperature. 
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Table 5: Colony-counting assay showing antimicrobial efficacy of accelerated aging of 
plasma-treated NAC solution. (Results are shown as log10(N) surviving bacteria.) 
 
 37O C 50O C 
Equivalent 
Days 
Days 
Incubated 
(-) 
Ctrl. 
(+) 
Ctrl. 
Plasma 
Treated 
NAC 
Days 
Incubated 
(-) 
Ctrl. 
(+) 
Ctrl. 
Plasma 
Treated 
NAC 
15 5 7.05 0 0 2 7.03 0 0 
30 11 7.03 0 0 4 7.09 0 0 
60 21 7.03 0 0 9 7.07 0 0 
90 32 7.04 0 0 13 7.05 0 0 
180 64 7.03 0 0 26 7.03 0 0 
360 127 7.02 0 0 52 7.06 0 0 
540 191 7.05 0 0 78 7.02 0 0 
720 255 7.04 0 0 103 7.03 0 0 
 
4.3.2 Antimicrobial Effect of Separated Components of Plasma-Treated NAC 
Solution: As explained in the Materials and Methods section of Chapter 4, powder of 
plasma treated NAC obtained by evaporation. Dried plasma-treated NAC powder was 
reconstituted in three different ways: 
 1st in PBS, using the same volume of evaporated liquid that yields to 5 mM final 
concentration,  
2nd in PBS, using the half of the evaporated liquid volume that yields to 10 mM 
final concentration and  
3rd in the same volume of evaporated liquid. (to yield a final concentration of 5 
mM) 
It is important to remember that given final concentrations don’t represent 
concentrations of plasma generated species and refers to the initial concentration of 
unreacted NAC. 
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In the first case no antimicrobial effect was observed. In the second and third cases 7-log 
reduction was observed. When condensed liquid portion of plasma treated NAC solution 
was used, no inactivation was observed. pH of reconstituted solutions was increased 
slightly and measured as 4.2, 3.5, and 3 for 1st, 2nd, and 3rd case respectively. Also 
condensed liquid retained its acidity, where the pH was measured as 3. Figure 38 
summarizes inactivation and pH measurement results of reconstitution experiments.  
 
Figure 38: Antimicrobial activity and pH of plasma-treated NAC solution following 
drying and reconstitution process. Antimicrobial activity and pH of condensed liquid 
portion of plasma-treated NAC solution is also demonstrated. 
 
 In case of DBD plasma treatment of NAC powder by itself and preparation of 
NAC solution with plasma-treated NAC powder, no inactivation effect was achieved 
with both 5 mM and 10 mM solutions. pH of prepared solutions were measured as ~6 
(Figure 39). 
7.08!
0.00! 0.00!
6.67!
0.00!
6.64! 6.50!
0.00!
6.2!
2.3!
4.2! 3.5!
2.4! 2.4! 3!
0!
1!
2!
3!
4!
5!
6!
7!
0.00!
1.00!
2.00!
3.00!
4.00!
5.00!
6.00!
7.00!
8.00!
Untreated!NAC! Treated!NAC! H2O2! Recons.!1:1!(Final!Conc.!5!mM)! Recons.!2:1!(Final!Conc.!10!mM)! Condensed!Liquid!(1:1!Bac.:CL)!! Condensed!Liquid!(1:2!Bac.:CL)! Recons.!1:1!Cond.!Liquid!(5!mM)!
pH
%
lo
g%
Su
rv
iv
in
g%
Ba
ct
er
ia
%
Conditions%
log!Surviving!Bacteria! pH!
! 109!
 
Figure 39:  pH and antimicrobial effect of NAC solution, where NAC powder first 
treated by itself and then dissolved in PBS. Final concentrations are 5 mM and 10 mM.  
 
 UV-visible spectra of reconstituted solutions showed a specific peak at 302 nm 
similar to plasma treated liquid. Peaks at 302 nm may represent ONOO- and 
concentrations of ONOO- were calculated as 0.18 and 0.36 mM for the above-mentioned 
1st and 2nd reconstitution cases respectively (Figure 40).  
 
 
Figure 40: UV-visible spectra of dried and reconstituted plasma-treated NAC solution. 
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4.3.3 Effect of Vitamin E on Antimicrobial Properties of Plasma-Treated NAC 
Solution: Scavenging effect of Vitamin E is closely related with its concentration and 
plasma treatment time. As represented in Figure 41, 100 mM of Vitamin E reduced 
inactivation of bacteria by ~1.3 log when 2 –minute plasma treated NAC was exposed. 
However even 100 mM of Vitamin E was not able to scavenge plasma-generated species 
in 3-minute plasma treated NAC. 1-minute plasma treated NAC solution hasn’t shown 
any antimicrobial effect on bacteria even in the absence of Vitamin E. Therefore 
scavenging effect of Vitamin E on 1-minute plasma treated NAC solution was unclear. 
 
 
Figure 41: Effect of various concentrations of Vitamin E on inactivation rates of 
bacteria following exposure to plasma-treated NAC.  
 
4.3.4 Repeated Exposures of Plasma Treated-NAC Solution: Our findings reveal that 
plasma-generated species in plasma treated NAC solution aren’t consumed immediately, 
and the consumption amount is closely related to bacteria number that is exposed to 
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plasma treated NAC. As demonstrated in Figure 42, 3-minute plasma treated NAC 
solution possesses sufficient plasma-generated species in it even up to 4th repetitive 
exposure to bacteria pellet.   
 
Figure 42: Antimicrobial effect of 3-minute plasma-treated NAC solution following 
consecutive exposure to bacteria. 
 
Furthermore, UV-visible spectrum of plasma treated NAC solution that is exposed to 
bacteria shows that 3-minute plasma treated NAC solution retains sufficient plasma-
generated species. As it can be seen in Figure 43, after the exposure of 3-minute plasma 
treated NAC solution to 107 CFU/ml of bacteria the peak at 302 nm still exists, and a 
new peak starts appearing at 286 nm. However after exposure of 3-minute plasma 
treated NAC solution to bacteria pellet, which was obtained by centrifuging 109 CFU/ml 
bacteria, complete inactivation couldn’t be achieved at repeated exposures and the peak 
at 302 nm disappears and the intensity of the peak at 286 nm increases. Also the 
intensity of the new peak that appears at 286 nm increases as the holding time increases. 
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Also UV-spectrum of ATL buffer (a kind of detergent used in DNA isolation process to 
break down the cell membrane) was also obtained after exposure to bacteria in order to 
investigate the peak at 286 nm, which will be discussed in detail in the discussion 
section of this chapter. 
 
Figure 43: UV-visible spectra of plasma-treated NAC solution in comparison with UV-
visible spectra of ONOO- and ATL buffer after exposure to bacteria. 
 
4.3.5 Cytotoxicity of Plasma-Treated NAC Solution: Following the exposure of 
plasma treated NAC solutions (untreated, and 1,2, and 3-minute treatement), cells were 
incubated in 10% serum containing media for recovery for 24 and 48 hours separately. 
As demonstrated in Figure 44, EA.hy926 human somatic umbilical vein endothelial cells 
that are exposed to 3-minute plasma treated NAC die after both 24 and 48 hours of 
recovery periods.   
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Figure 44: Cytotoxicity of plasma-treated NAC solutions on EA.hy926 human somatic 
umbilical vein endothelial cells after (a) 24 and (b) 48 hours of recovery period. 
 
However cells that are exposed to 2-minute plasma treated NAC solution for 15 minutes 
were able to recover to 95% and more than 100% viability after 24 and 48 hours of 
recovery period respectively. It is important to recall that in 96 well plate can 
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accommodate maximum ~3x104 cells when cells are confluent. Therefore, 2-minute 
plasma treated NAC solution was also exposed to 5x104 and 105 CFU/ml bacteria for 15 
minutes in order to evaluate its antimicrobial activity on given bacterial concentrations. 
Inactivation assay showed that 2-minute plasma treated NAC solution is able to 
inactivate 5x104 and 105 CFU/ml E. coli in 15 minutes of holding time. 
4.3.6 Systemic Toxicity of Plasma-Treated NAC Solution in Rats: As depicted in 
Figure 45, 3-minute plasma treated NAC solution lost its antimicrobial activity when it 
was exposed to bacteria suspension that was prepared in the presence of 25% and 50% 
blood. In other words, loss of the antimicrobial effect can be interpreted as the loss of the 
oxidation capacity of the plasma treated NAC. This in vitro result suggests that the 
administration of NAC solution to rats is likely to be safe. 
 
Figure 45: Effect of the presence of blood on the antimicrobial effect of 3-minute 
plasma-treated NAC solution. Antimicrobial effect of 3-minute plasma treated NAC 
solution diminishes in the presence of at least 25% blood. 
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 After administration of 3-minute plasma treated NAC solution to rats 
histopathological examination was performed on liver, kidney, lung and tail vein tissue 
samples. According to the histopathological examination report provided by ANTECH 
Diagnostics (Lake Succes, NY, USA) a general conclusion regarding the parenchymal 
organs (liver, lung and kidney) is absence of lesions, which are believed to be a direct 
consequence of the experimental manipulations. Special attention is directed to the 
kidney and liver, which are the concentrating and metabolizing organs most likely to be 
affected by toxic substances. Neither kidney nor liver in any of rats exhibits any lesions 
at the light microscopic examination, which are referable to toxicity. There is no 
hepatocellular degeneration/necrosis, inflammation, or hepatocellular vacuolation. Mild 
to moderate microvascular congestion is a feature shared in common by kidney, liver, 
and lung. It is either normal physiological congestion or perhaps artifactual congestion 
that is associated with terminal agonal cardiovascular collapse. Mild to moderate 
peribronchiolar lymphoid hyperplasia is observed in most of rats, a very common 
observation even in normal, healthy, non-experimental rats representing a cellular 
response to inhalant antigens and/or irritants, also most likely unrelated to the 
experimental protocol. This is a pulmonary arteriolar adaptation to vascular 
hypertension, which may be spontaneous or induced but generally not a sign of toxicity. 
There are several instances of mild to moderate tail vein thrombosis with generally mild 
non-necrotizing vasculitis and peri-vasculitis in a few instances also mild perivascular 
fibrosis. However, the vascular lesion is not sufficient to have caused regional infarction. 
The tail vein distal to the injection site is likely to be normal.  
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Even though there are some variations, blood tests don’t represent any specific signs of 
toxicity due to plasma treated NAC solution. Table 6 summarizes results of the blood 
test compared to reference values. As seen on Table 6, none of these variations can be 
correlated to any specific experimental group. 
 
Table 6: Acute toxicity assay: Findings on systemic administration of plasma-treated 
NAC solution. Comparative blood test results are shown with reference to normal 
values. 
 Control Untreated 
NAC 
3 ml/day x 3 
days 
3 ml/day x 
1day 
1ml/day x 3 
days 
AST H H H H H 
ALT H H  H  
ALP H H  H  
Glucose H  H H H 
Creatinine L     
K+  H  H  
WBC  L L L  
PO4-3   H H  
Na+   L   
Globulin    L  
H represents higher value of given parameter than the reference value and L represents 
the lower value of the given blood [parameter than the reference value. (AST: Aspartate 
transaminase, ALT: Alanine transaminase, ALP: Alkaline phosphatase, WBC: White 
blood cells) 
 
4.4 Discussion:  
 In our study plasma treated NAC solution retains its antimicrobial activity for 
longer period of time as compared to the limited existing literature [110,182]. It is 
important to consider the plasma treated liquid ratio to bacteria concentration and the 
exposure time while evaluating the antimicrobial effect over the time. For example 
Traylor et al. have exposed their plasma treated water to bacteria pellet for 3 hours, as 
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opposed to our experiments with bacteria suspension at 15 minute of exposure [110]. 
Thus, in their experiment the plasma treated water isn’t diluted by the bacteria 
suspension and reacts directly with bacteria rather than interaction with impurities that 
rise from liquid (such as PBS or growth media) that bacteria are suspended. The type 
and the amount of liquid that is being treated, plasma source and the treatment method 
all influence the ability of the plasma treated liquid to retain its antimicrobial activity. 
For example, in different studies with varying parameters mentioned above, plasma 
treated liquids lost their antimicrobial activities in a range from 30 minutes to 7 days 
after plasma treatment [110,156,178,182]. Furthermore in these studies, water, PBS or 
saline solution were treated. All these liquids are less complex as compared to NAC 
solution. Our accelerated aging experiment results revealed that plasma treated NAC 
solution can still inactivate 7-log bacteria 2 years after plasma treatment. Even though 2-
year time period is a theoretical value, which corresponds to the storage for 255 days at 
37OC (or 103 days at 50OC), it is still a way longer period than in the previous reports. 
We attribute this effect to the complexity of NAC solution as compared to water, PBS or 
saline solution. During plasma treatment of NAC solution not only ROS and RNS are 
generated, but also NAC molecule is modified. Products such as SNAC after 1 minute, 
and cysteic acid and acetic acid after 3 minutes are produced and some part of NAC 
molecule (~10%) remaines unreacted. All these products following the plasma treatment 
make plasma treated NAC solution more complex than plasma treated water, PBS, and 
saline solution and may be the main reason for longer retained antimicrobial activity by 
stabilization of short living ROS and RNS with an unknown mechanism. 
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 The UV-visible spectra obtained from reconstitution experiments reveal that the 
intensity of the peak at 302 nm is directly related with concentration. In other words 
following heating some peroxynitrite diminishes. When the remaining powder is 
reconstituted with PBS in a 1:1 ratio (same as the evaporated liquid), the absorbance of 
the peak at 302 nm is measured as 0.31, and when the powder is reconstituted with PBS 
in a 2:1 ratio (half volume of the evaporated liquid), the peak at 302 nm is measured as 
0.62. With a basic dilution calculation we calculated that if dried powder is reconstituted 
with PBS in a 1.5:1 ratio (0.75 times of evaporated volume), the peak intensity should be 
same as the 3-minute plasma treated NAC solution. Therefore, dried NAC powder was 
reconstituted with PBS in a 1.5:1 ratio, its antimicrobial effect was tested using colony 
counting assay, and nitrite, nitrate and hydrogen peroxide concentrations were measured 
using HACH nitrite/nitrate detection kit and hydrogen peroxide assay kit respectively 
and UV-visible spectrum was obtained. As demonstrated in Figure 46, intensity of the 
peak at 302 nm became 0.47 same as 3-minute plasma treated NAC solution. In addition, 
the dried powder that was reconstituted in 1.5:1 ratio achieved 7-log reduction and 
nitrate, nitrite and hydrogen peroxide concentrations were measured as 0.8 mM, 0 mM, 
and 0 mM respectively. Through these results we speculate that products of the NAC 
molecule somehow act similar to a spin trap and play a role in the stabilization of plasma 
generated reactive species. Spin trap is a molecule that reacts with a short living radical 
and forms a stable radical adduct [214]. However the stabilization process is unclear and 
further experiments are required in order to understand the mechanism of stabilization of 
plasma-generated species.  
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Figure 46: Comparison of UV-visible spectra of 3-minute plasma-treated NAC solution 
and reconstituted NAC powder. Note that, intensities of the peak at 302 nm are same for 
3-minute plasma treated NAC solution and 1.5:1 reconstituted NAC powder samples. 
The dashed line indicates the 302 nm. 
 
 NAC powder treatment experiments show that, presence of water in treatment 
medium is essential for acidic pH and antimicrobial activity. 
 We have shown that after 2-minute plasma treatment vitamin E (α-tocopherol) 
scavenges plasma-generated species and protects bacteria in to some extend. However 
after 3-minute plasma treatment vitamin E remains ineffective on scavenging plasma- 
generated species. In a previous study Joshi et al. have reported complete protection 
effect of vitamin E on microbial cells during direct plasma treatment [98].  In direct 
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plasma treatment ROS and RNS generated gradually and increases with time. During 
direct plasma treatment, generated ROS and RNS might be scavenged by vitamin E 
simultaneously. However when plasma treated NAC solution comes in direct contact 
with vitamin E, ROS and RNS would be scavenged to some extend and remaining ROS 
and RNS inactivate bacteria. 
 Similar to vitamin E scavenging capacity, species in plasma treated NAC 
solution are not completely consumed when exposed to 107 CFU cell pellet and plasma 
treated NAC solution retains its antimicrobial activity in subsequent exposures. However 
when the cell number is increased to 109 CFU, NAC solution completely inactivates 
bacteria and can’t retain its antimicrobial activity in further exposures. As it is 
demonstrated in Figure 43, when 3-minute plasma treated NAC solution is exposed to 
107 CFU bacteria and held for 15 and 45 minutes, intensity of the peak at 302 nm 
decreases slightly and the NAC solution retains its antimicrobial activity. However when 
3-minute plasma treated NAC solution is exposed to 109 CFU bacteria the peak at 302 
nm disappears and it can’t inactivate bacteria anymore. Source of the peak at 286 nm is 
unknown. The peak at 286 couldn’t be correlated to any specific potential reaction 
products of plasma-generated species (such as nitro fatty acids, nitro tyrosine through the 
attack of peroxynitrite to proteins and lipids in the membrane or cellular oxidation 
products). Thus we hypothesized that the peak at 286 nm can be attributed to leakage of 
cellular content due to membrane damage. In order to test this hypothesis, cell pellet was 
exposed to ATL buffer (detergent based compound that is used for DNA isolation to 
break down the cell membrane) and following exposure the peak at 286 nm was 
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observed. The increase in the intensity of the peak at 286 nm depending on holding time 
is attributed to more cellular content leakage due to cell membrane damage.  
 In cytotoxicity experiments even after 48 hours of recovery period, cell that were 
exposed to 3-minute plasma treated NAC solution died. This might be direct 
consequence of the ratio of cell number to plasma treated NAC solution. In antimicrobial 
experiments, 107 CFU/ml bacteria was exposed to plasma treated NAC solution in 
contrast to cytotoxicity experiments where maximum ~3x104 cell number can be 
achieved in 96 well plates when cells are 90% confluent. Therefore 2-minute plasma 
treated NAC solution was exposed to 5x104 and 105 CFU/ml bacteria and 100% 
inactivation was achieved. So we can conclude that, plasma treated NAC solution can 
effectively inactivate bacteria without toxic effects on eukaryotic cells. This 
phenomenon can be expressed as selectivity of plasma treated NAC solution similar to 
previously reported study where the selectivity of direct plasma treatment was sought 
[209]. There might be different reasons for the protection of eukaryotic cells compared 
to bacteria cells. First of all in cytotoxicity experiments cells were monolayer thus only 
some portion of cells come in contact with NAC solution. However in bacterial 
inactivation experiments, bacteria in suspension and the whole surface of bacteria come 
in contact with plasma treated NAC. In other words, surface area to volume ratio 
determines the damage on eukaryotic and bacterial cells. Also DNA damage repair 
mechanisms in eukaryotic cells are more advanced as compared to bacterial cells [209]. 
Cellular compartmentalization in eukaryotic cells can be considered to be another factor 
on protection against the stress induced by plasma treated NAC solution [215]. As 
provided in results section according to histopathological examination report provided 
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by ANTECH Diagnostics, plasma treated NAC solution, even high in high doses 
(3ml/day for 3 days), doesn’t induce any systemic toxicity. Similarly according to blood 
test that was performed by ANTECH Diagnostics alterations summarized in Table 6 are 
independent of injection conditions. 
 In conclusion plasma treated NAC solution can retain its antimicrobial activity 
up to 2 years, which is significantly longer than shown in previous studies. Also with an 
unknown mechanism, plasma treated NAC solution remains stable. Products of NAC 
molecule generated during plasma treatment might have a role in the stability of the 
plasma treated NAC solution. Due to limited literature on the chemistry and related 
stability of NAC solution, a general conclusion can’t be drawn. Further detailed 
chemical analyses and in vitro and in vivo experiments are needed in order to enlighten 
antimicrobial stability and interactions with eukaryotic cells and related toxicity. 
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5    CHAPTER V: CELLULAR RESPONSES IN E. coli UPON EXPOSURE TO 
PLASMA-TREATED NAC SOLUTION 
 
5.1 Introduction:  
Plasma treatment generates ROS (reactive oxygen species) and RNS (reactive 
nitrogen species) such as hydrogen peroxide, superoxide, hydroxyl radical, nitric oxide, 
peroxynitrite, etc. [85,93,98,102,184]. When various liquids and NAC solution are 
treated with non-thermal plasma generated ROS and RNS, both diffuse into liquid and 
reacts with the components of the treated liquids [93,184]. Treated liquids serve as a 
medium to transfer plasma-generated species to bacterial cells. Plasma-generated species 
leads oxidative and nitrosative stress in bacterial cells that induce various reactions with 
macromolecules in the cell. As previously reported direct plasma treatment causes 
membrane damage via lipid peroxidation and DNA damage [98]. Lipid peroxidation 
involves a series of reactions between polyunsaturated fatty acids (PUFA) in cell the 
membrane and ROS. Lipid peroxidation starts with the electron loss from fatty acids that 
leads to generation of fatty acid radicals. Fatty acid radicals react with molecular oxygen 
to form lipid peroxyl radical. As a result of the reaction between unreacted fatty acids 
and lipid peroxyl radical, lipid peroxide is generated [221].  
Glutathione is a tripeptide abundantly present in both eukaryotic and prokaryotic 
cells and acts as the main antioxidant system in cells. Glutathione consists of glutamate, 
glycine and cysteine amino acids. Because of the sulfhydryl group of the cysteine, 
glutathione can directly react with ROS by acting as an electron donor in a 
nonenzymatic way [223,224]. In cells glutathione may exist bound to protein and free 
forms. In healthy cells up to 98% of glutathione is in its reduced form (GSH). When 
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cells are exposed to oxidative stress, reduced glutathione is oxidized by ROS and 
oxidized form of glutathione (GSSG) is formed. Therefore the ratio of oxidized 
glutathione to reduced glutathione increases as result of oxidative stress and considered 
to be the indicator of oxidative stress [225,226].  
 RNS cause membrane damage through lipid nitration process. Lipoproteins and 
unsaturated fatty acids are potential targets for the lipid nitration. Peroxynitrous acid and 
peroxynitrite can diffuse through lipid membranes by passive diffusion with a diffusion 
rate close to water. Therefore accumulation of RNS at the inner side of membrane 
strongly induces the reaction of RNS with fatty acids. Peroxynitrite induces nitration of 
both free and esterified unsaturated fatty acids via different pathways involving 
homolysis of peroxynitrous acid to !OH and !NO2, reaction of lipid peroxyl radical with 
NO, oxidation of NO to NO2 [222,227-230]. 
 DNA damage is another consequence of oxidative and nitrosative stress. Even 
though NO is not reactive with DNA, peroxynitrite that is product of NO and O2- causes 
DNA damage through chemical modification of bases and strand breaks. DNA base 
modifications by RNS involve alkylation, deamination, oxidation and nitration reactions 
[231-232]. Peroxynitrite causes single strand DNA brakes by attacking C4` and C5` of 
deoxyribose that leads to C3`-phosphate bond cleavage. RNS are not capable of inducing 
double strand brake. However, the presence of base modifications and single strand 
brakes that are caused by RNS, in vicinity of replication fork may lead to double strand 
brakes [232-233]. Hydroxyl radical is the most remarkable source of oxidative DNA 
damage. Due to its lowest redox potential, guanine is oxidation is more dominant 
compared to other bases. The main target of hydroxyl radical in DNA is guanine base. 
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Hydroxyl radical (OH!) directly attacks to C8 of the guanine base and forms the 
oxidation product 8-hydroxydeoxyguanosine (8-OHdG). In addition, hydroxyl radical 
attacks other bases and yields to formation of thymine peroxide, thymine glycols, and 
hydroxymethyl uracil. Hydroxyl radical causes single and double DNA strand damage 
by breaking hydrogen and phosphodiester bonds [98,234-236]. Other ROS like hydrogen 
peroxide and superoxide are not as reactive with DNA as hydroxyl radical. However, 
their reactions with RNS and other ROS leads to DNA damage in a similar way to 
hydroxyl radical [217,234].  
 Tyrosine nitration is a chemical process induced by RNS, which leads to the loss 
of protein function and is considered as the indicator of nitrosative stress. Peroxynitrite 
is considered to be the main contributing agent to tyrosine nitration [237]. However, 
peroxynitrite doesn’t readily react with tyrosine residues. Instead protonation of 
peroxynitrite gives rise to its conjugated acid, peroxynitrous acid (ONOOH) and Lewis 
adduct formation with CO2 gives rise to ONOOCO2-, which are the main nitrosating 
sources of tyrosine. The tyrosine nitration process is triggered with the oxidation of 
tyrosine to tyrosine radical. When generated tyrosine radical reacts with!NO2, which is a 
product of peroxynitrite homolysis, the reaction yields to 3-nitrotyrosine, the final 
product [195,237,238].  
 In Chapter 5 we evaluated effects of plasma treated NAC solution on bacterial 
cells. Therefore we have investigated membrane, DNA, and protein damage caused by 
oxidative and nitrosative stress following exposure of plasma treated NAC solution. In 
order to better demonstrate mechanisms of bacterial inactivation we also investigated 
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genetic response of bacterial cell to the exposure of plasma treated NAC solution that 
can provide clues on the various reactions induced in the cells.  
5.2 Materials and Methods:  
5.2.1 TBARS Assay (MDA Quantification): Detection of Lipid Peroxidation: Lipid 
peroxidation is a well-known indicator of oxidative stress dependent cell damage. Lipid 
peroxides are unstable and decompose to natural byproducts of lipid peroxidation such 
as malondialdehyde (MDA) and 4-hyrdoxynonenal (4-HNE). MDA forms adduct with 
thiobarbituric acid reactive substance (TBARS). The MDA-TBA adducts (Figure 45) 
can be measured colorimetrically for the quantification of lipid peroxidation.  
 
 
Figure 47: MDA-TBA Adduct (from: http://www.cellbiolabs.com/tbars-assay) 
 
OxiSelectTM TBARS Assay Kit for the detection of lipid peroxidation was purchased 
from Cell Biolabs, Inc. (San Diego, CA, USA). 200 μl, 107 CFU/ml E. coli cells were 
exposed to 200 μl of untreated and 1,2 and 3-minute plasma treated NAC solution and 
held for 15 minutes. Following holding time 600 μl 1X sterile PBS solution was added 
on cells to quench the reaction between cells and plasma treated NAC solution and spun 
down at 8000 rpm for 10 minutes and supernatant removed. Remaining cell pellet was 
resuspended with 200 μl of butylated hydroxytoluene (BHT), 100 μl of SDS lysis buffer 
was added and it was incubated at room temperature for 5 minutes. Then 250 μl of TBA 
reagent was added and samples were incubated at 95OC for 60 minutes. Next, samples 
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were cooled down in the ice bath for 5 minutes. After that samples were centrifuged at 
3000 rpm for 15 minutes and 200 μl of supernatant was collected and transferred to 96 
well plate and absorbance reading was performed at 532 nm. Different concentrations of 
hydrogen peroxide solution (0.3% to 6%) were used as positive control. Standard curve 
was prepared by using MDA standards (0-125 μM) that was provided with the kit.  
5.2.2 Live/Dead BacLight Bacterial Viability Assay: LIVE/DEAD® BacLightTM 
Bacterial Viability Kit was purchased from Invitrogen life Technologies. The 
LIVE/DEAD BacLight Viability Assay Kit contains SYTO® 9 green-fluorescent nucleic 
acid stain and propodium iodide red-fluorescent nucleic acid stain. Spectral and 
penetration characteristics of these dyes are different. SYTO 9 dye can penetrate and 
stain all bacteria with both intact and damaged membranes. Adversely, propodium 
iodide can only penetrate to cells with damaged membranes. When SYTO 9 and 
propodium iodide present together, propodium iodide reduces SYTO9 fluorescence. 
Thus, when bacteria are stained with the mixture of SYTO9 and propodium iodide, cells 
with intact membrane, whereas stained green and cells with damaged membrane, 
whereas stained red can be detected. Both dyes are provided as powders in sealed plastic 
pasteur pipets. Both dyes were dissolved in 5 ml of sterile deionized water in order to 
achieve 6 μM SYTO 9 and 30 μM propodium iodide solutions. 200 μl of 3-minute 
plasma treated NAC solution was added on 200 μl of 107 CFU/ml E. coli and held for 15 
minutes. Following 15 minute of holding time, 600 μl of 1X sterile PBS was added on 
cells to quench the reaction between bacteria and plasma treated NAC solution. Then the 
bacteria suspension was centrifuged at 8000 rpm for 10 minutes and supernatant was 
removed. Remaining bacteria pellet was resuspended with 200 μl of dye mixture and 
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incubated at room temperature for 15 minutes in dark. After 15 minute incubation of 
samples, 10 μl of stained bacteria was trapped between a glass slide and a glass coverslip 
and viewed using AMG EVOS® FL cell imaging system. Images of bacteria samples 
were captured with green and red fluorescent filters and overlaid to distinguish live and 
dead cells. The images were captured from five randomly selected areas for three 
different sets of experiments. Untreated NAC solution was used as negative control.  
5.2.3 Intracellular Glutathione Levels: Glutathione is a tripeptide thiol composed of 
glutamic acid, cysteine, and glycine. Glutathione protects cells from oxidative stress 
damage by acting as an antioxidant. In cells, more than 90% of total glutathione exist as 
its reduced form (GSH) and less than 10% exist as its oxidized disulfide (GSSG) form. 
As a result of the oxidative stress in the cell GSH is converted to GSSG via oxidation. 
The increased GSSG/GSH ration in cells is to be considered as the indicator of oxidative 
stress [217,218]. Glutathione flurometric assay kit for the detection of intracellular GSH 
and GSSG levels was purchased from BioVision (Milpitas, CA, USA). In the kit OPA 
probe (o-phthaldehyde) reacts only with GSH and generates fluorescent signal. For the 
specific detection of GSSG, a GSH quencher is used to remove GSH without affecting 
GSSG. Then by adding a reducing agent, the excess quencher is removed and GSSG is 
converted to GSH. For the detection of intracellular GSH and GSSG, 100 μl of 107 
CFU/ml E. coli was exposed to 100 μl untreated and 1,2 and 3-minute plasma treated 
NAC solution and held for 15 minutes. Following 15 minutes of exposure, cell were 
homogenized in 200μl of ice cold Glutathione Assay Buffer. 100 μl of each homogenate 
was transferred in to pre-chilled tubes that are containing 30 μl of PCA (Perchloric acid) 
and was vortexed to have uniform emulsion and then incubated on ice for 5 minutes. 
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Following incubation on ice, samples were centrifuged at 14000 rpm for 2 minutes at 
+4O C and supernatant was collected for detection. 40 μl of collected supernatant was 
transferred to another tube and 20 μl of ice-cold 6N KOH (potassium hydroxide) was 
added to precipitate and neutralize samples. Samples were kept on ice for 5 minutes and 
then centrifuged at 14000 rpm for 2 minutes at +4O C. 10 μl of neutralized sample was 
transferred in to 96 well plate. For the detection of GSH, 80 μl of assay buffer was added 
to the samples. For the detection of GSSG, 60 μl of assay buffer was added to the 
samples. Then 10 μl of GSH quencher was added to the samples and incubated at room 
temperature to allow the GSH to quench. Next 10 μl of reducing agent was added to 
remove excess GSH and to convert GSH to GSSG. Standards of GSH were prepared by 
diluting GSH standard solution that was provided with the kit. Finally 10 μl OPA probe 
(o-phthaldehyde) was added into each sample and standard and fluorescent reading was 
performed at Ex/Em = 340/420 nm. Standard samples were used to generate a standard 
curve and GSH and GSSG concentrations in test samples were calculated by using the 
standard curve. Hydrogen peroxide and peroxynitrite were used as positive control. 
5.2.4 Nitrotyrosine Detection: Nitrotyrosine is a product of tyrosine nitration mediated 
by RNS (especially peroxynitrite) and is considered as to be indicator of nitrosative 
stress [219]. For the detection of intracellular nitrosative stress, 3-NT ELISA kit was 
purchased from Abcam (Cambridge, MA, USA). The kit contains a 96 well plate coated 
with 3-NT antibody. 200 μl of 107 CFU/ml E. coli was exposed to 200 μl untreated and 
1,2, and 3-minute plasma treated NAC solution and held for 15 minutes. Following 
exposure, bacteria suspension was centrifuged at 8000 rpm for 10 minutes and cells were 
rinsed with 1X sterile PBS twice. Centrifugation was repeated after each rinsing step. 
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After the last centrifugation, cell pellet was homogenized in 100 μl of Extraction Buffer 
that was provided with the kit and incubated at room temperature for 20 minutes. 
Following incubation period, cells were centrifuged at 15000 rpm for 20 minutes at 4OC, 
supernatants collected and transferred into clean tubes and remaining pellet was 
discarded. 100 μl of supernatant collected for each sample was transferred into 96 well 
plate coated with 3-NT antibody and incubated on plate shaker at 300 rpm for 2 hours at 
room temperature. Following incubation each well was aspirated and washed twice with 
300 μl of 1X wash buffer, provided with the kit. After washing step 50 μl of 1X detector 
antibody was added into each well and plate was incubated on plate shaker at 300 rpm 
for 1 hour at room temperature. After incubation aspiration and washing step was 
repeated. Following washing step 50 μl of 1X HRP label was added into each well and 
plate was incubated on plate shaker at 300 rpm for 1 hour at room temperature. Reacted 
HRP label in each well was aspirated and wells were washed for three times as described 
above. After washing step, 100 μl of TMB development buffer was added into each well 
and incubated for 15 minutes at room temperature then after 100 μl of 1N HCl was 
added and absorbance of each well was read at 600 nm with a spectrophotometer. By 
using different dilutions of nitrotyrosine standard solution, a standard curve was plotted. 
Nitrotyrosine concentration in each sample was quantified by using the standard curve.  
5.2.5 Detection of DNA Damage: Agarose gel electrophoresis was used to demonstrate 
physical DNA disintegration as previously reported [220]. 1 ml of 107 CFU/ml E. coli 
was exposed to 1 ml of untreated and 1, 2, and 3-minute plasma treated NAC solutions 
and held for 15 minutes. Following holding time 2 ml of 1X sterile PBS was added on 
bacteria in order to quench reaction between bacteria and plasma treated NAC solution 
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then bacteria suspension was centrifuged at 8000 rpm for 10 minutes and supernatant 
was removed. Qiagen DNeasy Blood & Tissue Kit (Valencia, CA, USA) was used for 
DNA extraction.  Remaining cell pellet was resuspended in 180 µl of ATL buffer (a 
compound to lyse cell membrane that was provided with the kit) and 20 µl of proteinase 
K was added, and samples were incubated for 1 hour at 56OC. Following incubation, 40 
µl of RNase was added into samples and incubated for 2 minutes by vortexing 
rigorously. Next 200 µl of buffer AL and 200 µl of 100% ethanol was added and 
samples were incubated for 1 hour at -20OC. After incubation, samples were transferred 
into DNeasy Mini spin column placed in 2 ml microcentrifuge tube, centrifuged at 8000 
rpm for 1 minute and flow-through was discarded. DNeasy Mini spin column was placed 
in a clean 2 ml microcentrifuge tube, 500 µl of Buffer AW1 was added on samples and 
centrifuged at 8000 rpm for 1 minute and flow-through was discarded. Again, DNeasy 
Mini spin column was placed in a clean 2 ml microcentrifuge tube, 500 µl of Buffer 
AW2 was added on samples and centrifuged at 14000 rpm for 3 minutes and flow-
through was discarded. Finally DNeasy Mini spin column was placed in a clean 1.5 ml 
microcentrifuge tube, 20 µl of Buffer AE was added on samples, incubated for 1 minute 
at room temperature and centrifuged at 8000 rpm for 1 minute and extracted DNA was 
collected. Last step was repeated twice in total in order to increase DNA yield. The DNA 
concentration was determined using BioPhotometer plus nanodrop spectrophotometer 
(Eppendorf AG, Hamburg, Germany). 20 µl of DNA extracted from each sample was 
loaded into wells on 0.1% agarose gel in TBE buffer and subjected to electrophoresis for 
30 minutes at 100 V and 400 mA. Ethidium bromide stained gel was visualized with UV 
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transilluminator GelDoc system (Labnet International Inc., Edison, NJ, USA). 1 kb DNA 
ladder was used as control.  
5.2.6 DNA Microarray: Microarray analysis was performed with Affymetrix GeneChip 
E. coli Genome 2.0 Array 900551 (Santa Clara, CA, USA). Sublethal dose (1-minute 
treated) of plasma treated NAC solution was exposed to bacteria in order to extract intact 
mRNA. 1ml of 107 CFU/ml E. coli was exposed to 1-minute plasma treated and held for 
15 minutes. Following holding time 4 ml of 1X PBS was added on bacteria suspension 
to quench the reaction between bacteria and plasma treated NAC solution and samples 
were centrifuged at 8000 rpm for 10 minutes and supernatant was removed. Bacteria 
pellet was resuspended in 500 µl of 1X sterile PBS solution and 1 ml of bacteria protect 
reagent (provided in the kit) was added on samples and incubated at room temperature 
for 5 minutes. Next samples were centrifuged at 6000 rpm for 10 minutes and 
supernatant was removed. 100 µl of lysozyme solution that was prepared by dissolving 
12 mg of lysozyme enzyme powder and 15 µl of proteinase K in 750 µl TE buffer was 
added on bacteria pellet and samples were incubated at room temperature with frequent 
vortexing. After that 350 µl of RLT buffer that was prepared by dissolving 10 µl of βME 
(beta-mercaptoethanol) and 250 µl of 100% ethanol was added on samples, mixed well 
by pipetting. Well-mixed samples were transferred in to spin columns placed in to 2 ml 
of collection tubes and centrifuged at 9000 rpm and flow-through was discarded. Next 
700 µl of RW1 was added on samples in spin column, incubated at room temperature for 
3 minutes and then centrifuged at 9000 rpm for 1 minute and flow-through was 
discarded. Spin columns were placed in to clean collection tubes and 500 µl of RPE 
buffer was added on samples and centrifuged at 9000 rpm for 1 minute. The last step 
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was repeated one more time and followed by a final centrifugation at 10000 rpm for 2 
minutes. Next spin columns were placed in to 1.5 ml microcentrifuge tubes and 20 µl of 
nuclease free water was added, incubated at room temperature and centrifuged at 10000 
rpm for 2 minutes. The last step was repeated one more time in order to increase mRNA 
yield. The extracted mRNA concentration was determined with BioPhotometer plus 
nanodrop spectrophotometer (Eppendorf AG, Hamburg, Germany). The extracted 
mRNA was purified with DNase treatment. Following DNase treatment 1μl of DNase 
inactivation buffer was added on samples and samples were centrifuged at 10000 rpm 
for 10 minutes. Supernatant was collected as DNA free mRNA samples. Amplification 
and labeling of mRNA was performed using the Ovation Pico WTA-system V2 RNA 
amplification system (NuGEN Technologies, Inc., San Carlos, CA, USA) Briefly 50 ng 
of total RNA was reverse transcribed using a chimeric cDNA/mRNA primer, and a 
second complementary cDNA strand was synthesized. Purified cDNA was then 
amplified with ribo-SPIA enzyme and SPIA DNA/RNA primers (NuGEN Technologies, 
Inc.) Amplified cDNA was purified with Qiagen MinElute reaction clean up kit. The 
concentration of purified cDNA was measured using the nanodrop. 2.5 µg of cDNA was 
fragmented and chemically labeled with biotin to generate biotinylated cDNA using FL-
Ovation cDNA biotin module V2 (NuGEN Technologies, Inc.) Affymetrix gene chips 
were hybridized with fragmented and biotin labeled target in 110 µl of hybridization 
cocktail. Target denaturation was performed at 99oC for 2 minutes and then 45oC for 5 
minutes, followed by hybridization for 18 hours. Arrays then washed and stained using 
gene chip Fluidic Station 450, and hybridization signals were amplified using antibody 
amplification with goat IgG and anti-streptavidin biotinylated antibody. Chips were 
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scanned on an Affymetrix Gene Chip Scanner 3000, using Command Console Software. 
Background correction and normalization were done using Iterative Plier 16 with 
GeneSpring V11.5 software (Agilent, Palo Alto, CA, USA). 2-fold differentially 
expressed gene list was generated. 
5.2.7 Differential Expression of Selected Genes: Based on the data obtained from 
microarray experiment, differential expression levels of katG, grxA, ahpF, nrdE, nrdF, 
nrdI, and nrdH genes were examined and normalized according to 16s rRNA gene. The 
initial concentration of bacteria to be treated and holding time were optimized in order to 
determine the appropriate sublethal dose of plasma treated NAC solution and achieve 
sufficient RNA yield. For the optimization reason 107 and 108 CFU/ml E. coli was 
exposed to equal volumes of untreated, 1,2, and 3-minute plasma treated NAC solutions 
and peroxynitrite solution as positive control and 1X PBS as positive control 
(background for normalization), held for 3 and 5 minutes and RNA concentration was 
measured with BioPhotometer plus nanodrop spectrophotometer (Eppendorf AG, 
Hamburg, Germany). 108 CFU/ml initial bacterial concentration and 3 minutes of 
holding time were found to be appropriate treatment parameters for sufficient RNA 
yield.  
 In brief, 1 ml of 108 CFU/ml E. coli was exposed to 1 ml of PBS, peroxynitrite, 
untreated NAC, and 1, 2, and 3-minute plasma treated NAC solutions and held for 3 
minutes. Following 3-minute holding time, 4 ml of 1X sterile PBS was added on 
samples immediately in order to quench reaction between bacteria and plasma treated 
NAC solutions. Bacteria samples were centrifuged at 8000 rpm for 10 minutes and RNA 
isolation was performed as described in detail in previous section. Extracted RNA was 
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diluted to 50 ng/μl concentration. cDNA conversion master mix was prepared by adding 
3.6 μl of RNase free water, 4 μl reaction buffer 6.4 μl dNTP, 4 μl random primer and 2 
μl Taq polymerase enzyme in to 20 μl of diluted RNA. The extracted RNA was 
subjected to cDNA conversion using cMasterTM RTplusPCR system (Eppendorf, 
Hamburg, Germany). qPCR was performed to analyze differential gene expression 
levels of the above-mentioned genes using Mastercycler® ep realplex2 S (Eppendorf, 
Hamburg, Germany).  Reaction mixture for gene expression level analysis was prepared 
by mixing 1.25 μl cDNA, 0.5 μl reverse and forward primers and 5 μl SYBR Green 
(Applied Biosystems, Grand Island, NY, USA). Forward and revers primers for each 
gene was designed using web based, Primer BLAST, primer-designing tool (from 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The forward and reverse primers 
(listed in Table 7) were synthesized by Integrated DNA Technologies (Coralville, IA, 
USA). 
Table 7: Sequences of forward and revers primers used in this study. 
Genes Froward Primer Reverse Primer 
katG 5`-TTCTAACTCCGTCCTGCGTG-3` 5`-ATGCCGCCACGAAGTCTTTA-3` 
grxA 5`-TGTGCGTGCAAAAGATCTGG-3` 5`-GTGATCCCTTCCGCACGAAT-3` 
ahpF 5`-AAACCAACGTGAAAGGCGTG-3` 5`-AGAGAGGCTTTGGCACCTTC-3` 
nrdE 5`-CGGTAAACCGTGCTAACCCT-3` 5`-GGCGCTGTTAACCTGCAAAA-3` 
nrdF 5`-TGAATCTGGGCTACGAACCG-3` 5`-ATTTTCATCGGCATTCGGCG-3` 
nrdI 5`-CTTCGCGGCGTTATTGCTTC-3` 5`-TTCCGGGCAATCACATCTCC-3` 
nrdH 5`-TGTCGATCGCGTTCCTGAAG-3` 5`-AGCAATCACTACCGGCAACT-3` 
16s rRNA 5`-TGCCTGATGGAGGGGGATAA-3` 5`-CCGAAGGTACCCCTCTTTGG-3` 
 
Quantification of gene expression level of each gene was based on the CT value, which is 
the number of cycles required for the qPCR fluorescent signal crosses the detection 
threshold. The CT value was determined by using the Realplex software (Eppendorf, 
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Hamburg, Germany). Fold increase in gene expression was calculated using 2!∆∆!! 
method. In order to apply 2!∆∆!! method following calculations were done:  
• ∆!!!"#$%"&! = !!!"#"!!"!!"#$%$&#! − !!!!!!"#$!!""#$%&!!"#"!  
• ∆!!!"#!! = !!!"#"!!"!!"#$%$&#! − !!!!!!"#$!!""#$%&!!"#"! 
• ∆∆!! = ∆!!!"#!! − !∆!!!"#$%"&! 
• !"#$!!"#$%&'% = !2!∆∆!! 
Where ∆!!!"#$%"&!is the CT value of control group (bacteria exposed to PBS), 
     ∆!!!"#!!  is the CT value of each tested condition (including positive controls). 
 
5.3 Results:  
5.3.1 Membrane Lipid Peroxidation: Cell membrane lipid peroxidation was detected 
using TBARS assay kit. MDA concentration upon exposure to hydrogen peroxide and 
plasma treated NAC solution was calculated from the standard curve plotted using 
different concentrations of MDA standard solution As demonstrated in Figure 48 upon 
exposure to hydrogen peroxide solution lipid peroxidation was observed depending on 
hydrogen peroxide concentration. However no lipid peroxidation was observed after 
plasma treated NAC solution exposure.  
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Figure 48: Cell membrane lipid peroxidation levels upon 
exposure to plasma-treated NAC solution and hydrogen peroxide 
solutions. 
 
5.3.2 Live/Dead BacLight Bacterial Viability Assay: To demonstrate the cell 
membrane damage due to plasma treated NAC solution exposure, cells were stained with 
Live/Dead BacLight dye. As demonstrated in Figure 49, number of dead cells increases 
gradually with the increasing duration of plasma treatment. The scale bar on the pictures 
shows 50 μm. Relatively less cell number after exposure to 3-minute plasma treated 
NAC solution is probably due to complete disintegration of bacterial cells. 
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Figure 49: Cell membrane damage after plasma-treated 
NAC solution exposure to cells. Green cell are alive and red 
cells have leaky/compromised cells. Scale bar shows 50 μm. 
 
5.3.3 Intracellular Glutathione Levels: Intracellular levels of reduced form (GSH) and 
oxidized disulfide form (GSSG) of glutathione were measured, and GSSG/GSH ratio 
was demonstrated in Figure 50 as an indicator of the intracellular oxidation. The 
GSSG/GSH ratio increases gradually till to the exposure of 2-minute plasma treated 
NAC solution and drastically following the exposure of 3-minute plasma treated NAC 
solution. GSSG/GSH ratios after exposure of 1% H2O2 and 0.28 mM ONOO- solutions 
to bacterial cells were shown as positive control groups.  
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Figure 50: GSSG (oxidized form of glutathione) to GSH (reduced form of 
glutathione) shown as the indicator of intracellular oxidation. Note that 
GSSG/GSH increases drastically after exposure of 3-minute plasma-treated 
NAC solution. 
 
5.3.4 Intracellular Nitrotyrosine Levels:  ELISA was performed for the quantification 
of intracellular nitrotyrosine following exposure of plasma treated NAC solutions to E. 
coli. Nitrotyrosine concentration, which is an indicator of intracellular nitrosative stress, 
increases in bacteria proportional to plasma treatment duration. As demonstrated in 
Figure 51, the concentration of nitrotyrosine in cells upon exposure to 3-minute plasma 
treated NAC solution increases drastically as compared to other NAC solutions treated 
for shorter duration.  
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Figure 51: Intracellular nitrotyrosine concentration upon exposure to plasma-treated 
NAC solution and peroxynitrite solution as positive control.  
 
5.3.5 DNA Damage Detection: Figure 52 depicts an agarose gel after electrophoresis 
representing fragmented DNA damage upon exposure of cells to plasma treated NAC 
solution that are treated for various durations. After exposure of cells to 1 and 2-minute 
plasma treated NAC solutions DNA can remain intact, however 3-minute plasma treated 
NAC solution causes complete disintegration of the genomic DNA in E. coli cells.  
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Figure 52: DNA extracted from bacteria exposed 
to plasma treated NAC solutions were run on 
agarose gel. 3-minute plasma-treated NAC solution 
causes complete DNA fragmentation of DNA.  
 
5.3.6 Gene Expression Analysis Through Microarray: Microarray analysis was 
performed after exposing E. coli cells to 1-minute plasma treated NAC solution. 
Microarray was carried out not only to demonstrate gene expression levels but also 
identify genes to evaluate in detail after exposure of untreated NAC and 1, 2, and 3-
minute plasma treated NAC solutions. Results of the microarray data analysis yielded 
104 differentially expressed transcripts (59 upregulated and 45 downregulated).  
Microarray results showed that, genes coding inner membrane proteins, genes that have 
function on iron-sulfur cluster pathway, oxidative stress, universal stress protein, 
peroxide resistance protein were upregulated. Table 8 summarizes expression levels of 
upregulated and down regulated genes, which can be considered as indicator of oxidative 
and nitrosative stress, and also shows cellular response to the overall stress caused by 
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plasma treated NAC solution. Mostly genes belong to fli gene family that code flagellar 
proteins are downregulated. 
Table 8: Summary of microarray data, showing expression levels of some genes that 
play role in response to oxidative and nitrosative stress in E. coli. 
Gene Gene Function Fold 
increase/decrease 
oxyS Regulon, that induces response to oxidative stress 99.31 
ybjM Inner membrane protein 63.39 
yeaR Transcription of year increases in response to nitrite, nitrate 
and nitric oxide 
30.49 
yaaA Peroxide resistance protein 11.32 
trxC Thioredoxin 10.99 
soxS Transcription induced due to increased superoxide levels 8.14 
uspD Universal stress protein, involves in resistance to UV 
irradiation 
7.42 
yjcB Inner membrane structural protein 7.08 
gor Glutathione reductase 5.14 
yfeO Ion channel protein 5.15 
yedR Inner membrane protein 5.13 
uraA Uracil permease -19.55 
fliI Flagellum specific ATP synthase -13.63 
fliJ Flagellar protein, one of three soluble components of 
flagellar export system 
-8.01 
upp Uracil phosphoribosyltransferase -7.27 
fliQ Flagellar biosynthesis protein -7.07 
fliO Internal membrane component of flagellar export apparatus -6.27 
fliG Flagellar motor component -6.26 
fliR Flagellar export protein -5.07 
nmpC Outer membrane porin -4.08 
flgH Flagellar basal body protein -3.57 
  
Through the data obtained from microarray analysis, katG, grxA, ahpF, nrdE, nrdF, 
nrdI, and nrdH genes were selected to evaluate expression levels versus plasma 
treatement time of NAC solution. 
5.3.6 Differential Expression of Selected Genes: Based on the microarray data, 
expression levels of katG, grxA, ahpF, nrdE, nrdF, nrdI, and nrdH genes were 
investigated depending on plasma treatment duration of NAC solution using qRT-PCR. 
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Expression levels were obtained following 3-minute holding time and normalized 
according to E. coli that was exposed to 1X sterile PBS. As depicted in Figure 53, 
antioxidant effect of untreated NAC solution was observed, where evaluated genes were 
downregulated following exposure of untreated NAC solution to E. coli. All genes were 
upregulated following exposure of plasma treated NAC solution and ONOO- solution 
with a decreasing pattern as the longer treatment duration. Only nrdI was downregulated 
after exposure of 3-minute plasma treated NAC solution. 
 
Figure 53: Differential expression of selected genes in E. coli after exposure to plasma-
treated NAC solution 
 
5.4 Discussion: In Chapter 5 we present extensive evaluation of interactions of plasma 
treated NAC solution with E. coli cells. As it is depicted in Figure 49, following 
exposure of plasma treated NAC solution to bacteria, cell membrane becomes leaky due 
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to cell membrane damage induced by NAC solution. Also as explained in detail in 
Chapter 4 a new peak at 286 nm appears on UV-visible spectra that are collected after 
exposure of plasma treated NAC solution. This new peak was not attributed to any 
possible product that may arise after exposure of plasma treated NAC solution. 
Furthermore to investigate the cell membrane leakage as a result of plasma treated NAC 
solution exposure, we have treated cells with buffer ATL, which is a reagent that is used 
to lyse cell membrane for DNA isolation. Following treatment of cells with buffer ATL 
we have observed the same peak at 286 nm on UV-visible spectrum. Thus UV-Vis 
spectra results also suggest cell membrane damage and leakage of cellular content. 
However, according to our lipid peroxidation experiments, even though it has oxidative 
capacity, plasma treated NAC solution doesn’t initiate lipid peroxidation in cell 
membrane. Therefore we postulate that lipid nitration causes cell membrane damage, 
which is induced by plasma generated RNS in NAC solution. Also oxidative and 
nitrosative damage of membrane proteins may contribute cell membrane damage. 
Furthermore as it was summarized in Table 8 according to microarray results, 
upregulation of genes coding membrane related proteins such as ybjM (inner membrane 
protein), yfeO (ion channel protein), and yedR (inner membrane protein) indicates that 
cell membrane damage is a collective destruction of both membrane lipids and proteins. 
  The main source of intracellular nitrosative stress is reported as peroxynitrite 
[195,219,240]. When peroxynitrite is decomposed it yields to super oxide and nitric 
oxide. Even though peroxynitrite is capable of initiating lipid peroxidation, peroxynitrite 
derived NO inhibits lipid peroxidation [229,241]. Nitric oxide inhibits lipid peroxidation 
via radical chain termination by the abstraction of H atom from lipid peroxyl radical and 
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yields to secondary reactive nitrogen containing products [229,240-242]. Another 
possibility of not observing the lipid peroxidation may be the higher permeability of 
peroxynitrite compared to ROS in plasma treated NAC solution. Diffusion rate of 
peroxynitrite through phospholipid membrane is close to that of water and ~400 times 
more than superoxide [196]. Thus, cell wall of the bacteria acts as a barrier between 
ROS and at the same time peroxynitrite diffuses into cell because of its higher diffusion 
rate and induces RNS originated membrane damage before lipid peroxidation starts.   
 Peroxynitrite is responsible not only for nitrosative stress, but also for oxidative 
stress. Superoxide, as the product of peroxynitrite homolysis product induces 
intracellular oxidation [195,219,243]. Plasma generated ROS in plasma treated NAC 
solution also has influence on intracellular oxidation [244]. Glutathione oxidation is 
considered to be the indicator of intracellular oxidation. In normal physiological 
circumstances most of the glutathione is present in its reduced GSH form, and GSH is 
converted to oxidized form of glutathione in case of oxidative stress [225,226]. 
Increased GSSG/GSH ratio indicates the oxidative stress and oxidative damage of 
proteins. As it was demonstrated in Figure 48, intracellular GSSG/GSH ratio increases 
slightly after exposure of 1 and 2-minute plasma treated NAC solution and drastically 
after exposure of 3-minute plasma treated NAC solution. The intracellular GSSG/GSH 
ratio, measured after exposure of 3-minute plasma treated NAC solution is significantly 
higher than the ratio measured after exposure 1% hydrogen peroxide, which suggests 
that plasma treated NAC solution is a mixture of various potent oxidizing compounds. 
Similar to glutathione oxidation, peroxynitrite also oxidizes sulfur containing amino 
acids such as cysteine. Oxidation of sulfur containing amino acids leads to inactivation 
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of critical enzymes involved cellular respiration such as glyceraldehyde-3-phosphate 
dehydrogenase. Enzymes involving cellular respiration are also inactivated by nitration 
of tyrosine residues [195,245]. Thus intracellular oxidative and nitrosative stress induced 
by peroxynitrite, which has influence on bacterial death via protein damage. 
  As demonstrated in Chapter 2, for all tested strains, bacterial inactivation was 
insignificant when 1 and 2-minute plasma treated NAC solutions were exposed and 7-
log reduction was observed after exposure of 3-minute plasma treated NAC solution. 
This drastic bacterial reduction by 3-minute plasma treated NAC exposure can be 
attributed to intracellular oxidation level, which similarly increases drastically after 
exposure of 3-minute plasma treated NAC solution. Also a similar trend, which can be 
attributed to significant bacterial inactivation, has been observed at nitrotyrosine 
detection as well, where intracellular nitrotyrosine level increases significantly after 
exposure of 3-minute plasma treated NAC solution compared to 1 and 2-minute plasma 
treated NAC solutions.  
 DNA damage is also another consequence of plasma treated NAC solution 
exposure to bacteria. In a previous report Joshi et al. have reported DNA fragmentation 
caused by direct plasma treatment of E. coli cells using gel electrophoresis [98]. In the 
present study we have also observed complete DNA fragmentation with gel 
electrophoresis following exposure of 3-minute plasma treated NAC solution. As it is 
shown in Figure 52, when 1 and 2-minute plasma treated NAC solution exposed to E. 
coli cells, DNA is not compromised as oppose to 3-minute plasma treated NAC solution 
exposed sample, where there is no visible band on agarose gel electrophoresis due to 
complete disintegration of DNA. Similar to GSSG/GSH ratio and intracellular 
! 147!
nitrotyrosine formation results, also DNA damage becomes significant when 3-minute 
plasma treated NAC solution is exposed to E. coli, which suggest that 1 and 2-minute 
plasma treated NAC solution remains non-lethal while 3-minute plasma treated NAC 
causes complete inactivation of 107 CFU/ml E. coli. These results together with 
glutathione oxidation and tyrosine nitration results show that after 3-minute plasma 
treatment, plasma-generated species reaches a critical concentration that will cause lethal 
oxidative and nitrosative stress.  
 One of the remarkable responses of bacterial cells is to reduce their surface area 
and motility in order to reduce both exposure to stress factor and energy consumption 
[98, 246].  Microarray results, as summarized in Table 8, show down regulation of 
various flagellar genes. This genetic response is attributed to tendency of bacterial cells 
to be protected from stress factors. Also universal stress proteins regulate expression of 
flagella associated genes by suppressing their expression levels as a response to stress 
[247]. Further more it was reported that nitrosative stress induces the suppression of 
motility and adherence, of P. aeruginosa. Motility and adherence properties have 
influence on the virulence of bacteria [248]. Therefore down regulation of flagellar 
genes indicate that, even complete inactivation cannot be achieved, plasma treated NAC 
can still eradicate biofilm formation by compromising adhesion of biofilm. As it was 
described in Chapter 2 after plasma treatment pH of NAC solution drops significantly. It 
was demonstrated that acidic pH suppresses expression of flagellar genes [249,250]. 
Thus our results on down regulation of flagellar genes indicate how low pH, which is 
common consequence of plasma treatment of liquids and reported widely, affects 
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microbial physiology and reduces bacterial virulence, by suppressing bacterial motility 
and adherence. 
 Uracil metabolism related genes, uraA and upp, are other remarkable down 
regulated genes. Nitrosative stress induces deamination of cytosine to form uracil [251]. 
Therefore down regulation of upp and uraA indicates increasing uracil amount in 
bacterial cells and postulated as indicator of nitrosative stress that is induced by plasma 
treated NAC solution.  
 In the light of microarray data, particular genes were selected to investigate 
bacterial genetic response to plasma treated NAC solution using qRT-PCR. 
Peroxynitrite was used as positive control for investigating nitrosative stress on 
differential gene expression levels. As it is depicted in Figure 53, untreated NAC 
solution shows its antioxidant property, where the all genes are down regulated. Also 
following exposure of 3-minute plasma treated NAC solution, gene expression levels 
were significantly less than 1 and 2-minute plasma treated NAC solution exposed 
conditions. This trend is similar to trends that were observed with GSSG/GSH ratio, 
intracellular nitrotyrosine concentration, DNA damage and microbial inactivation 
experiments. In all mentioned experiments significant changes of investigated 
parameters were observed after exposure of 3-minute plasma treated NAC solution. 
Therefore less expression levels following exposure of 3-minute plasma treated NAC 
solution compared exposure of 1 and 2-minute treated ones is attributed to intense 
nucleic acid damage originated from ROS and RNS that reached critical concentration 
capable of causing destructive reactions in bacteria cells.  
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 Following exposure of plasma treated NAC solution oxidative stress genes such 
as katG and ahpF were upregulated. katG has been reported to act as peroxynitritase in 
M. tuberculosis and S. enterica and similarly ahpF have been reported as peroxynitritase 
in S. enterica [252-254]. Furthermore these genes were upregulated when peroxynitrite 
solution was exposed to E. coli. Similar findings related the upregulation of katG and 
ahpF following peroxynitrite exposure to E. coli are also available in the literature 
[243]. Thus, we postulate that katG and ahpF have important role in response to 
nitrosative stress arises from peroxynitrite in plasma treated NAC solution. 
 grxA, glutaredoxin, is under control of oxyR regulon and plays major role in 
reduction of oxidized glutathione as the part of oxidative stress along with other 
oxidative and nitrosative stress genes such as ahpF and katG [255]. In addition to 
activation of oxyR regulon by oxidative stress, it is reported as the sensory mechanism of 
nitrosative stress in E. coli and glutaredoxin has been reported as “S-nitrosyl sink” in 
defense against nitrosative stress [256,258]. Furthermore it was reported that grxA 
expression is induced along with katG and ahpF by exposure of NaNO2 and S-
nitrosoglutathione (GSNO), which acts as NO donor and induces nitrosative stress, 
[257]. The activation of grxA expression as response to nitrosative stress in E. coli is 
induced by reaction of redox active cysteine residue of oxyR, with RNS in a similar way 
to nitrosylation [257]. Thus upregulation of grxA indicates potent oxidative and 
nitrosative stress induced by exposure of plasma treated NAC solution. ! All four genes of nrdHIEF operon are closely coregulated and activation of it by 
addition of NO to anaerobically grown E. coli culture suggests that nrdHIEF operon 
plays a role in the response to nitrosative stress in E. coli [259,264]. Also in aerobic 
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conditions, introduction of GSNO leads to significantly more upregulation of nrdHI 
compared to nrdEF [264]. In nrdHIEF operon nrdE and nrdF responsible for coding 
ribonucleotide reductase class Ib, while nrdI enhances the conversion of ribonucleotides 
to deoxyribonucleotides and nrdH functions as the electron donor to for nrdEF 
[260,261]. Furthermore because of thioredoxin-like activity of nrdH, it also functions as 
scavenger and plays role in repair mechanisms of damaged proteins [262]. It was 
reported that nrdH could also be upregulated especially in response to nitrosative stress 
or during repair of nitrosative damage, which is consistent with our data [263].  
 Overall, gene expression results obtained from both microarray and qRT-PCR 
indicates that, plasma treated NAC solution is a mixture of plasma generated RNS and 
ROS, which induce potent intracellular oxidative and nitrosative stress. As it is 
demonstrated in Figure 53, following 1 and 2-minute plasma treated NAC solution 
oxidative and nitrosative stress genes are vastly upregulated. Lesser expression levels of 
investigated genes, following exposure of 3-minute plasma treated NAC solution could 
be attributed to rapid nucleic acid damage originated from potent oxidative and 
nitrosative effect of 3-minute plasma treated NAC solution. Indeed lower expression 
levels after exposure of 3-minute plasma treated NAC solution is consistent with 
significant inactivation of bacteria, increase in GSSG/GSH ratio and an increase in 
intracellular nitrotyrosine concentration compared to 1 and 2-minute plasma treated 
NAC solution exposure. Also as it is depicted in Figure 52, observing DNA damage only 
after 3-minute plasma treated NAC solution exposure supports the explanation for the 
less expression levels after 3-minute plasma treated NAC solution compared to 1 and 2-
minute ones.  
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 Upregulation of above-mentioned genes following exposure of 0.28 mM 
peroxynitrite, indicate that those genes are effective in response to nitrosative stress. 
Also lower differential expression levels of mentioned genes after exposure of 
peroxynitrite solution compared to expression levels after exposure of plasma treated 
NAC solution suggests, that plasma treated NAC solution is way more complicated 
mixture of ROS and RNS. Only nrdI was downregulated after 3-minute plasma treated 
NAC solution exposure. However this result is most likely due to severe nucleic acid 
damage induced by the 3-minute plasma treated NAC solution.  
 In conclusion, plasma treated NAC solution initiates a series of intracellular 
oxidative and nitrosative stress that are resulted as the damaged biomolecules including 
lipids, nucleic acids and proteins. Both oxidative and nitrosative stress are responsible on 
antimicrobial activity originated from plasma treated NAC solution. Differential gene 
expression experiments also suggest contribution of oxidative and nitrosative stress on 
bacterial inactivation effect of plasma treated NAC solution. However lack of lipid 
peroxidation especially suggests that plasma generated RNS seems to have more 
dominant effect on microbial inactivation as compared to ROS.  
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6    CHAPTER VI: CONCLUDING REMARKS 
 
6.1 Summary of the Research and Conclusion:  
 In the present study we have developed a novel antimicrobial compound that is 
effective against common sources of hospital-acquired infections. We have utilized non-
thermal dielectric barrier discharge (DBD) plasma treatment method and treated N-
acetyl cysteine (NAC) solution in order to develop an antimicrobial compound.  
Hospital-acquired infections are an important challenge for health care professionals, 
hospitalized patients, and public health and cost millions of dollars every year. Bacterial 
resistance is the source of multidrug resistant bacteria that cause hospital acquired 
infections. Bacterial colonization on inanimate surfaces serves as the sources of spread 
of hospital-acquired infections. Bacteria colonize on inanimate surfaces in biofilm 
forms, which is more resistant to antibiotics and disinfectants. Currently used 
disinfectants are insufficient to eradicate bacterial biofilms and also have toxic effects. 
Therefore a non-toxic, broad-spectrum effective an antimicrobial agent is required. 
 In Chapter 2, we have determined the optimum plasma treatment parameters and 
designed a new plasma treatment setup for the treatement of 1 ml NAC solution in 
contrast to the 100 μl of treatment volume that has been previously used in our 
laboratory. We have evaluated antimicrobial activity of plasma-treated NAC solution on 
planktonic and biofilm forms of different bacteria and fungus including multidrug 
resistant bacteria such as K. pneumonia NDM 1, MRSA300, MRSA 400 and A. 
baumannii clinical isolate. We have shown that 3-minute plasma treated NAC solution is 
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able to inactivate up to 108 CFU/ml initial bacterial load when exposed at least for 15 
minutes. 
 In Chapter 3, we have evaluated chemical modifications in NAC solution due to 
plasma treatment and quantified plasma-generated species using various analytical 
chemistry methods and species-specific detection kits. We have determined occurrence 
of acidic pH after plasma treatment of NAC solution, which is widely reported result of 
plasma treatment of fluids. Following the detection and quantification of plasma-
generated species we have tested their contribution to antimicrobial effect. Our data 
revealed that acidic pH does not contribute to antimicrobial effect. Further more, 
antimicrobial effects of detected amounts of plasma-generated species were tested by 
themselves and in combination with each other. However we didn’t see any 
antimicrobial activity. Thereupon the antimicrobial effect of superoxide was tested and 
we have demonstrated that the mixture of superoxide and nitrite could inactivate 7-log 
bacteria. Therefore we evaluated the contribution of reactive nitrogen species (RNS) on 
antimicrobial effect and found that peroxynitrite is the species most dominantly 
contributing to antimicrobial effect.  
 In Chapter 4, we assessed the stability, cytotoxicity and acute systemic toxicity 
of the plasma treated NAC solution. Our results show that 3-minute plasma treated NAC 
solution retains its antimicrobial activity for up 235 days when stored at 37OC, which is 
equivalent to 2 years at room temperature. Additionally, we presented that when the 
plasma treated NAC solution is dried and reconstituted, it can retain its antimicrobial 
activity, which suggests the plasma-generated species responsible for the antimicrobial 
activity can be stabilized by the products of NAC solution. Also we tested cytotoxicity 
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of plasma treated NAC solution and found that plasma treated NAC solution can 
inactivate bacteria while not damaging eukaryotic cells. In our systemic toxicity 
experiments, for the first time in the literature, we have injected the 3-minute plasma 
treated NAC solution in rats and demonstrated that plasma treated NAC solution doesn’t 
cause any systemic toxicity.  
 In Chapter 5, we have investigated intracellular mechanisms of bacterial 
inactivation following exposure to plasma treated NAC solution. Our data suggest that 
plasma treated NAC solution triggers series of reactions in the cells, which are mediated 
by nitrosative stress and oxidative stress. Overall when bacteria are exposed to plasma-
treated NAC solution, it compromises the cell membrane integrity, induces intracellular 
oxidative and nitrosative stress and causes DNA fragmentation. Also our gene 
expression analysis that was carried out by using microarray and qPCR demonstrated the 
response of the bacterial cell to plasma treated NAC solution, which supports our 
findings related with nitrosative and oxidative stress.      
 
6.2 Research Contributions: 
 The main research contribution of this thesis has been to introduce a new stable, 
broad spectrum, and non toxic antimicrobial agent that potentially can be used as 
catheter lock solution, to eradicate biofilms in respiratory tract, disinfectant for the 
disinfection of medical devices and for treatment of infected wounds. This thesis 
research will help to improve our understanding on the generation and diffusion of 
plasma generated reactive species in liquid-gas interface and the antimicrobial 
capabilities and mechanism of action of plasma treated solutions on their antimicrobial 
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effect. This study will improve the knowledge and novel explanations in plasma 
medicine field.  We believe that we have presented extensive novel data that will make 
the plasma treated NAC solution a new tool for both infection control and disinfection 
purposes, especially against multidrug resistant bacteria, in clinical practice.  
 The specific contributions of this thesis are as follows:  
• For the first time we have demonstrated that the depth of the liquid is a 
crucial parameter of plasma treatment for diffusion of plasma-generated 
species. 
• For the first time we have demonstrated antimicrobial effect of plasma 
treated NAC solution on planktonic and biofilm forms of wide range of 
pathogens including fungus and multidrug resistant bacteria. 
• We have demonstrated the antimicrobial effect of plasma-treated, 
nebulized NAC solution on biofilm forms of pathogens. Our results 
indicate that the plasma-treated NAC solution can be a new, promising 
treatment method for mechanical ventilator associated infections and 
upper respiratory tract infections.  
• To the best of our knowledge, for the first time we have shown that a 
plasma-treated liquid (NAC solution) can retain its antimicrobial activity 
for years.  
• We have studied the cytotoxicity of plasma-treated NAC solution and for 
the first time, and presented that plasma-treated NAC solution can 
inactivate bacteria at the same time doesn’t harm eukaryotic cells. 
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• For the first time, we have assessed the acute systemic toxicity of a 
plasma-treated liquid by administrating it to rats. 
• For the first time, we have demonstrated cell membrane damage, DNA 
damage and intracellular nitrosative stress upon exposure of plasma-
treated NAC solution to bacterial cells. 
• For the first time we have demonstrated differential gene expression in 
cells that are exposed to plasma treated liquid, which improves our 
understanding of how plasma treated NAC solution inactivates bacteria. 
 
6.3 Suggested Future Work: 
6.3.1 Bacterial Resistance Against Plasma Treated Liquids: Antibiotic resistance is a 
well-known phenomenon that reduces the efficacy of antibiotics against particular 
bacteria. Bacteria can generate resistance against antibiotics via various routes such as 
enzymatic destruction of antibiotics, modification of antibiotic target, efflux pumps, etc. 
[9]. Bacteria can generate resistance against not only antibiotics but also various 
disinfectants. One of the main motivations of this thesis is increasing number of resistant 
bacteria [8,9]. Therefore evaluation of resistance against plasma generated RNS and 
ROS is as important as findings presented in this thesis. One way to evaluate resistance 
against plasma generated RNS and ROS is the consecutive exposure of non-lethal doses 
of plasma treated liquids (direct plasma treatment should be considered as well). After 
each treatment with non-lethal dose, a new culture should be started from the preceding 
culture for particular number of passages. Once desired passage number is achieved, 
each bacterial passage can be evaluated for its susceptibility against various doses of 
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plasma treated liquids (also direct plasma treatment). Moreover comparison of gene 
expression levels of specific genes such as oxidative and nitrosative stress response 
genes for each bacterial passage will provide information not only to determine potential 
resistance, but also to better understand interactions between plasma treated liquids  (or 
direct plasma treatment) and bacteria. 
6.3.2 Determination of Inactivation Dose of Fluid Mediated Plasma Treatment: 
Fluid mediated plasma treatment and disinfection has become an emerging research field 
in plasma medicine. Different research groups have reported antimicrobial activity of 
plasma treated liquids that are treated by different plasma sources. As per data presented 
in this thesis, power supply settings (voltage, pulse duration, frequency), plasma 
treatment duration, discharge gap amount and depth of liquid being treated, holding 
time, initial bacterial load and the ratio of plasma treated liquid volume to bacteria 
amount influences desired antimicrobial effect. Therefore developing an empirical 
model would be beneficial for the comparison of various data presented by various 
groups.  An empirical model would help us to better understand interactions between 
plasma and liquid being treated, diffusion kinetics of plasma-generated species to liquid 
and chemical modifications in liquid caused by plasma treatment. From a practical 
application point of view, an empirical model will be helpful for quality control purpose 
and to determine required plasma dose for various cases of infections. 
6.3.3 Bacterial Persistence Against Plasma-Generated Species: Investigating 
bacterial persistence should be considered as another way to understand response of 
bacteria to plasma-generated species. Bacterial persistence is defined as epigenetic 
ability of bacteria that is developed against various stress factors and considered to be 
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the cause of chronic infections. Bacterial persistence cannot be inherited to future 
generations, but enhances current infection. Persistent bacteria present different 
physiological state compared to wild type bacteria [239]. Thus investigating bacterial 
persistence against various plasma doses and ROS and RNS, will enhance our 
knowledge on the action of mechanism of fluid mediated plasma treatment and how 
bacteria respond to plasma treated liquids. This novel information will be 
complementary to currently existing data and suggested future work mentioned above. 
Interpretation of the novel data together with currently existing data, will eventually lead 
us to a better understanding of the entire process starting from plasma treatment and to 
bacterial inactivation.  
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